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Abstract
Besides systemic infection, proinflammatory signals in the CNS are also 
recruited by epileptic activity. Chronic stimulation of proinflammatory signals by 
seizures, or a persistent proinflammatory situation in brain may contribute to 
the establishment of a pathological substrate (i.e. neurodegeneration, neuronal 
hyperexcitability, blood-brain barrier damage, etc) playing a role in 
epileptogenesis and in the acute manifestation or reinforcement of seizures.
Interestingly, in humans and in experimental models of epilepsy, seizure 
susceptibility and associated neuronal damage are age-dependent. Therefore, 
we wondered whether a hypothetical age-dependent relationship between 
proinflammatory molecules and seizure-susceptibility and related 
neurodegeneration there might exist and to what extent.
A first group of experiments investigated the hypothesis that activation of 
glia and subsequent production of proinflammatory molecules such as 
interleukin-1 (IL-1(3) and tumor necrosis factor-a (TNF-a), as well as the 
naturally occurring anti-inflammatory molecule interleukin-1 receptor antagonist 
(IL-1Ra), are age-dependently involved in seizure-induced neuronal damage.
A second group of experiments investigated whether a pre-existing LPS- 
induced inflammatory state in the CNS may enhance the predisposition of rat 
pups to develop seizures.
We concluded that the induction of proinflammatory cytokines, per se, 
cannot be regarded as a general mechanism which underlies the appearance 
of neurodegeneration. In addition, there were no clear indications emerging 
from our data concerning the role of proinflammatory cytokines in modulating
25
seizure-susceptibility in rat pups. Nonetheless, we showed that prostaglandin 
E2 (PGE2) production and the activation of the Hypothalamic-Pituitary-Adrenal 
axis play a relevant role in the modulation of seizure-susceptibility in rat pups. 
Interestingly, our experiments seem to support the hypothesis that production 
of proinflammatory molecules such as IL-1 (3 and TNF-a in rat pups might be 
down-regulated upon elevation of parenchymal PGE2 levels.
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“...make everything 
as easy as possible, but 
not simpler”
A. Einstein
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1. Introduction
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1.1 Foreword
Tiergartenstrasse 4 in Berlin still represents the address of the building 
that used to be the headquarter of the authority responsible for the 
accomplishment of the so-called Euthanasia Operation T4 (T4 stood just for 
Tiergartenstrasse 4), a ruler promulgated in Germany, 1940, according to the 
Third-Reich theories on Racial Hygiene. All people not conforming to Aryan 
standards were to be definitely eliminated thus making the society free from 
racial imperfections. Among them, people affected by the so-called hereditary 
falling sickness. ‘Hereditary falling sickness’ was the generic terminology by 
which many symptoms of epilepsy used to be classified at that time. After mass 
sterilization imposed by the Law for the Prevention of Offspring with Hereditary 
Disease (promulgated on 15th July 1933, fig. 1) the final step of building gassing 
chambers was undertaken, as it was probably intended from the start.
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Fig. 1. Excerpt from the Reichsgesetzblatt Part I, from 15.07.1933. 
English translation follows.
Gesetz zur Verhutung erbkranken 
Nachwuchses 
§1
Wer erbkrank ist, kann durch 
chirurgischen Eingriff unfruchtbar 
gemacht (sterilisiert) werden, wenn nach 
den Erfahrungen der arztlichen 
Wissenschaft mit grower 
Wahrscheinlichkeit zu erwarten ist, daS 
seine Nachkommen an schweren 
korperlichen oder geistigen Erbschaden 
leiden werden.
Erbkrank im Sinne dieses Gesetzes ist, 
wer an einer der folgenden Krankheiten 
leidet:
1. angeborenem Schwachsinn,
2. Schizophrenie,
3. zirkularem (manisch-depressivem) 
Irresein,
4. erblicher Fallsucht,
5. erblichem Veits-Tanz (Huntingtonsche 
Chorea)
6. erblicher Blindheit,
7. erblicher Taubheit,
8. schwerer erblicher korperlicher 
Mil2>bildung.
Ferner kann unfruchtbar gemacht 
werden, wer an schwerem Alkoholismus 
leidet.
Law for the Prevention of Offspring 
with Hereditary Diseases
§1
People who suffer from a hereditary 
disease can be made infertile surgically 
(sterilised), if the knowledge gained from 
medical science points to the probability 
that the offspring will suffer from severe 
physical or mental hereditary damage.
The law views people as suffering from 
a hereditary disease if they have the 
following:
1. congenital mental deficiency,
2. schizophrenia,
3. circular (manic depressive) insanity,
4. hereditary falling sickness,
5. hereditary Huntington's Disease,
6. hereditary blindness,
7. hereditary deafness,
8. severe hereditary physical deformity.
People suffering from severe alcoholism 
can also be sterilised.
Source: German Epilepsymuseum Kork - Museum for epilepsy and the history of 
epilepsy
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Thus, History simply shows that even the modern and rational-based XX 
century witnessed a strong discrimination against people suffering from 
epilepsy. Indeed, what joins the majority of people suffering from epilepsy 
throughout ages and civilizations is a strong social discrimination which likely 
originates from the feelings of fear and horror linked to the image with which 
epilepsy is usually associated, the grand mal attack.
Epilepsy is an illness as old as human kind and it is one of the most 
documented pathologies in the history of medicine, and can be traced back to 
the dawn of the most ancient civilizations.
As may be expected, the multitude of descriptive terms by which epilepsy 
used to be referred to throughout the ages directly reflected the medical, cultural 
and social history surrounding this disease at those times. A significant example 
is shown in fig. 2 but also in more recent times, terms such as lunatism (a 
disorder caused by the phases of the moon), daemonic suffering (brought about 
by evil spirits) or the scourge of Christ, were used, among many others, to 
define epilepsy.
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Fig. 2. The origin of the ancient Egyptian name for epilepsy, nesejet
spoken hieroglyphics
wave line: n
bails of fabric: s
silent hieroglyphics
cobra: "coming from 
God"
man with stick: "Danger'
ft
I 
s 2 reed leafs: j
loaf of bread: t
In order to pronounce the word 
'nsjt' add an 'e' between the two 
consonants ("nesejet").
Sources: H. Schneble, Krankheit der ungezahlten Namen, Huber-Verlag Bern, 
1987, p. 9-11; German Epilepsymuseum Kork - Museum for epilepsy and the 
history of epilepsy
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In the last two centuries, scientific progress and dissociation between 
Science and the dominant culture has yielded fundamental insights towards a 
better, though still limited, understanding of the intrinsic nature of this 
neurological disorder. Although the medical treatments of many patients 
affected by epilepsy have improved in the last half-century, from the point of 
view of medical sciences epilepsy still remains an unresolved matter and still 
represents one of the most common neurological disorder affecting about 0.5 to 
0.8% of worldwide population.
The Greek word from which the term epilepsy comes from, epilambanein, 
(to seize upon -  to attack unexpectedly) describes the main feature of such a 
neurological disorder well. Thus, epilepsy is a disease that causes seizures to 
occur. Often, aetiologies are well-determined, such as stroke or head injury, but 
in a high percentage of cases they can be unknown.
The singular term epilepsy is not appropriate to describe what actually is 
a cluster of disorders rather than a single disease, hence the plural term 
epilepsies is the most correct, (see tab. 1 and 2 for official classifications of 
epilepsies and seizures). Nonetheless, the singular term is still in use among 
neurologists and so it will be in this work as well, unless differently specified.
33
Table 1: Classification of epileptic seizures
Partial (focal, local) seizures
1- Simple partial seizures (consciousness not impaired)
• With motor signs (ex: facial motor, vocalisation, arrest of speech..)
•. With autonomic symptoms (ex: epigastric sensation, piloerection..) 
•With somatosensory symptoms (ex: visual, vertiginous..)
•With psychic symptoms (ex: hallucinations, affective-fear, anger...)
2- Complex partial seizures (with impainnent of consciousness)
• Simple partial onset followed by impairment of consciousness
• With impairment of consciousness at onset
• With simple partial features (AI-4) followed by impairment of 
consciousness
•With automatisms
Generalised seizures (convulsive or nonconvulsive)
/. Absence seizures
• Impairment of consciousness only
• With mild clonic components
• With atonic components
• With tonic components 
•With automatisms
2. Atypical absence
• Myoclonic seizures
• Clonic seizures
•Tonic seizures
• Tonic-clonic seizures
• Atonic seizures
3. Unclassified epileptic seizures
Correspond to all seizures that cannot be classified according to the 
descriptions above, due to incomplete or inadequate data.
According to Commission on Classification and Terminology of the International 
League Against Epilepsy. Proposal for revised clinical and electroencephalographic 
classification of epileptic seizures (Epilepsia, 1981,22:489-501)
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Table 2: Classification of epileptic syndromes
Localisation-related (focal, local, partial) epilepsies and syndromes
• Idiopathic with age-related onset
• Benign childhood epilepsy with centrotemporal spike
• Childhood epilepsy with occipital paroxysms
• Symptomatic
• Syndromes are of great individual variability, mainly based on the anatomical 
localisation. Examples are:
Frontal lobe epilepsies (ex: motor cortex)
Temporal lobe epilepsies (ex: Hippocampus -  mesiobasal limbic) 
Parietal lobe epilepsies 
Occipital lobe epilepsies
Generalized epilepsies and syndromes
A. Idiopathic with age-related onset
• Benign neonatal familial convulsions
• Benign neonatal convulsions
• Benign myoclonic epilepsy in infancy
• Childhood absence epilepsy
• Juvenile absence epilepsy.
• Epilepsy with "grand mal" seizure on awakening
Other generalized idiopathic epilepsies, if they do not belong to the above 
syndromes, can still be classified as generalized idiopathic epilepsies.
Idiopathic and/or symptomatic, in order of age of appearance 
. -Westsyndrome
• Lennox-Gastaut syndrome
• Epilepsy with myoclonic-astatic seizures
• Epilepsy with myoclonic absences 
Symptomatic
• Non-specific aetiology (early myoclonic encephalopathy)
• Specific syndromes (several aetiologies can be included here)
Epilepsies and syndromes undetermined as to whether they are focal or 
generalized
with both generalized and focal seizures
• Neonatal seizures
• Severe myoclonic epilepsy in infancy
• Epilepsy with continuous; spike waves during slow-wave sleep
• Acquired epileptic aphasia (Landau-Kleffner syndrome)
• Without unequivocal generalized seizures (many cases of sleep grand-mal)
Special syndromes
• Situation-related seizures (ex: febrile convulsions, sleep deprivation, drugs..)
• Isolated unprovoked epileptic events
According to the classification and Terminology of the International League Against 
Epilepsy. Proposal for revised clinical and electroencephalographic classification of 
epilepsies and epileptic syndromes (Epilepsia, 1989,30:389-399)
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Epilepsy can arise at any age and the mechanisms leading to 
epileptogenesis are still unknown. At the cellular level, epileptic tissue 
comprises neurons whose pattern of discharge depends on intrinsic and/or 
environmental alterations, giving rise to a peculiar neuronal firing named as 
burst Burst is a functional consequence of what is called the paroxysmal 
depolarizing shift (PDS), this feature being considered as the hallmark of 
epilepsy from the electrophysiological point of view. Since neurons within 
epileptic tissue are particularly prone to fire in bursts, and as such a pattern of 
discharge requires a prolonged state of depolarization of the membrane 
potential (PDS), nerve cells involved in seizure generation have been classified 
as hyperexcitable neurons.
Hence, an old common definition of epilepsy stated that such 
neurological disorder is characterized by excessive discharge of cerebral 
neurons due to their intrinsic hyperexcitability. This definition has been 
somewhat misleading since it focuses attention mainly, if not exclusively, on the 
abnormal behaviour of the individual neuron. Indeed, speaking of a single 
epileptic neuron is meaningless since a seizure is the macroscopic 
manifestation of a synchronizing mechanism involving broad neuronal 
populations. Thus, nowadays, although research on epilepsy has been focused 
on the properties of neuronal networks with greater attention than that it used to 
be, significant knowledge is still missing.
From a clinical perspective, seizures are associated with a variety of 
manifestations, spanning from auras to behavioural convulsions, often 
accompanied by a loss of consciousness, depending on which cerebral areas 
(and to what extent) are actively involved in seizures.
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A simplified classification of clinical epilepsies is depicted in Fig. 3, 
according to the International Classification of Epilepsies and Epileptic 
Syndromes (tab. 2) which, despite current advancements in knowledge, has not 
been amended yet, although suggestions for more clinically practical and 
updated classification (and related glossary) have already been proposed. In 
Fig. 3 terms as cryptogenic and localization-related are preserved despite, 
nowadays, their inappropriateness. Nonetheless, these terms and others are 
still common among neurologists, and are therefore adopted in this discussion.
Generally, two main categories of epilepsies can be sketched out (Fig. 3), 
idiopathic and symptomatic, being cryptogenic a synonym of “symptomatic with 
unknown aetiology due to technical limitations of available diagnostic tools”.
Both categories can be subdivided in generalized and localization-related 
clusters, depending on the origin and the extent of the cerebral areas involved in 
seizure propagation. Symptomatic localization-related epilepsies constitute a 
prominent group which comprises epileptic syndromes originating from cerebral 
lesions as brain tumours, traumatic scars, vascular malformations, dysplasia, 
etc...(often affecting neocortex and named lesional partial epilepsies) and 
cryptogenic partial epilepsies as well.
Of particular relevance among symptomatic localization-related 
epilepsies are those of temporal-lobe origin, usually referred to as Temporal 
Lobe Epilepsy (TLE) which represents the most common form of human 
epilepsy. In fact, in the majority of patients affected by epilepsy seizures have a 
localized onset and, among these patients, about one third actually present 
seizures originating from temporal lobe.
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Fig. 3. Schematic classification of epilepsies.
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TLE can be subdivided into three groups as well, within which definitions 
as lesional TLE and cryptogenic TLE preserve the same meaning as before.
Indeed, the most relevant and frequent epileptic syndrome of temporal- 
lobe origin is named Mesial Temporal-Lobe Epilepsy (MTLE) and it constitutes 
one of the major challenges that epileptologists have been facing as it 
represents one of the most diffuse and problematic forms of human epilepsies.
The clinical relevance of MTLE stems from the observation that patients 
affected by MTLE often experience at least one of the two main problems 
characterizing this form of epilepsy, i.e. refractoriness to antiepileptic drug 
(AED) treatment and structural abnormalities of specific brain areas leading to 
cognitive dysfunctions.
Refractoriness to AEDs affects about 25% of epileptic patients and, 
among them, 70% is diagnosed with MTLE. Antiepileptic drug resistance is 
commonly defined as lacking of seizure control when at least three appropriate 
drugs have been used at the maximum therapeutic doses. Drug resistance to 
AEDs is probably a multifactorial phenomenon (Sisodiya, 2003) and among 
several prognostic factors particularly relevant are structural abnormalities such 
as hippocampal and amygdaloid sclerosis, the former being a very common 
feature of MTLE which will be discussed in detail below. It should be stressed 
that, however, structural abnormalities, together with the totality of known 
prognostic factors, cannot account for drug resistance in clear terms of a 
cause-effect relationship.
Conversely, the relationship between structural abnormalities and 
cognitive impairments affecting people with MTLE is undoubtedly much clearer 
since patients often exhibit memory impairments as deficits in acquiring facts
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and events related to their personal past (declarative memory) and strongly 
reduced performance in tasks related to spatial memory (Helmstaedter et al., 
2001; Abrahams etal., 1999).
Also these cognitive dysfunctions are strongly related to the damage of 
neuroanatomical structures involved in memory processes such as the 
hippocampus. The nature of this damage is well established since early studies 
in the XIX century and essentially relies on a pronounced cell death affecting (to 
varying degrees) principal and non-principal neuronal populations in the 
hippocampus. This peculiar pattern of cell loss represents the hallmark of the 
so-called hippocampal sclerosis which is the major histopathological finding 
frequently associated to MTLE.
Thus, neuronal cell loss (also referred to as neurodegeneration) often 
associated with MTLE appears to be involved in both resistance to AEDs 
treatment and cognitive impairments affecting patients. Indeed, 50% to 70% of 
patients with drug refractory MTLE present hippocampal damage and 30% to 
60% are found with amygdaloid damage (Pitkanen, 2002; Engel, 1996). Hence, 
neuronal damage can be well regarded as a hallmark of MTLE, in particular 
hippocampal sclerosis where neurodegeneration is most prominent. As 
mentioned before, such structural abnormality was already known since XIX 
century from studies conducted by visual and microscopic inspection of brains 
post-mortem. At that time it was also observed that neurodegeneration often 
involves other cerebral areas as well as enthorinal cortex, amygdala and midline 
thalamic nuclei.
The aetiology of neurodegeneration still remains unknown. A basic 
question still largely unanswered concerning epileptogenesis is whether
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structural abnormalities are already present at the time of the first spontaneous 
seizure or they appear later as a consequence of recurrent epileptic symptoms, 
or both. This applies in particular to hippocampal sclerosis. This topic has long 
been debated and, substantially, still remains controversial. On the one hand, 
surgical resection of sclerotic hippocampus is usually associated with a good 
outcome for seizure control/remission (thus pointing hippocampal structural 
alteration as a leading cause of seizure generation) while, on the other hand, 
recent high-resolution magnetic resonance imaging has repeatedly revealed 
that seizures can induce hippocampal atrophy per se, thus suggesting 
hippocampal sclerosis is a consequence of recurrent seizures. Nowadays, a 
growing amount of evidence has been accumulating in support of the latter 
hypothesis. Many studies have repeatedly shown that intense and prolonged 
seizures involving the limbic temporal-lobe can induce neuronal damage, in 
particular of some neuronal populations in the hippocampus.
A partial explanation, although still hypothetical, conciliating seizures, 
hippocampal atrophy and epileptogenesis involves an initial insult to 
hippocampus, as it is known to occur following prolonged febrile seizures and/or 
status epilepticus. Then, after a silent period while structural alterations appear 
to take place, spontaneous and recurrent seizures occur, that is, the patient 
becomes affected by epilepsy with all its possible consequences, such as 
refractoriness to AEDs treatment and cognitive dysfunctions. Usually, the origin 
of seizures is the hippocampus.
Whether the risks/benefits ratio is considered acceptable, surgery is 
undertaken. However, it should be stressed that in the majority of cases (80%), 
operated patients do not become really seizure-free, but they reach an
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acceptable level of responsiveness to common AEDs, thus keeping seizures 
under a pharmacological control which was previously impossible to achieve 
before surgery. The number of real seizure-free patients is variable and often 
depends on the underlining pathology associated with epilepsy. However, it 
never reaches 100%. For instance, 60% of patients affected by some forms of 
cortical dysplasia become seizure-free after surgery and this is considered a 
good outcome. Moreover, total or partial resection of hippocampus, while not 
improving memory dysfunction, is always associated with an increased risk of 
post-surgery anterograde amnesia which can be severe and permanent.
Hence, understanding the causes leading to neurodegeneration is an 
absolute priority since neuronal cell loss appears to be the substrate of a series 
of severe clinical problems associated to MTLE, which are difficult, often 
impossible, to manage.
Among the possible, hypothetical, causes of neurodegeneration 
associated with seizure occurrence, the involvement of pro-inflammatory 
cytokines and related molecules has been gaining increasingly greater attention. 
In particular, clinical evidence exists of inflammatory markers in the brains of 
epilepsy sufferers and experimental work (using animal models of seizures and 
human MTLE) demonstrates that tissue expression of inflammatory markers 
increases during seizures, following a time-course that can be correlated to the 
onset of neuronal damage.
The subsequent chapters will deal in greater detail with the many aspects 
of this topic, adding novel information from experiments undertaken using 
animal models of seizures.
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Before entering the core of this work, it is of interest to see fig. 4 which 
shows famous people who had (or were presumed to have) epileptic seizures 
during their life or who suffered of a chronic form of epilepsy for many years. 
Thus, from fig. 4, it may be inferred that the social and political decline of some 
famous people could be plausibly explained in terms of neurological impairment 
arisen as a consequence of what, nowadays, it is known as epilepsy-related 
neurodegeneration.
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Fig. 4. Famous people who had epileptic seizures at a certain 
stage of their life or who suffered of a chronic form of epilepsy for 
many years (German Epilepsymuseum Kork - Museum for epilepsy 
and the history of epilepsy)
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1.2 Mesial temporal lobe epilepsy with 
hippocampal sclerosis
1.2.1 Clinical signs, symptoms and therapeutic intervention 
in human
Key clinical features of mesial temporal lobe epilepsy with hippocampal 
sclerosis (MTLE with HS) are characteristic aura, arrest, alteration of 
consciousness (and amnesia) and automatisms (Weiser, 2004).
The most common aura, usually occurring in isolation, is in the form of 
epigastric sensation (40 to 70% of patients, depending on the diagnostic tools 
such as MRI or histopathology by which HS has been proven) often evolving 
into ictal oral or manual automatisms, while, to a lesser extent, olfactory- 
gustatory auras may occur. Up to 50% of patients experience emotional auras 
which trigger fear and anxiety and autonomous-vegetative auras such as 
widened pupils, palpitations, arrhythmia, etc may occur as well. In children, 
abdominal pain associated with fear is more frequent. It is interesting to note 
that about 20% of patients who were rendered seizure-free after resection of 
sclerotic hippocampus still have persistent auras (Fried et al., 1995), this finding 
suggesting that in patients with HS an anatomic dissociation may occur between 
seizures and auras.
Alteration of consciousness is frequently observed to varying degrees, 
ranging from preservation to loss of consciousness and, generally, it is assumed
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that the more severe the alteration of consciousness, the larger the ictally 
perturbed brain volume will be.
Although non-specific for MTLE with HS, aphasia/anomia may occur 
during the ictal as well as the postictal period. Also automatisms can happen 
during ictal and postictal periods as well; usually, oroalimentary ictal 
automatisms prevail over gestural or manual automatisms.
On seizure spread to suprasylvian brain areas, positive motor symptoms 
may occur ranging from contralateral, predominantly clonic (or clonic/tonic) 
facial-brachial motor symptoms to secondary generalized motor symptoms with 
a clonic-tonic-clonic pattern.
In the postictal period, some degree of dysfunction is always present. 
The deficits most frequently observed are cognitive impairments, memory 
deficits, mood changes and language deficits.
In general, neuropsychological examination of patients affected by MTLE 
with HS reveals specific memory impairment and, often, additional general 
intellectual impairment, although the latter is a non-specific symptom for this 
pathology. The impairment of long-term memory consolidation or retrieval of 
newly acquired information (episodic memory) are the most typical types of 
cognitive dysfunction. In this contest, material-specific memory impairments 
develop, depending on hemispheric language dominance and the affected 
hemisphere.
Memory impairments found in patients affected by MTLE with HS have 
been shown to be progressive and significant memory changes can be 
expected after an interval of about 30 years (Helmstaedter and Eiger, 1999). 
This time interval has also been suggested for hippocampal neuron loss to
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occur as a consequence of repetitive seizures (Helmstaedter and Eiger, 1999; 
Mathern et al., 2002). However, it should be noted that HS can account for 
memory impairments in no more than 30% of patients affected by MTLE and 
additional determinants such as age at the onset of the lesions, medication 
frequency, severity of seizures, IQ, chronical age, etc should always be kept in 
consideration.
Among partial epilepsies, MTLE with HS is the most resistant to AED 
treatment for the majority of patients. However, a small percentage of subjects 
achieve good control over seizures and it is likely that prevalence/incidence of 
good responders is indeed higher than it used to be thought in the past. 
Interestingly, Ozkara et al. (Ozkara et al., 2004) reported that although both 
responder and non-responders to AEDs had significantly lower memory scores 
than control patients, no relevant differences were detected between the two 
groups of subjects thus showing that memory impairment in subjects affected by 
MTLE with HS was permanent and might be related to the direct effect of HS 
itself, independently from the rate of response to AED treatment.
Indeed, for AED resistant subjects, surgery still represents the most 
effective therapeutic intervention with highest rates of seizure-free patients, 
being generally graded as patient-group of outcome class I, according to Engel 
(Engel et al., 1993; Paglioli et al., 2004, TAB 3). However, a relevant percentage 
of operated patients (15-20%) still have convulsions after surgery and this 
percentage increases over time from surgical intervention (Paglioli et al., 2004). 
Seizures occurring after surgery can still be more or less disabling at varying 
degrees although, in the majority of cases, their frequency is reduced. However,
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no worthwhile improvement or even seizure worsening can occur in a small 
percentage of subjects after surgery (outcome class III and IV, TAB 3).
Generally, the majority of operated patients are still administered with 
AEDs which usually have their efficacy increased due to total or partial resection 
of presumed-to-be-epileptogenic sclerotic hippocampus, alone or together with 
other limbic structures such as amygdala and temporal cortex as well.
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Table 3: Engel’s classification of the surgical outcome
Class I: Free of disabling seizures
IA, completely seizure-free since surgery;
IB, non disabling simple partial seizures only since surgery;
IC, some disabling seizures after surgery, but free from disabling 
seizures for > 2 years;
ID, generalized convulsions with antiepileptic drugs withdrawal only.
Class II: Rare disabling seizures (“almost seizure-free”).
IIA, initially free of disabling seizures but has rare seizures now;
IIB, rare disabling seizures since surgery;
IIC, more than rare disabling seizures after surgery, but rare seizures 
for > 2 years;
IID, nocturnal seizures only.
Class III: Worthwhile improvement.
IIIA, worthwhile seizures reduction;
IIIB, prolonged seizure-free intervals amounting to more than half the 
follow-up period, but < 2 years.
Class IV: No worthwhile improvement.
IVA, significant seizures reduction;
IVB, no appreciable change;
IVC, seizures worse.
Neuropsychological evaluations of post operated patients have long 
established that surgery always increases the risk of additional memory 
impairment, with verbal memory most often affected, in particular in left-side 
operated patients (~ 25%), usually being this cerebral area the language- 
dominant hemisphere, whereas a worsening in visual memory often occur in 
right-side operated patients (~ 20%) (Paglioli et al., 2004; Gleissner et al., 
2002; Lee et al., 2002).
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1.2.2 Histopathology of hippocampal sclerosis in adult 
humans
Hippocampal sclerosis (HS), which often occurs unilaterally, is the most 
common lesional pathology identified in patients with TLE and, although it has 
been intensively studied over the last decades, its aetiology still remains elusive.
A general histological evaluation of resected tissue reveals the classical 
pattern of HS affecting about 70% of patients, with severe neuronal loss in CA1 
area and the bordering, proximal, part of the subiculum, accompanied by more 
or less severe cell loss in the hilus. CA3 sector is also affected, whereas 
pyramidal cells of CA2 subfield are usually relatively preserved (Babb and 
Brown, 1987; Sloviter, 1994; Proper et al., 2000). The less frequent patterns of 
hippocampal neurodegeneration affecting the remaining patients comprise the 
so-called end-folium sclerosis (cell loss essentially limited to the hilus only), mild 
neurodegeneration involving about 30% of neurons in CA1 area with general 
sparing of hilar neuronal populations and, for a small percentage of patients, 
severe cell populations loss affecting all hippocampal subfields, CA2 area 
included. All patterns of neurodegeneration manifest, however, a prominent 
astrocytic gliosis (Thom et al., 2004).
Specific to HS is the architecture of the granule cell (GC) population. 
With the exception of end-folium sclerosis and generalized severe 
neurodegeneration, where a depletion of GCs occurs as well, the most evident 
pattern affecting this cell population is dispersion (Houser et al., 1990). This 
pattern of granule cell architecture is evident in ~40% of HS specimens and 
consists of the broadening of granule cell layer, in particular toward the
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molecular layer of the dentate gyrus. In the majority of cases, the degree of 
dispersion ranges from mild to severe, the latter being also detected together 
with nests of GCs toward the hilus and, also, in ectopic locations within the hilus 
or CA3 area (Thom et al. 2002). Less frequently, an extensive or localized 
bilaminar pattern of the granule cell layer also occurs, this too with clusters of 
GCs in the molecular layer.
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1.2.3 Major morphological and immunohistochemical 
findings in adult human HS
Beyond stereotypical loss of pyramidal cells in CA1 and CA3 fields, and 
relative sparing of CA2 neurons and GCs, several non-principal cell populations 
are shown to be selectively involved in the neurodegeneration characterizing 
HS.
Thus, compared to autopsy controls and lesion-associated TLE 
specimens, hippocampal tissue from patients with HS presents a significant 
decrease of hilar mossy cells, a morphologically peculiar cell population resident 
in the polymorphic cell layer, that are known to be glutamatergic thus excitatory 
(Blumcke et al., 2000).
Generally, fascia dentata of HS specimens shows the highest number of 
cell populations involved at varying degrees in neurodegeneration and this has 
attract the attention of investigators since this hippocampal subfield is 
considered the “gatekeeper” to whole hippocampal circuitries. Thus 
neuropeptide-targeted immunocytochemical studies have shown a loss of hilar 
somatostatin (SOM) and neuropeptide Y (NPY) immunoreactive interneurons, 
usually subgranular-located, with a preferential involvement of SOM positive 
cells (Robbins et al., 1991; Mathern et al., 1995). About 30% of hilar cells 
present a double immunostaining for both SOM and NPY and, moreover, a 
subpopulation of these peptide-immunoreactive hilar cells have been shown to 
co-localized with glutamic-acid-decarbossylase (GAD), the enzyme responsible 
for y-aminobutyric-acid (GABA) synthesis.
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As far as GABAergic neurons are concerned, one of the most abundant 
hippocampal GAD-positive cell population is represented by basket-like 
interneurons which are located in all hippocampal subfields. These cells have 
been shown to be relatively preserved in specimens affected by HS as well as 
immunoreactivity reported from fibres and synaptic terminals, suggesting a 
GABA hyperinnervation on surviving cells. This finding, in a scenario of diffuse 
loss of cellular populations, make GABAergic interneurons to become 
proportionally abundant as compared to normal hippocampal tissue, thus 
suggesting an apparent increase in inhibitory neurotransmission (Babb et al., 
1989; De Lanerolle et al., 1989; Mathern et al., 1995).
A relevant phenomena occurring in HS, also involving the same cellular 
populations directly involved in neurodegeneration, is reactive synaptogenesis 
also known as sprouting. This terms equally refers to arborisation of both axonal 
projections of surviving interneurons and axonal projections of GCs.
Sprouting of GCs axons (mossy fibres) is one of the most striking 
aberrant finding related to HS. The richness in Zn2+ of mossy fibres synaptic 
terminals have made these axonal projections amenable to be easily marked by 
Timm’s staining (Danscher, 1981). Thus, whereas a normal hippocampus 
shows a dense staining in the hilus and CA3 area, corresponding to ordinary 
synaptic contacts of GCs axonal projections, a sclerotic hippocampus directly 
involved in seizures generation clearly shows a strong decrease of staining in 
fascia dentata and CA3 subfield, with a strong, peculiar, Timm-positive region 
located in the inner molecular layer of the dentate gyrus. These terminals were 
actually shown to make new synaptic contacts onto proximal apical dendrites of 
GCs and their immunoreactivity to synaptophysin (a calcium-binding
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glycoprotein located in the membrane of neurotransmitter-containing small 
vesicles at presynaptic terminals) and presynaptic growth-associated protein 
(GAP-43, usually overexpressed in newly forming presynaptic terminals) 
suggests intrinsic synaptic activity of sprouted mossy fibres (Proper et al., 
2000).
However, although GC axons sprouting appears to be one of the most 
prominent synaptic reorganization related to HS, other cellular populations show 
similar patterns of reactive synaptogenesis, here again almost exclusively 
located in the fascia dentata. Thus, enhanced immunoreactivity to SOM, NPY 
and substance-P (SP) have been particularly shown in dentate gyrus where 
electron microscope studies revealed new synapses deriving from sprouted 
axon terminals in the molecular layer (De Lanerolle et al., 1992), with SOM- and 
NPY-positive synaptic terminals mostly localized in the region of proximal apical 
dendrites of GCs (inner molecular layer, de Lanerolle et al., 2003).
Particular attention was paid to sprouting of GAD-positive fibres which 
were shown to hyperinnervate GC bodies and the full length of their apical 
dendrites, i.e. involving inner and outer molecular layer in GABAergic reactive 
synaptogenesis (Mathern et al., 1995; Babb et al., 1989). Also CA1 and CA3 
areas of sclerotic hippocampus were shown to be involved in hyperinnervation 
of surviving pyramidal neurons by GAD-positive fibres which preferentially make 
significant new synaptic contacts on cell bodies and proximal apical dendrites, 
that is, GABAergic hyperinnervation is oriented toward stratum pyramidale and 
stratum oriens of these Ammon’s horn subfields which are affected by 
neurodegeneration as particularly reported to occur in CA1 (Babb et al., 1989).
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The importance of intracellular Ca2+ concentration with respect to 
intracellular signalling and potential excitotoxic damage, has raised the question 
as to whether patterns of cell death and survival in HS could be explained in 
terms of alterations of buffering capabilities of intracellular calcium-binding 
proteins.
Thus, the expression of calbindin-D28k, normally detected in principal 
and non-principal cell populations of all hippocampal subfields with the 
exception of CA1 pyramidal cells, was shown to significantly decrease in GCs 
whereas interneurons appear generally preserved although morphological 
alterations make them actually different from comparative control specimens 
(Magloczky et al., 1997; Sloviter et al., 1991).
A different pattern of degeneration affects cells expressing parvalbumin 
(PV), a calcium-binding protein exclusively localized in non-principal neurons. In 
control tissue, PV is usually detected in interneuronal populations throughout all 
layers of hippocampal areas, whereas in HS specimens PV immunoreactivity 
shows a generalized decrease in Ammon’s horn subfields and a strongly 
pronounced loss of PV-positive cells close to pyramidal neurons in fascia 
dentata (Arellano et al., 2004; Zhu et al., 1997; Sloviter et al., 1991).
Another calcium-binding protein, calretinin (CR), is frequently used as a 
marker for a cell population morphologically identifiable as Cajal-Retzius like, 
although CR is not specific for these cells since it is also present in interneurons 
where was shown to be co-localized with GABA. Cajal-Retzius cells, 
neurochemically characterized by p73-immunoreactivity (Abraham et al., 2003), 
have attracted the attention of investigators since they represent the major 
releasing source of the extracellular matrix protein reelin, which is known to play
59
a fundamental role in neuronal migration and targeting during development 
(Mienville, 1999). This cell population, commonly resident in all hippocampal 
subfields and in particular in the molecular layer of dentate gyrus and in stratum 
granulosum-moleculare, is known to strongly decrease in number as 
development approaches maturation. In HS specimens it was shown a higher 
persistent number of these cells as compared to control tissue as well as tissue 
resected from patients affected by TLE with extrahippocampal origin. This 
finding has been suggested to be related to GC dispersion as a sign of a 
pregressed hippocampal maldevelopment as a potential factor contributing to 
the establishment of HS as a malformation perse not directly related to seizures 
occurring (Thom et al., 2002 ; Blumcke et al., 1996).
Considering the morphology of surviving cell populations, it has been 
shown that, in up to half of patients, cytoskeletal abnormalities are generally 
prominent, for instance, in residual hilar neuronal populations. Morphology is 
altered, showing enlargement and/or ballooning of cell bodies and processes at 
varying degrees, accompanied by extensive dendritic ramifications. The number 
of mitochondria is usually increased. Morphological alterations are actually 
confirmed by specific immunohistochemistry for structural proteins. Thus, 
immunostaining for neurofilament proteins reveals accumulation of both 
phosphorilated and non-phosphorilated neurofilaments, both in cell bodies and 
dendritic processes (Blumcke et al., 1999). Microtubule-associated protein 2 
(MAP2) immunostaining which appears prominently in molecular layer 
projecting apical dendrites of granule cells is also increased (Thom et al., 2002).
Glial cells are always involved in HS mainly in terms of activated 
microglia and reactive astrocytic gliosis which are particularly prominent in the
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hippocampal subfields mostly involved in neurodegeneration (CA1 and DG), 
whereas in CA3 and CA2 they appear to a lesser extent. Indeed, an increased 
number and size of astrocytes can be shown by immunoreactivity to GFAP, thus 
confirming a strong proliferation and replacement of dead principal and non­
principal cells by astrocytes, with frequently observed radial infiltrates of glial 
fibres among surviving pyramidal and granular cell populations (Thom, 2004).
61
1.3 Seizures and epilepsy in infants and children
The incidence of epilepsy is approximately 5-7 cases per 10,000 children 
from birth to age 15 years, and in any given year, about 5 of every 1,000 
children. Increasing risk factors include congenital malformations of the central 
nervous system (CNS), moderate and severe head trauma, CNS infections, 
certain inherited metabolic conditions and genetic factors. However, these 
factors are not able to account for more than 45% of occurring epilepsies thus 
leaving the remnant cases without any identifiable aetiology (Cowan, 2002).
Although epilepsies in infants and children can be still classified 
according to the official classification, i.e. idiopathic, symptomatic and 
cryptogenic, a re-clustering of ictal disorders in the following four groups 
probably better characterizes the occurrence of seizure disorders in infants and 
children, that is i) symptomatic epilepsies, ii) epileptic encephalopathies, iii) 
febrile seizures and iv) seizures of temporal lobe origin.
As well as in adults, symptomatic epilepsies originate from injuries and/or 
acute insults induced by underlying neuropathologies as cerebral 
malformations, tuberous sclerosis or acute insults as hypoxia. Differently from 
adults, as a general peculiarity, status epilepticus (SE) is more likely to occur in 
infants and children in response to neuropathologies and/or acute insults and it 
is known to often anticipate epilepsy in 30-75% of children, in particular when 
afebrile and drug refractory (Maytal et al., 1989; Sahin et al., 2001).
Epileptic encephalopathies represents a cluster of disorders in which 
cognitive, sensorial and/or motor functions deteriorate as a consequence of
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epileptic activity which consists of frequent seizures and/or so-called interictal 
paroxysmal activity (Nabbout et al., 2003). Electroclinical features yield to a 
subdivision of these disorders in i) epileptic encephalopathies produced by 
frequent and/or severe seizures such as Dravet syndrome and Rasmussen’s 
encephalitis (both occur in infants within the first year of life) and ii) epileptic 
encephalopathies with continuous or nearly continuous spike and slow wave 
activity such as West syndrome in infants and Lennox-Gastaut syndrome in 
age-school children. Generally, epileptic encephalopathies are age-related 
syndromes whose pathophysiology is largely unknown, although sometimes 
they can be partially accounted for by structural and genetic alterations.
Febrile seizures are common ictal events affecting infants and children 
older than 1 month, originating from febrile illness (body temperature > 38.5°C) 
without CNS infections and/or metabolic imbalances. Usually, they represent 
the very first ictal event thus without any afebrile seizures occurring 
beforehand. They can be short lasting seizures or febrile SE, although the latter 
being more common when neurological dysfunctions are present.
The clinical seizure semiology in infants and children affected by epilepsy 
of temporal lobe origin is different as compared to adults and adolescents.
Generally, with regard to the aspects of seizures of temporal lobe origin 
in infancy and childhood, a distinction can be made between young children 
aged less than 3 years and older children. The main differences characterizing 
seizures in infants and young children can be summarized as i) a predominance 
of behavioural arrest, ii) no identifiable auras before the age of 5 years, iii) the 
automatisms are predominantly oroalimentary and less gestural and/or 
purposeful, iv) seizure duration is substantially longer and more convulsive with
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tonic, clonic and myoclonic activity, v) from the perspective of electrophysiology, 
interictal EEG discharges are less frequent and ictal discharges may be less 
focal (Yamamoto et al., 1987; Duchowny, 1987). The impairment of 
consciousness often observed in adults as a feature of complex partial seizures 
is difficult to evaluate in infants and young children (aged < 3 years). An attempt 
at measuring the degree of altered consciousness was made by Duchowny 
(Duchowny, 1987) who observed that infants did not react to visual threat or 
loud noise during seizures, thus concluding that also in infants consciousness 
was impaired at least in part. Interestingly, histopathology reveals that structural 
abnormalities associated with seizures of temporal lobe origin mostly consist of 
dysplasias, migrational disorders, hamartomas and low-grade tumors such as 
gangliogliomas. Differently from what is encountered in adult and adolescent 
epilepsy sufferers, a neurodegenerative pattern of mesial temporal sclerosis has 
a reduced prevalence, ranging from 15 to 40%, often detected together with 
aforementioned structural alterations thus ascribing a dual-pathology pattern 
which occurs more frequently in children than in adults (Murakami et al., 1996; 
Duchowny et al., 1992; Wyllie et al., 1993). Generally, several studies have 
shown that the older the children the higher the prevalence of mesial temporal 
sclerosis among neuropathological findings, as assessed both by histopathology 
of surgical specimens (Mizrahi et al., 1990; Duchowny et al., 1992; Wyllie et al., 
1993; Kuzniecky et al., 1993; Bourgeois, 1998; Bocti et al., 2003) and by MRI 
studies which show that although HS can also be detected in children as aged 
as 2 years, the incidence of this neuropathological finding remains very low as 
far as the age is less than 5 years (Cross et al., 1993; Harvey et al., 1995; 
Harvey et al., 1997; Murakami et al., 1996).
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1.3.1 Ictal events in infants and children as predisposing 
risk factors for MTLE development in adulthood
Studies in humans have not yet provided any clear relationship between 
MTLE in adulthood and any epileptic-like activity occurring in infancy and early 
childhood, the latter evaluated in terms of being either an epiphenomenon or a 
causative factor. Generally, investigations on epilepsy in the field of pediatric 
neurology are affected by the question of whether ictal events occurring in 
infancy and early childhood are a cause of structural abnormalities such as HS, 
or the consequence of an already damaged cerebral structure that should be 
ascribed as the pathological substrate for seizures. Information available from 
human studies on the evaluation of febrile seizures as a predisposing risk factor 
for MTLE to develop in adulthood ranges from data showing the high proportion 
of patients with HS who had experienced prolonged febrile seizures in early 
childhood (Abou-Khalil et al., 1993; Cendes et al., 1993 (b); Kuks et al., 1993) 
as well as data showing a lack of any relationship in long-term follow-up (Tarkka 
et al., 2003). The association between febrile SE and the severity of 
hippocampal atrophy in patients with MTLE is better defined. Thus a history of 
febrile SE correlates positively with the degree of HS (Cendes et al., 1993 (a)) 
and children with long lasting febrile seizures, such as SE, were shown to have 
a higher incidence of MTLE than siblings (even twins) with short lasting febrile 
seizures. This supports the hypothesis that seizure duration may be directly 
related to the development of epilepsy in patients with common genetic 
background (Jackson et al., 1998).
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Generally, the diversity of early childhood as compared to adults is also 
manifested in the different prognostic significance of the occurrence of status 
epilepticus (SE), both in association with febrile illnesses (see above) and as a 
consequence of more or less manifested neurological alterations. In adult 
patients, SE usually occurs following a neurological insult resulting in a lesion or 
underlying pathology, have a relatively high mortality rate (Wu et al., 2002) and 
it was shown to be the first manifestation of epilepsy in about 10% of adult 
patients (Janz, 1983) . Conversely, afebrile SE in childhood, often precedes the 
onset of epilepsy (30-75% of cases), although a first seizure rarely presents as 
SE in the absence of a neurological insult (Maytal et al., 1989; Aicardi et al., 
1970). Mortality induced by SE is lower in children compared to adult patients 
although children are more prone to manifest SE, in particular when the brain is 
compromised such as in cerebral malformations (Sisodiya, 2004) and cerebral 
palsy (Gururaj et al., 2003). Although common in infants (the incidence of both 
febrile and afebrile SE is higher in the first year of life) as well as in people aged 
over 60 years there are no studies at present that definitively prove SE as a 
source of permanent injury to the brain, since prospective data in human beings 
is still missing. Thus, SE in children may be an ictal event triggering HS that will 
boost MTLE in adulthood as well as a consequence of a pre-existing 
pathological substrate that will progress towards hippocampal atrophy the more 
the age of children approaches adolescence (Haut et al., 2004; Sutula et al., 
2003; Berg and Shinnar, 1997).
It should be emphasized, however, that data so far collected from human 
beings are retrospective, thus making separation of seizure-induced pathology 
from the cause of the seizure difficult.
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1.3.2 Experimental studies on the susceptibility to seizure- 
induced damage of immature as compared to adult 
brain
The major limitation of human studies is the lack of prospective data as 
patients undergoing diagnosis for the very first time have usually suffered a 
seizure already. Hence, brain condition before the ictal event is actually 
unknown. Experimental models of SE as well as epileptogenesis, resembling 
human pathology, are therefore important for elucidating basic mechanisms. In 
particular, animal models of SE are well known to be associated with an age- 
dependent onset of neuronal injury, hence making prospective studies possible.
As in humans, investigations exploiting experimental models have 
focused on evaluating structural and functional alterations.
Anatomical consequences of SE
A pattern of neurodegeneration resembling human MTS occurs in adult 
rats treated with kainic acid (KA) and pilocarpine or undergoing continuous 
electrical stimulation of the hippocampus or the amygdala in order to trigger a 
SE originating from limbic structures. Thus, neuronal loss appears in CA1, CA3 
and hilus of DG, with neurodegeneration involving extrahippocampal areas as 
well (Ben-Ari, 1985; Turski et al., 1986; Sloviter, 1994; Nadler, 1981). The 
extent of damage is positively correlated with SE duration and cell death can be 
detected as early as 2 h, lasting up to 2 months (Ben-Ari, 1985; Covolan et al.,
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2000), and accompanied by synaptic reorganization (Nadler, 1981; Yang et al., 
1998 (a); Haas et al., 2001).
Conversely, although immature rats are more prone to seizures and show 
a decreased threshold to epileptogenic stimuli as compared to adults (Pitkanen 
et al., 2002 (b); Cavalheiro et al., 1987), the neuronal damage affecting limbic 
structures, as well as synaptic reorganization, are absent or little expressed. 
They are usually undetectable until rats are aged > 3 weeks (Haas et al., 2001; 
Cavalheiro et al., 1987; Nehlig et al., 1996; Sperber et al., 1999; Wasterlain et 
al., 2002). However, SE early in life may prime the brain to the harmful effects of 
subsequent insults as seizure-induced brain injury in adulthood (Koh et al.,
1999).
Association ofSE with development of epilepsy
In adult rats, induction of SE by administration of KA leads to 
spontaneous seizures in 2-3 months, as it also occurs after SE induced by 
electrical stimulation (Wasterlain et al., 2002; Stafstrom et al., 1992; Gorter et 
al., 2003).
In immature rats, spontaneous seizures subsequent to KA-induced SE do 
not occur until animals are aged > 3 weeks, and seldom occur in lithium- 
pilocarpine model of SE (Wasterlain et al., 2002). At postnatal (PN) 21 it was 
shown that spontaneous seizures can occur in 10-73% of immature animals as 
compared to 100% of adults (Wasterlain et al., 2002 ; Stafstrom et al., 1992 ; 
Rochet al., 2002).
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Anatomical consequences of febrile SE and the development of epilepsy
A peculiar pattern of neuronal damage affects immature rats undergoing 
hyperthermia-induced seizures, a model of febrile seizures in humans. 
Hippocampus and amygdala show acute neuronal damage which appears to be 
transient as no long-term decrease of neuronal number or neurogenesis is 
detectable. However, the density of mossy fibres increases in adulthood as well 
as the likelihood of seizures (Baram et al., 2002; Bender et al., 2003).
Brief seizures and seizure-induced damage
In the kindling model of epileptogenesis in adult rats, it was shown that a 
single electrical stimulation of the hippocampus (resulting in a long-lasting 
electrographical afterdischarge without behavioural seizures) slightly increases 
apoptosis in the DG (Bengzon et al., 1997). Repeated seizures cause 
cumulative damage in adult affecting the hippocampus and accompanied by 
synaptic reorganization, shown exploiting experimental models in which brief 
single seizures where induced by pentylenetetrazole, electroshock and kindling 
(Haas et al., 2001; Pitkanen et al., 2002 (a); Bengzon et al., 1997; McCabe et 
al., 2001; Lukoyanov et al., 2004).
In immature brains, the general trend confirms that despite having more 
severe seizures, neuronal damage is often absent or mild compare to that 
observed in adult animals. This has been shown for kindling and tetanus-toxin 
induced recurrent seizures as well. It is interesting to note that in both these 
models susceptibility to seizures persists in adulthood despite the lack of any
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detectable neuronal loss in immature brains (Haas et al., 2001; Lee et al.,
2001).
Similar observations were made also for recurrent neonatal seizures 
(Holmes et al., 2002) while brief hyperthermic seizures in early life may or may 
not increase seizure susceptibility in adulthood (Chang et al., 2003; 
McCaughran et al., 1982).
Overall, the available data converge to point out that seizure-induced 
injury is age-dependent and the most convincing evidence comes from animals 
studies as data collected from human beings are retrospective, thus making the 
discerning of seizure-induced pathology from the cause of the seizure difficult. 
Experimental studies strongly suggest that although immature brains are highly 
prone to develop seizures and SE, they are more resistant to seizure and SE- 
induced damage than adult brains, in particular as concerns the development of 
a neurodegenerative pattern as MTS.
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1.3.3 Current hypothesis for the resistance of the immature 
brain to SE-induced changes
The mechanisms underlying the decreased vulnerability of immature 
brain to seizure-induced neuronal death remain unknown. Some hypothesis 
have been proposed, supported by experimental evidence.
Overall, the leading hypothesis towards all experimental investigations 
have been related to a reduced sensitivity of the immature brain to excitotoxic 
damage. Indeed, both immature and adult animals release equivalent amount of 
glutamate following SE (Liu et al., 1997), therefore, any plausible hypothesis 
should contemplate a different ability of immature brain to manage the toxic load 
carried by excessive glutamate release (excitotoxicity) such as the huge 
increase of Ca+2 influx.
An early investigation (Friedman et al., 1997) was aimed to evaluate the 
expression, in terms of both mRNAs and protein levels, of three subunits 
involved as assembling monomers in the ionotropic receptors for AMPA, namely 
GLUR1, GLUR2 in particular and GLUR3 .
The presence of subunit GLUR2 confers the heteromeric AMPA receptor with 
impermeability to Ca+2 influx and it is known that most of the principal neurons 
of the adult hippocampus contain this subunit in their AMPA receptors, thus 
making them Ca+2 impermeable. In adult rats, SE has been shown to reduce the 
expression of GLUR2 mRNA in CA3 pyramidal neurons at times preceding 
significant cell loss (Pollard et al., 1993; Friedman et al., 1994 (b)), thus 
suggesting that a decrease of GLUR2 expression yields to an increased 
formation of Ca+2 permeable AMPA receptors in CA3 neurons and possibly
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contribute to the delayed hippocampal neuronal cell loss following kainate- 
induced seizures.
The hypothetical age-dependent effect of SE on GLUR2 as well as 
GLUR1 and GLUR3 was tested by triggering SE in PN5 and PN14 rats, then 
comparing results with those obtained in adult rats following KA administration 
(Friedman et al., 1997). In the same experimental session the authors also 
investigated the expression of mRNAs of NMDA receptor (NMDAR1) and a1- 
subunit of GABAa receptor.
In PN5 animals, no significant changes in glutamate or GABAa receptor 
mRNA was detected in CA1, CA3 and DG at 24 h after the induction of SE, 
whereas a marked increase of GLUR1 and GLUR2 mRNAs were shown to 
occur in DG, but not in the other hippocampal subfields, in PN 14 rats. However, 
these changes in mRNA expression were transient, then approaching the 
respective basal level in about 1 week. Protein levels of AMPA receptor subunit 
where measured by immunohistochemistry in PN 14 rats, i.e. in the age-group 
where mRNA expressions were shown to be increased after SE. No detectable 
changes for any subunit studied were shown in CA3 subfield at 24 and 48 h 
after induction of seizures. Also the DG did not show any increased level for all 
subunits studied. Therefore, despite the transient higher level of expression of 
GLUR1 and GLUR2 mRNAs induced by SE, corresponding protein levels were 
not affected. Thus, conversely to reports from adult animals where KA-induced 
SE was shown to significantly decrease both mRNA and protein level of GLUR2 
in the vulnerable CA3 hippocampal subfield, in young rats aged PN 5 and PN 14 
levels of expression of both mRNA and respective GLUR2 protein are still 
sustained and preserved after SE in CA3, hence giving support to the
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hypothesis that CA3 pyramidal cell resistance to neurodegeneration in young 
animals might be due to a diffuse presence of GLUR2 subunit among the 
monomers making up AMPA receptors. Also in DG, the unaltered expression of 
protein GLUR2 is in accordance with the resistance of this hippocampal subfield 
to neuronal cell loss in pups and, also, in adults since it was shown that SE 
induces a prolonged enhancement of GLUR2 mRNA expression in DG thus 
supporting the potential protective role of this subunit to neurodegeneration in 
this age-group as well (Friedman et al., 1994 (a)). The authors also paid 
attention to age-dependent effect of SE on GABAergic system since GABA 
represents the major inhibitory neurotransmitter in the CNS, hence, it is of 
particular relevance to counteract the excess of excitation occurring during 
seizures. Thus, the observation of unchanged levels of mRNA expression of 
a1-subunit of GABAa receptor in PN 5 and PN 14 rats after KA-induced SE 
(Friedman et al., 1997), has prompted the authors to hypothesize that the 
sustained expression of this subunit may contribute to reduce the vulnerability of 
developing CA3 neurons to seizure-induced damage. To support this, in adult 
animals SE was shown to decrease the mRNA expression in the same subfield 
at times preceding the occurrence of neuronal cell loss (Friedman et al., 1994 
(a)). However, immunohistochemistry for a1-subunit was not performed.
More recently, the electrophysiological properties and the subunit 
composition of GABAa receptors localized on GCs in PN 10 rats that underwent 
lithium-pilocarpine administration have been investigated (Zhang et al., 2004) 
thus attempting to integrate the early results reported by Friedman et al, 
described above. In this study it was shown that unlike rats experiencing SE as 
adults, PN 10 rats present alterations affecting GABA receptors that are much
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less pronounced and in the opposite direction compared to those seen in the 
adult rats. In particular, the mRNA expression of the a1-subunit was shown to 
be increased two-fold compared to control. This was the only change detected 
in pups by this group of investigators concerning the effect of SE on subunit 
mRNA expression. This result is somewhat different from that reported by 
Friedman and colleagues, where no change in mRNA expression of a1-subunit 
was detected. In contrast, this study confirmed that in adult animals SE 
decreases a1-subunit expression, whereas significantly increases subunits a4 
and 5. Electrophysiological investigation revealed that the application of type I 
benzodiazepine agonist, such as zolpidem, elicited a higher level of GABA- 
induced current. As GABA receptors made of at least one a1-subunit are known 
to be more sensitive to type I benzodiazepine agonist and since a1 was the only 
subunit to show a significant increase in relative expression after SE induced in 
PN 10 rats, it appears that the greater zolpidem augmentation of GABA currents 
in GCs in young animals most likely reflects an increased number of a1 
containing GABAa receptors on the membrane of these cells, hence a 
subsequent increase of inhibitory current on GCs following SE.
The effect of SE on GABAergic system was also investigated by 
determining the rate of synthesis of GABA at different ages. The rate of 
synthesis of GABA in immature rat hippocampus increases during normal 
development. During SE induced by lithium-pilocarpine administration, the rate 
of GABA-synthesis was shown to be significantly lower as compared to control 
rats, in all age-groups ranging from 1 to 4 weeks (Sankar et al., 1997). This 
trend was also observed in adult rats (Wasterlain et al., 1993), together with a 
consistent reduction (40-45%) in GABA release from slices collected from rats
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undergoing KA-induced SE (Arias et al., 1990). The ratio expressed as a 
percentage of GABA synthesis during SE to that under basal conditions was 
taken as a measure of the capability of the hippocampus to maintain GABA 
synthesis under conditions of metabolic stress. Thus, in the hippocampus of 1- 
week-old rats, the GABA synthesis rate was shown to have declined from 74.5 
% to 44.1 % in 4-week-old animals (Sankar et al., 1997). Since the basal rate of 
GABA synthesis increases with maturation, it appears that only a progressively 
smaller fraction of the basal rate can be maintained in the face of SE, 
suggesting a relative collapse in inhibition. The authors speculated that the 
resistance of immature hippocampus to SE-induced neuronal cell death as well 
as to mossy fibre sprouting may be related to the capability of the developing 
hippocampus to maintain high levels of GABA in the face of SE compared to 
basal levels.
Thus, although with slightly different results, all data reviewed so far 
converge onto a persistent functionality of the GABAergic system in pups with 
no corresponding system in adults.
Other hypothetical mechanisms that might account for the resistance of 
immature brain to SE-induced neurodegeneration focus on mitochondrial 
functionality.
Linked to intense neuronal excitation is the production of reactive oxygen 
species (ROS) in mitochondria that may lead to insurgence of oxidative stress. 
Oxidative stress is defined as an imbalance into which production of ROS 
overwhelm endogenous antioxidant defences and repair. An important mediator 
of oxidative stress is the superoxide radical 0 2 “ which is known to both directly 
oxidise minor cellular targets and, most importantly, constitute the precursor of
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much more powerful reactive species such as hydroxyl radicals OH- and 
peroxynitrite ONOO'. The intracellular concentration of O2" is usually kept at a 
constant level by superoxide dismutases (SODs) which are located in the 
cytoplasm, mitochondria and extracellular compartment. These enzymes 
catalyze the conversion of 0 2" into H20 2 and 0 2 at a rate which approaches the 
diffusion limit.
It has been shown that in adult rats the production of mitochondrial 
superoxide radical increases following KA-induced seizures, at times preceding 
the death of vulnerable neurons affected in the subsequent hippocampal 
damage. Moreover, scavenging of 0 2' by endogenous or synthetic antioxidants 
was shown to protect against seizure-induced neuronal damage (Liang et al., 
2000).
The hypothesis of age-dependent oxidative mechanisms as a possible 
explanation for the resistance of immature brain to seizure-induced neuronal 
damage was tested in rats at different ages (PN 12, 21, 30, 45 and 60) by 
assays aimed at evaluating the degree of aconitase inactivation and 8-hydroxy- 
2-deoxyguanosine (8-OHdG) concentration as compared to 2-deoxyguanine, as 
markers of mitochondrial oxidative stress and oxidative DNA damage 
respectively. Results obtained are in support of age-dependent oxidative 
damage induced by seizures triggered by KA administration. Thus, immature 
animals (PN 12-21) did not show an increase of mitochondrial aconitase 
inactivation or 8-OHdG, suggesting that both levels of 0 2‘ and the amount of 
oxidative DNA damage did not increase following SE. These animals did not 
show hippocampal cell loss. Conversely, adult rats (PN 30-60) were shown with 
a significantly increase of aconitase inactivation and a significantly higher
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concentration of 8-OHdG at times preceding hippocampal neuronal loss (Patel 
et al., 2003). The investigators also showed that the lack of oxidative stress in 
immature brains was not due to increased levels of either mitochondrial and 
cytoplasmatic SOD, which were shown to be comparable to those detected in 
control animals in all age-groups. Among hypothesised mechanisms that could 
account for a reduced oxidative stress in immature rats as compared to adults, 
an intrinsically lower production of 0 2‘ by itself or as a consequence of immature 
neurotransmitter/receptor systems in the developing brain have been proposed.
The lack of a significant increase of ROS production and mitochondrial 
dysfunctions following KA-induced seizures in neonatal rat brains compared to 
adults was also confirmed by another group of investigators (Sullivan et al., 
2003) and associated to mitochondrial uncoupling protein-2 (UCP-2) expression 
that was shown to be significantly higher in neuronal mitochondria of immature 
hippocampus. Uncoupling proteins (UCPs) are members of the superfamily of 
mitochondrial carriers which transport small molecules across the inner 
mitochondrial membrane. In particular, these proteins were shown to dissipate 
the mitochondrial proton gradient by transporting protons across the inner 
membrane, thereby uncoupling electron transport from ATP production that 
become dissociated from oxygen consumption. One of the main consequences 
of UCPs activity is a reduced production of ROS. Hence, it is conceivable that 
resistance of limbic neurons of immature rat to seizure-induced cell death may 
due, at least, to partial uncoupling of mitochondria in these neurons as a result 
of the high levels of UCP-2 expression. Researchers showed the UCP-2 
function and uncoupling capacity of neuronal mitochondria from immature rat 
brain (PN 10) are significantly greater than in mitochondria from limbic neurons
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of the adult. In particular, UCP-2 immunoreactivity in immature brain appears to 
be more pronounced in neurons located in hippocampal areas which are known 
to be sensitive to seizure-induced neuronal injury in adults, such as CA3. As a 
possible explanation for the role of UCP-2 in counteracting excitotoxicity, an 
overall picture depicts UCPs to dissipate mitochondrial membrane potential with 
subsequent decrease of ROS production as well as decrease of mitochondrial 
uptake of Ca2+ that was shown to be associated with glutamate-induced neuron 
death (Stout et al., 1998). Indeed, these two steps are interlinked since, usually, 
mitochondrial dysfunction due to Ca2+ overload is known to lead to ROS 
production, hence UCP-2 may reduce ROS formation also by limiting 
mitochondrial Ca2+ concentration.
Finally, interesting results come from the evaluation of brain-derived 
neurotrophic factor (BDNF) as a possible candidate involved in neuroprotection 
of immature brain with respect to SE-induced neuronal damage. BDNF is the 
most abundant and widely expressed neurotrophin in the brain, involved in 
neuronal growth, differentiation and survival of neurons in both the developing 
and the adult brain (Schmidt-Kastner et al., 1996). BDNF has been shown to be 
protective against hypoxic-ischemic injury in neonatal brain (Cheng et al., 1997) 
and seizures are known to increase BDNF mRNA in both the adult and the 
immature brain (Dugich-Djordjevic et al., 1992; Kornblum et al., 1997). 
Moreover, regulation of BDNF expression and release from hippocampal 
neurons is known to be mediated by non-NMDA glutamate receptors (Wetmore 
et al., 1994) thus further showing that seizures not only lead to excitotoxicity and 
neuronal loss but also elicit trophic responses in neurons. Using PN 20 rats 
injected with KA as an animal model of SE, it was shown that blockade of the
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increased expression of BDNF elicited by KA-induced seizures resulted in a 
long-lasting SE and loss of protection from neuronal damage. Control animals, 
whose BDNF production was not impaired, did not show any evidence of cell 
loss and alteration of SE duration (Tandon et al., 1999), thus supporting the 
hypothesis that BDNF may protect neurons of immature brain from seizure- 
induced excitotoxicity.
In summary, although all proposed mechanisms seem to be fairly robust, 
evidence so far collected can not be allowed to infer any general mechanism 
accounting for resistance of immature brain to seizure-induced 
neurodegeneration, which actually appear to be a multifactorial phenomenon.
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1.4 Inflammation and epilepsy
As has been shown in other neurodegenerative disorders such as 
Alzheimer’s disease, Parkinson’s disease, Hungtington’s disease, multiple 
sclerosis and amyotrophic lateral sclerosis, specific histopathological 
evaluations of brain specimens of epilepsy sufferers have made it possible to 
observe that also some epileptic encephalopathies and febrile seizures in 
children as well as epilepsy in adults share common features directly related to 
immune/inflammatory reactions, in particular mediated by proinflammatory 
cytokines and related molecules which have been described in brain after 
seizures in clinical cases and in experimental models of epilepsy.
Little is known about the role of inflammation in epilepsy. It has been 
hypothesized that activation of the innate immune system, and associated 
inflammatory reactions in brain, may mediate some of the molecular and 
structural changes occurring during and after seizure activity. Indeed, as for 
other mechanisms, two issues have been raised as to i) whether these 
proinflammatory signals represent a mere epiphenomenon or ii) if they are 
significantly involved in the etiopathogenesis of seizures and possibly contribute 
to epileptogenesis.
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1.4.1 Evaluation of proinflammatory cytokines in
association with epilepsy in humans
In adults, levels of immunoreactive IL-1a were found to be elevated in 
surgically resected human temporal lobe tissue from patients with intractable 
epilepsy as compared to post-mortem tissue from neurologically unaffected 
subjects (Sheng et al., 1994). Quantitative evaluation of IL-1a -immunoreactive 
cells revealed a threefold increase of these cells in epileptic than in control 
tissue, also showing that these cells had the morphological features of activated 
microglia.
In cortical specimens from patients affected by focal cortical dysplasia 
and glioneuronal tumors (both pathologies being recognized as causes of 
chronic intractable epilepsy) IL-1(3 and its signalling receptor IL-1RI were shown 
to be highly expressed by more than 30% of neurons and glia whereas the 
decoy receptor IL-1RII and IL-1Ra were expressed to a lesser extent by 
approximately 10% and 20% of cells, respectively. Moreover, the number of IL- 
1P- and IL-1RI-positive neurons was positively correlated with the frequency of 
seizures, whereas the number of IL-1Ra-positive neurons and astroglial cells 
was negatively correlated with the duration of epilepsy (Ravizza et al., 2006).
Inflammatory reactions in MTLE with HS have also been reported by 
measuring increased expression of NF-kB both in reactive astrocytes and in 
surviving hippocampal neurons (Crespel et al., 2002).
The aforementioned results actually suggest that in HS inflammatory 
processes that might be chronically active or transiently re-induced by recurrent 
seizures, or both, can take place.
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Recent genetic studies have shown that a polymorphism in the promoter 
region at position -511 of the IL-1(3 gene is associated with therapy resistant 
epilepsy in subjects affected by MTLE with HS and in children with febrile 
seizures (Kanemoto et al., 2000; Virta et al., 2001). This polymorphism when 
present in homozygotes appears to be associated with an overexpression of 
cytokine production upon stimulation. Thus, minor events during development 
such as febrile convulsions could set up in these subjects a cascade of 
proinflammatory events leading to HS. However, several studies did not confirm 
the evidence reported by Kanemoto and Virta (Heils et al., 2000; Buono et al., 
2001; Jin et al., 2003; Tilgen et al., 2002). This apparent discrepancy may be 
due to specific ethnicity (Heils et al., 2000) or the existence of methodological 
bias (Tan et al., 2004).
Interesting results were reported by studies aimed to evaluate 
proinflammatory molecules in the CSF and serum of epileptic patients.
IL-6 is the cytokine consistently found to be significantly enhanced in 
plasma and CSF of epilepsy sufferers with recent tonic-clonic seizures. 
Contrasting results are reported for IL-1 |B in CSF where either no increase or 
significant elevation was measured. Analysis of peripheral blood mononuclear 
cells highlighted in some but not all (Hulkkonen et al., 2004) instances an 
enhanced ability of these cells to produce inflammatory molecules and express 
markers of inflammation when harvested from epileptic patients, or children with 
recent febrile seizures (Pacifici et al., 1995; Helminen et al., 1990). Therefore, 
these data are compatible with an inflammatory state in the epileptic brain and 
perhaps in peripheral monocytes from epileptic patients.
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Increased serum or brain levels of proinflammatory cytokines and 
markers of immune system activation have been described in patients with West 
syndrome (Liu et al., 2001) and tuberous sclerosis (Maldonado et al., 2003). In 
particular, expression of molecules involved in cytokine signalling (ICAM-1 and 
NF-kB) and TNF-a, have been found in dysplastic neurons and giant cells in 
tubers. This observation leads to the hypothesis that initiation of an 
inflammatory response in tubers may be directly related to epileptogenesis in 
these lesions.
Finally, one of the best indication of an involvement of inflammatory and 
immune reactions in the pathogenesis of human CNS disorders associated with 
epilepsy comes from studies on Rasmussen’s encephalitis. Neuropathological 
examinations of affected brain tissue revealed both perivascular lymphocytes 
and scattered microglia nodules in close proximity with neurons. In addition, a 
huge increase in the expression of several inflammatory-related genes (i.e. IL- 
1P and TNF-a) was described in brain specimens from a patient affected by 
Rasmussen’s encephalitis and active seizures (Baranzini et al., 2002).
Table 4 describes Inflammatory markers in human epilepsies and 
convulsive disorders. Pharmacological treatment in clinical practice is also 
indicated.
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1.4.2 Evaluation of proinflammatory cytokines in
experimental models of epilepsy
Seizure activity induced in experimental models of SE has been reported 
to rapidly increase the production of proinflammatory cytokines, as well as 
various markers of the innate immunity (i.e. NF-kB system, prostaglandins and 
their pathway enzymes, Toll-like receptors, monocytes chemoattractant protein- 
1, complement system) both in glia and in neurons (Jankowsky and Patterson, 
2001; Peltola et al., 2001). The increase is rapid (< 30 min) and reversible after 
SE in rats developing spontaneous seizures, with the exception of IL-1 p which is 
still upregulated in brain 60 days after induction of SE (De Simoni et al., 2000). 
Cytokines were shown to specifically increase in brain regions involved in 
seizure onset and spread (De Simoni et al., 2000; Minami et al., 1991; Oprica et 
al., 2003). Evidence of increased production of inflammatory molecules in brain 
has also been reported in genetic models of audiogenic seizures and in kindling 
(Gahring et al., 1997; Plata-Salaman et al., 1992).
Microglia and astrocytes are the first cells producing cytokines during 
seizures and, in general, they represent the main sources of proinflammatory 
molecules in brain. However, cytokine receptors are localized both in glia and 
neurons in normal brain. This suggests that proinflammatory cytokines are 
soluble mediators which may establish functional communication among 
microglia, astrocytes and neurons (Ban et al., 1991; Benveniste, 1992; De 
Simoni et al., 1998). In this respect, electrophysiological findings support a 
neuromodulatory role of glia-born cytokines showing that these molecules affect
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ionic conductances in neurons, and synaptic plasticity (i.e. LTP) (Zeise et al., 
1997; Wang et al., 2000; Kelly et al., 2003).
So far, it appears that proinflammatory molecules and their signalling 
pathways are similarly activated by systemic infections and seizures. Indeed, 
there are clear differences in the duration of these events and in the cell specific 
distribution of these changes.
The inflammatory response observed following pilocarpine-induced 
seizures in mice is different in many aspects from that described after systemic 
injections of bacterial LPS (Rivest, 2003; Turrin and Rivest, 2004 (a)). Thus, 
proinflammatory molecules are predominantly and firstly expressed after 
endotoxemia in circumventricular organs, the choroid plexus, the leptomeninges 
and along brain microvessels; the involvement of parenchymal microglia is 
delayed and more restricted. Neurons do not typically express inflammatory 
markers after endotoxemia. On the other hand, seizures induce a massive 
inflammatory response in parenchymal cells involving both microglia and 
neurons (i.e. NF-kB and COX-2 are significantly expressed by neurons after 
seizures but not after LPS). Moreover, changes induced by endotoxemia are 
relatively short-lasting when compared to those observed after seizures. These 
observations suggest that inflammation induced by seizures results from 
complex neurophysiological events specific to brain tissue which differ in their 
duration, and in the cell populations involved, from classical immune reactions 
triggered by bacterial/viral infections.
The lasting stimulation of the innate immune response and related 
inflammatory reactions observed after seizures may eventually promote 
infiltration of lymphocytes and the establishment of acquired immunity in the
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CNS. Although there is indication of a late wave of CD-45 positive monocyte 
penetration into the brain parenchyma after seizures, Turrin and Rivest (Turrin 
and Rivest, 2004 (a)) recently reported that markers of adaptive immunity, such 
as production of IL-12 and IFN-y by activated T-cells, are undetectable across 
the brain of pilocarpine-treated mice, at least up to 72 h after seizure induction. 
Accordingly, immunostaining for T-cells, B-cells and NK-cells was negative in 
the brain of KA treated rats 8-72h after seizure induction, although granulocytes, 
macrophages/monocytes and microglia cells were all detected (Dinkel et al., 
2003). Thus, the innate immune response in experimental models of seizures 
does not appear to be associated with adaptive immune and B- or T-cells 
infiltration and differentiation with a restricted time window after induction of 
seizures.
The evidence that seizures can trigger lasting inflammatory reactions 
opened the additional question as to whether a protracted inflammatory state in 
CNS may enhance the predisposition of brain tissue to develop seizures and 
brain damage.
Using models of hippocampal seizures or SE in rodents, it has been 
shown that the IL-1 p system significantly exacerbates seizure activity. Thus, 
pre-administration of this cytokine using concentrations in the range of those 
endogenously produced during seizures, prolongs the duration of electrographic 
and behavioural kainate-induced seizures (Vezzani et al., 1999). Subsequent 
studies have shown that the intracerebral administration of IL-1 ra, a naturally 
occurring molecule which antagonizes the effect of endogenous IL-1 p, has 
powerful anticonvulsant activity (Vezzani et al., 2002). Accordingly, IL-1 ra 
overexpressing mice display a reduced susceptibility to seizures (Vezzani et al.,
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2000). These findings suggest that an endogenous rise in IL-1 (3 levels has 
proconvulsant effects. It appears that IL-1 (3 prolongs seizures by increasing 
glutamatergic neurotransmission (Vezzani et al., 1999). In this respect, 
functional interactions at the molecular level have been reported between IL-1 p 
and N-Methyl-D-Aspartate (NMDA) receptors which are co-expressed by 
hippocampal neurons (Viviani et al., 2003). Other actions may account for the 
excitatory effect of this cytokine: IL-1 p can inhibit glutamate uptake by 
astrocytes (Ye et al., 1996) and decreases the peak magnitude of GABA- 
mediated currents in cultured hippocampal neurons (Zeise et al., 1997; Wang et 
al., 2000).
On the other hand, the effect of TNF-a on seizures is still controversial. 
Data obtained using in vivo pharmacological approaches in wild-type and TNF-a 
knock-out mice, showed that TNF-a reduces seizure activity by interacting with 
TNF-a type II (p75) receptors (Balosso et al., 2005). Mice overexpressing TNF-a 
in glia show a decreased sensitivity to kainate-induced seizures (Balosso et al., 
2005). However, seizures and brain damage in a rat model of bacterial 
meningitis were attenuated by large spectrum inhibitors of both matrix 
metalloproteinases and TNF-a converting enzyme, which reduce the soluble 
form of TNF-a (Meli et al., 2004). These apparent discrepancies can be 
reconciled by taking into account either differences in TNF-a concentrations or 
the receptor subtypes predominantly involved in the various experimental 
models. In accordance with this view, relatively high concentrations of TNF-a 
exert suppressive effects on Shigella dysenteriae-induced seizures while lower 
concentrations were proconvulsive (Yuhas et al., 2003).
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Table 5 summarizes the inflammatory markers occurring in experimental 
models of seizures and the effect of anti-inflammatory pharmacological 
treatment on seizure susceptibility.
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Table 5. Inflammation in experimental models of seizures
Exp Models Inflammatory markers
Pharmacological Treatments 
Anticonvulsant Proccnvulsant
*Kaiatc acM Cytokine and their receptors Lew corticostcron - High corticortcton
*
’’Bicuculline Signaling pathways TNF-dpha/p75 receptor IL-lbeta
Pilocarpine (NFkB; F38MAPK) IL-1 Ra COX-1/2 inhibitors
COX-2, mPGES Aspirin (10 mg/kg)
Adhesion molecules Caspase-1 inhibitor
Chcmokines Pheniddne
Aspirin (<15 mg/kg’d
lipoxygenase mhibitcr
Hyperthermia IL-ibeta IL-lRa IL-lbeta
Infection IL-lbeta,TNFalpha IL-lbeta, TNP-alpha
Penicillin n.d Nonsteroidal
MES n.d
anti-inflammatory dn 
Aspirin
JgS
PTZ n.d (100-500 mg/kg) COX-1/2 inhibitors
Paracetamol
Audiogenic sei mres IL-i alpha
Rodent Kindling Cytokine and their Receptors IL-1 beta
Cat Kindling n.d Immunoglobulin
*Refers to pharmacological experiments carried out in rats 
intracerebrally or systemically injected with kainic acid, or 
intracerebrally injected with bicuculline methiodide (for IL-1 beta and 
IL-1Ra only).
MES, maximal electroshock test; PTZ, pentylenetetrazol; mPGES, 
membrane/microsomal prostaglandin E synthase.
After hyperthermia or infection the cytokines were measured in 
plasma only; n.d., not determined.
Adapted from Vezzani and Granata, 2005
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Seizure susceptibility was also assessed in transgenic mice 
overexpressing IL-6 in glia, showing that they have a profound increase in 
sensitivity to glutamatergic (but not cholinergic) agonists (Samland et al., 2003). 
Interestingly, IL-6 overexpressing mice showed neuronal loss of GABA- and 
parvalbumin-positive neurons in the hippocampus.
In different studies, TNF-a and IL-6 transgenic mice develop 
neurodegenerative changes and behavioural seizures in an age-dependent 
manner when overexpressing these cytokines in glia, but not in neurons 
(Campbell et al., 1993; Akassoglou et al., 1997). These studies with transgenic 
mice suggest that a pre-existing chronic proinflammatory state in the brain can 
predispose to seizures and promote neurological dysfunctions. Accordingly, 
systemic administration of LPS to mice was reported to decrease their threshold 
to pentylenetetrazole-induced seizures. This effect was blocked by anti­
inflammatory drugs (Sayyah et al., 2003). Finally, sequential infusion of 
individual proteins of the membrane attack pathway (MAC) of the complement 
system into the rat hippocampus induced both behavioural and electrographic 
seizures as well as cytotoxicity (Zhi-Qi et al., 2003). This implies that deposition 
of the complement MAC in brain tissue may contribute to epileptic seizures and 
cell death in diverse CNS diseases (i.e. Rasmussen’s encephalitis).
Experimental models have also been exploited in order to evaluate the 
effects of anti-inflammatory drugs on seizures.
Various pharmacological studies reported inhibition of seizures using 
nonsteroidal anti-inflammatory drugs. An early report shows attenuation of 
penicillin induced electrocorticographic and motor seizures in rats using 
ibuprofen, paracetamol and indomethacin (Wallenstein, 1987). Aspirin was also
91
reported to protect mice from MES and pentylenetetrazole-induced seizures and 
to potentiate the anticonvulsant action of diazepam and sodium valproate 
(Srivastava et al., 2001).
Interestingly, both sodium valproate and carbamazepine inhibit the 
production of inflammatory mediators in vitro. In particular, among the 
commonly used AEDs, sodium valproate inhibits LPS-induced activation of NF- 
kB as well as the production of TNF-a and IL-6 in monocytes and glioma cells; 
carbamazepine was shown to decrease LPS-induced production of 
prostaglandins and activity of phospholipase A in rat glial cells (Ichiyama et al., 
2000; Matoh et al., 2000). Conflicting data are available on the effect of 
prostaglandins on seizures. Several studies have demonstrated increased 
synthesis of cerebral prostaglandins following convulsions; however, it appears 
that they can either reduce or promote seizures depending on the type of 
prostaglandins produced. For instance, it was shown that tacrine-induced 
seizures in rats, and the consequent hippocampal damage, can be abolished by 
inhibiting PGE2 production using COX-2 inhibitors (Paoletti et al., 1998). 
Similarly, a cyclooxygenase/lipoxigenase inhibitor protected from irreversible 
brain lesions and reduced the severity of seizures induced by KA in rats (Baran 
et al., 1994).
The possible relationship between inflammation and seizure-induced 
long-term sequelae has also been investigated. Inflammatory processes have 
been implicated in both acute and chronic neurodegenerative conditions. 
Accumulating evidence has shown that brain injury per se in the absence of 
seizure activity is accompanied by a marked inflammatory reaction 
characterized by increased expression of various proinflammatory molecules,
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activation of microglia and infiltration of monocytes/macrophages (Allan and 
Rothwell, 2001). However, in the presence of seizures triggered by damage to 
brain structures, it is difficult to distinguish between the cytokine response to 
injury and seizures that might contribute to cell death.
When administered individually, cytokines tend not to induce cell death 
directly, but rather to have synergistic effects with other molecules that can 
result in neurotoxicity (e.g. IL-1 plus TNF-a). Intracerebral injections of TNF-a or 
IL-1 exacerbate excitotoxic injury in vivo while IL-1 ra reduces excitotoxic, 
traumatic and ischemic brain damage (Allan et al., 2005). An involvement of 
cytokines in apoptotic mechanisms has also been shown (Allan and Rothwell, 
2001). A study by Dinkel (Dinkel et al., 2003), shows that the extent of damage 
in the hippocampus after an excitotoxic insult correlates significantly with the 
antecedent inflammatory cell infiltration (granulocytes and macrophages) and 
activation of microglia. This study supports the hypothesis that neuronal 
damage is, at least in part, caused by a preceding state of inflammation. 
Cytokines can also have neurotrophic actions on neurons, possibly mediated by 
an increase in the production of neurotrophins (Jankowsky and Patterson, 2001; 
Spranger et al., 1990). Glia, in particular astrocytes, are a principal source of 
neurotrophins and growth factors which are induced by cytokines and exert 
neuroprotective actions.
Other actions of cytokines which may be relevant for epilepsy are their 
reported effects on brain microvasculature (IL-1 can induce neovascularization) 
and damage to the blood-brain barrier (BBB) leading to its increased 
permeability to normally excluded substances and cells (i.e. up regulation of cell
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adhesion molecules such as ICAM-1 and e-selectin in endothelial cells are 
involved in leucocytes infiltration).
As regards neurogenesis, an inhibitory action of inflammatory molecules 
such as IL-6 has been reported (Monje et al., 2003). In particular, 
neuroinflammation induced by radiation injury or by LPS inhibits neurogenesis 
while inflammation blockade with indomethacin or inhibition of microglia 
activation by minocycline, restore neurogenesis (Monje et al., 2003; Ekdahl et 
al., 2003).
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1.4.3 Involvement of proinflammatory cytokines in CNS
injury and neurodegenerative diseases
Cytokines are a heterogeneous and complex group of polypeptide 
mediators which act as communication signals among cells of the immune 
system as well as among other cells and tissues in the body. Cytokines include 
interleukins, interferons, tumor necrosis factor and chemokines, and their 
production as well as that of related receptors are well documented among 
neuronal and glial cells within the CNS. Generally, glial and endothelial cells 
produce TNF-a, IL-1 and IL-6 (Riccardi-Castagnoli et al., 1990; Fabry et al., 
1993; Sebire et al., 1993), whereas in neurons the expression of these 
cytokines is hardly detectable in normal brain.
However, astrocytes and microglia represent the main source of cytokine 
production and each of them express receptors for almost any cytokine. 
Proinflammatory cytokines are known to exert central effects such as fever, 
sleepiness, anorexia, activation of the hypothalamic-pituitary-adrenal axis, and 
to trigger and sustain the machinery of innate immunity. It is important to note 
that the inflammatory response is not confined to pathogenic infection but also 
occurs as a consequence of brain injuries, and in both acute and chronic 
neurodegenerative conditions. Indeed, among proinflammatory cytokines, IL-1 p 
and TNF-a appear to be particularly relevant to several CNS disorder, since 
their levels of mRNA, protein or both, are increased in these conditions in both 
animals and humans.Thus, experimental models of global and focal ischemia 
have shown an increase of both mRNA transcription and level of protein for both 
IL-1 p and TNF-a in cerebral areas particularly vulnerable to this kind of insult
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such as hippocampus, striatum ad cortex (Minami et al., 1992; Orzylowska et 
al., 1999; Buttini et al., 1994; Saito et al., 1996; Liu et al., 1994). These changes 
occur in both the core and the penumbral regions within a few minutes of the 
insult, can peak in a few hours, and the overexpression may last for several 
days.
Proinflammatory cytokines are elevated in terms of both mRNA and 
protein expression in experimental models of traumatic CNS injury. For 
instance, IL-1 p protein levels are increased in the rat hippocampus following 
transection of the perforant pathway (Fagan and Gage, 1990), and in the CNS 
parenchyma after a stab wound injury (Fan et al., 1995; Herx et al., 2000; 
Rostworowski et al., 1997). Similarly TNF-a mRNA and protein levels increase 
rapidly in the rat brain after traumatic brain injury. (Fan et al., 1996 ; Shohami et 
al., 1997; Taupin et al., 1993). TNF-a mRNA and protein levels also increase in 
several brain structures in mice receiving a stab or surgical injury (Tchelingerian 
et al., 1993; Tchelingerian et al., 1994).
Considerable data is available concerning proinflammatory cytokine 
levels in patients affected by neurological diseases. Inflammatory processes 
have been shown to occur in the CNS of sufferers of Alzheimer’s disease, 
Parkinson’s disease, Huntington’s chorea, multiple sclerosis and amyotrophic 
lateral sclerosis, as confirmed by elevated levels of IL-1 p, TNF-a and IL-6 in the 
serum and cerebrospinal fluid of these patients (Pasinetti, 1998; Gonzalez- 
Scarano et al., 1999; Julien, 2001). Increased levels of TNF-a were observed in 
plasms serum of humans after severe head injury (Goodman et al., 1990) and 
increased levels of IL-1 (3 are seen following neurotrauma (Fassbender et al.,
2000).
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The observation that inflammatory processes occur in association with 
several neurodegenerative disorders as well as together with traumatic brain 
injuries has raised the question as to whether neuroinflammation plays a 
beneficial or detrimental role, maybe directly or indirectly contributing to the 
pathology itself.
In the context of the aforementioned findings about increased levels of IL- 
1P and TNF-a in CNS injuries, it has been demonstrated that injections of IL-1 p 
in the lateral ventricle during ischemia produces an increase in the infarction 
size, whereas injections of anti-IL-1 p monoclonal antibody produces a decrease 
in post-ischemic infarction size (Stroemer and Rothwell, 1998; Yamasaki et al.,
1995). Analogous results were obtained by administration of IL-1 ra in a model of 
focal ischemia thus showing that neuronal death was decreased in the 
penumbral region and infarction size was reduced as well (Garcia et al., 1995; 
Relton and Rothwell, 1992). Similar experiments have also been done with 
TNF-a. Thus, rats undergoing focal cerebral ischemia exhibit neuronal loss 
when TNF-a is injected into the CNS (Barone et al., 1997), whereas inactivation 
of TNF-a activity by administration of either the soluble TNF-a type I receptor or 
antibody anti-TNF-a yields to a reduced ischemic brain injury (Barone et al., 
1997; Nawashiro et al., 1997; Yang et al., 1998 (b)).
Indeed, increasing evidence shows that proinflammatory cytokines can 
provoke an increase in extracellular glutamate by acting on the mechanisms of 
its release and re-uptake, as well as potentiating the function of ionotropic 
glutamate receptors and enhancing the production of mediators of oxidative 
stress (i.e. arachidonic acid and nitric oxide) (Xu et al., 2003).
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However, despite several observations showing a detrimental role of IL- 
1(3 and TNF-a in CNS injury, a number of observations support the hypothesis 
that these cytokines may also act as relevant neurotrophic mediators in the 
CNS. For example, microglia-derived IL-1 (3 can induce the synthesis of 
neurotrophic factors from astrocytes, such as nerve growth factor, ciliary 
neurotrophic factor, insulin-like growth factor which can promote repair of the 
CNS (Juric and Carman-Krzan, 2001; Mason et al., 2001). Interestingly, IL-1 (3 
was shown to induce neuronal sprouting in residual dopaminergic neurons in 
the ventral tegmental area in an animal model of Parkinson’s disease yielding to 
a functional recovery (Wang et al., 1994) as well as in rat hippocampal 
cholinergic neurons following transection of perforant pathway (Fagan and 
Gage, 1990). TNF-a was shown to be protective in rat embryonic cultures of 
hippocampal, septal and cortical neurons with respect to injury induced by 
glucose deprivation and excitatory amino acid toxicity (Cheng et al., 1994). 
Moreover, in animal models of seizure, TNF-a was shown to act as a 
neurotrophic factor thus improving neuronal survival (Jankowsky and Patterson,
2001). In vivo application of TNF-a to the injured adult rabbit optic nerve has 
been reported to produce regeneration of axons that traverse the site of injury 
(Schwartz etal., 1991).
IL-1 p and TNF-a have been shown to exert a synergistic stimulation of 
nerve growth factor release from cultures of rat astrocytes (Gadient et al., 1990). 
Conversely, whereas individual low concentrations of either IL-1 (3 or TNF-a 
were shown to stimulate insulin release, their combination was suppressive 
(Mehta et al., 1994).
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Thus, the available evidence show that proinflammatory cytokines such 
as IL-1 p and TNF-a can either exacerbate excitotoxic cell death or be 
neuroprotective depending on the brain microenvironment. In particular, it is 
increasingly clear that the action of proinflammatory cytokines on cell function 
and survival is highly dependent on the extent to which these molecules are 
produced, the length of time the tissue is exposed to their action, and the 
balance between the neurotrophic and inflammatory effects mediated by these 
molecules.
Finally, it is worth remembering that the regional and cellular patterns of 
induction of inflammatory molecules, and their time-course of activation and 
persistence in brain tissue, appear to depend on the nature of the CNS injury. 
For instance, IL-1 and TNF-a producing cells in the CNS may differ depending 
on stimuli as well as on diseases involved. Thus, TNF-a appears to be mainly 
produced by glial cells in experimental autoimmune encephalomyelitis (Renno 
et al., 1995), whereas in excitotoxic and ischemic brain injury a TNF-a 
production of neuronal origin has been reported (Liu et al., 1994; Bruce et al., 
1996).
99
1.4.4 Proinflammatory molecules and the 
Hypothalamic Pituitary-Adrenal axis
A system linked to the inflammatory response and that deserves 
attention is the Hypothalamic-Pituitary-Adrenal (HPA) axis. Indeed, any 
modulation or induction of an inflammatory state in the periphery as well as in 
the CNS cannot be dissociated from the activation of the HPA axis. In 
particular, proinflammatory molecules such as LPS and proinflammatory 
cytokines such as IL-1 (3 are known to increase the corticosterone levels in 
rodents when administered both systemically and centrally. However, 
proinflammatory cytokines and the HPA axis reciprocally affect their levels of 
expression and functionality. The main feature of the HPA axis activation is the 
synthesis and secretion of glucocorticoids (GCs, cortisol in humans and 
corticosterone in rodents) from the adrenal cortex. This facilitates the 
mobilization of substrates which are used as an energy source, potentiates the 
release of catecholamines, increases the cardiovascular tone and suppresses 
biological systems which are not considered essential to the organism’s 
response to stressors. Among these suppressed systems are, growth, 
reproduction and immunity. In relation to the immune response, the classical 
anti-inflammatory action of corticosteroids, the inhibition of transcriptional 
activation of proinflammatory molecules such as IL-1 p and TNF-a has been 
well documented. Nonetheless, the mechanism by which proinflammatory 
cytokines activate the HPA axis which turns to inhibit proinflammatory cytokines 
production at genomic level may not hold true for the immature organism. As it
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will be discussed in the following paragraphs, the ability to respond to stressful 
events at this stage of development is remarkably different from that 
encountered in adults. From this perspective, a massive release of 
proinflammatory cytokines in the developing brain may lead to long-term 
consequences. For instance, the induction of proinflammatory cytokines in the 
fetal environment following intraperitoneal injection of LPS to pregnant rats has 
been shown to increase the mRNA levels of CRH in the whole fetal brain, thus 
possibly influencing the degree of neuronal excitability of immature brain and 
possibly affecting the response of the immature brain to stressful stimuli by 
abnormal activation of hypothalamic-pituitary-adrenal (HPA) axis (Gayle et al., 
2004). This latter phenomenon has been shown to prime this system to 
inadequate responses to stressors in adulthood, as it was shown to occur 
following immune challenge during prenatal stages of life (Reul et al., 1994). 
Generally, the exposure to high levels of proinflammatory cytokines during 
perinatal life, together with documented long-term alterations of relevant 
biological systems such as HPA axis could induce significant changes in 
immature brain (e.g. elevation of brain excitability, neuronal circuitries 
hypomyelination, excessive induction of innate immune cell response, 
abnormal activation of HPA axis) such to account, in principle, for an increased 
susceptibility to seizures and neurodegeneration in later stages of life. It should 
be mentioned, however, that corticosterone and, in particular, agonists to 
mineralocorticoid receptors have been shown to be anticonvulsant at young 
ages, as it will be discussed in the following paragraphs. Thus, in principle, the 
activation of the HPA axis may positively affect seizure susceptibility as long as 
it occurs at young ages.
101
The following paragraphs will briefly outline the ontogeny of the HPA 
axis in rodents, with particular emphasis on the limbic-HPA axis system.
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1.4.4.1 The adult limbic-HPA axis
Interactions between the endocrine system and the CNS result in a 
diurnal rhythm of GCs secretion, with a peak occurring at the time of awaking 
and a nadir during the first few hours of sleep. Blood levels of circulating GC 
increase in response to virtually any type of stimulus that is perceived as a real 
or potential threat to body homeostasis. The regulation of blood levels of GC is 
subject to diverse sensory inputs, and this information is integrated at the level 
of the hypothalamus. Relevant within this brain structure are the parvocellular 
neurons of the paraventricular nucleus (PVN) which constitute the main source 
of the 41-amino acid peptide corticotrophin releasing hormone (CRH), which is 
the major physiological regulator of pituitary ad renocorticotropin hormone 
(ACTH) secretion. Indeed, parvocellular neurons also express, to a lesser 
extent, the peptide arginine vasopressing (AVP) which together with CRH is a 
secretagogue of the HPA axis. Neuron producing CRH and AVP in the PVN 
project to the external zone of the median eminence (ME) where, in response to 
physiological and psychological stressors, CRH and AVP are released into a 
specialized capillary network from which hypophysial portal vessels arise and 
vascularize the anterior pituitary. Within the anterior pituitary, CRH and AVP 
synergistically stimulate the synthesis of the ACTH precursor peptide 
proopiomelanocortin (POMC) and the secretion of ACTH and other POMC- 
derived peptides. ACTH, transported in the circulation, interacts with adrenal 
cortex receptors causing steroidogenesis and elevation of plasma GCs.
Generally, the stress response of the HPA axis is meant to be acute or 
limited in duration. The time-limited nature of this process makes the
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accompanying antireproductive, antigrowth, catabolic and immunosuppressive 
effects not detrimental to the organism. Thus, inhibition of steroid secretion is 
also an important feature of the system. The termination of the response to 
stressful stimuli appears to be mediated mainly by two feedback mechanisms 
which seem to be independent from each other, i.e., a rate sensitive fast 
feedback and a delayed feedback (Vazquez, 1998).
By the fast feedback mechanism, which operates on a time scale of 
minutes, CRH and ACTH are inhibited by the direct action of GC in a rate 
sensitive manner, that is, the quicker the rise of GC levels the more effective the 
inhibition. It has been shown that fast feedback inhibition is influenced by GC 
binding to specific receptors in limbic structures, mostly in the hippocampus. 
Indeed, specific lesions to neural connections from the hippocampus to the 
hypothalamic CRH neurons and/or a decrease of GC receptors as occurs in 
aging, result in a selective decrease in the termination of the stress response 
(Jacobson etal., 1991; Sapolsky, 1984).
Delayed feedback operates on a time scale of hours and its inhibitory 
action is accomplished by the translocation of corticoid-receptor complex to the 
nucleus where it acts at transcriptional level by suppressing gene expression, 
hence decreasing the ACTH stores in the pituitary and all key molecules in the 
limbic-HPA structures such as hypothalamic CRH and hippocampal 
glucocorticoids receptors (Fremeau et al., 1986).
Several lines of evidence support the hippocampus as a key structure in 
the limbic-HPA interaction. For instance, hippocampectomy results in an 
upregulation of hypothalamic CRH mRNA expression even with high levels of 
circulating GCs (Herman et al., 1989; Jacobson et al., 1991). Moreover,
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genomic inhibitory feedback exerted by GCs on hypothalamic parvocellular 
neurons fails in animals that underwent hippocampectomy (Jacobson et al.,
1991).
As far as corticoid receptors are concerned, two types have been 
described in the brain. At the cellular level, they both are located in the 
cytoplasm. The type I receptor, also known as the mineralocorticoid receptor 
(MR), selectively binds corticosterone (CS) in rodents and is usually described 
as a high affinity corticoid receptor. In the adult rodent brain, MRs are mostly 
localized in hippocampal and septal neurons. Conversely, the type II receptor, 
also known as the glucocorticoid receptor (GR), is usually defined as a low 
affinity corticoid receptor. These receptors are widely distributed in brain 
neurons (including hippocampus and hypothalamus), glial cells and pituitary 
cells.
GRs bind corticosterone with a lower affinity compared to MRs. It is 
largely accepted that MRs appears to be operative at low CS concentrations 
thus playing a tonic inhibitory role on HPA axis during the nadir of circadian 
rhythm. When high concentration of CS occurs, MRs saturate and the return to 
homeostasis appears to be mediated by GRs (Vazquez, 1998).
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1.4.4.2 The limbic-HPA axis in the immature brain
The first two postnatal weeks are characterized by a hyporesponsiveness 
to stressors (a time-window also known as stress hyporesponsive period, 
SHRP), in that the rat pups respond weakly to a variety of acute stressful stimuli 
such as ether inhalation, surgery or handling, whereas the same stimuli would 
considerably increase the levels of plasma CS in older animals.
Indeed, several studies have shown how this hyporesponsiveness 
appears at all levels of the HPA axis at this developmental stage. Measures of 
anterior pituitary peptide content and POMC mRNA levels have shown a clear 
age-dependency. The anterior pituitary content of peptides derived from 
cleavage of POMC (ACTH, (3-lipotropin and P-endorphin, the latter from 
cleavage of p-lipotropin) increases specifically with age for each individual 
peptide (Vazquez and Akil, 1992), showing that ACTH and p-endorphin increase 
4-8 fold from newborn to PN 21. Interestingly, by comparing the amount of each 
processed peptide to the amount of its immediate precursor, it is evident that in 
the developing anterior pituitary there is a greater proportion of cleaved and 
acetylated end products as compared to adults, thus showing that corticotroph 
appears to process the POMC precursor at a faster rate than the adult 
corticotroph, in particular during the first two postnatal weeks, reaching adult 
rate at PN 21. In this contest, POMC mRNA was shown to parallel the age- 
dependent increase of peptides in the anterior pituitary (Vazquez and Akil,
1992).
The plasma levels of ACTH released by the developing pituitary have 
been shown to maintain a low steady state until PN 21 after which time a
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significantly increase occurs (Vazquez and Akil, 1992). The CS levels show an 
initial decrease after birth, than increase on PN 14 and 21 (Sapolsky et al., 
1986; Vazquez, 1998). Two interesting observations arise by considering the 
pattern of plasma ACTH and CS levels in PN 14 and 21 rats (fig. 5) i) at PN 14 
the adrenal cortex appears more sensitive to ACTH since a tendency to 
increase CS is evident despite plasma levels of ACTH being unchanged at this 
age, ii) at PN 21, although the levels of circulating ACTH are significantly 
increased, there is not a corresponding rise in CS levels (fig. 5). This latter 
observation appears to be consistent with the decrease in adrenal sensitivity to 
circulating ACTH and limited adrenal steroidogenic capacity observed at this 
age (De Kloet et al., 1988; Henning et al., 1985).
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The response of the immature HPA axis to stressful stimuli is worth a 
comment. Repeated maternal isolation, used as a paradigm of chronic 
intermittent stressor (Vazquez and Akil, 1992), causes activation of the limbic- 
HPA axis in the pups. Under this stressful challenge (isolation from the 
respective mother for 1 hour, on 3 consecutive days), pups aged at the second 
and third week of life do not exhibit changes in stored anterior pituitary peptides 
with the exception of the PN 21 rats that showed a depleted content of all 
peptides descending from the POMC precursor (Vazquez and Akil, 1992). 
Indeed, it was shown that during the SHRP the developing corticotroph, under 
stressful conditions, processes the POMC precursor at a faster rate compared to 
age-matched unstressed animals (Vazquez and Akil, 1992). This leads to a 
minimal (if not absent) increase of anterior pituitary peptide content and a limited 
increase of circulating POMC related peptides.
The pattern of peptide content at different ages are paralleled by similar 
changes in POMC mRNA levels. Thus, at PN 21 a decrease of POMC mRNA 
occurs whereas no changes appear in younger animals.
Animals challenged with repeated maternal isolation show an increase of 
CS as early as PN 7 although ACTH levels were unaltered by stress, suggesting 
a greater adrenal sensitivity to circulating ACTH levels at this developmental 
stage. The response to stress by increasing CS levels becomes gradually more 
pronounced in PN 14 and PN 21 rats despite ACTH levels appearing unaffected 
by stress at all ages, with the exception of PN 21 where a decrease in plasma 
levels of circulating ACTH occurs.
Therefore, in general, animals which undergo stressful stimuli during the 
first three weeks of life maintain a greater level of CS as compared to
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unstressed controls. It is interesting to note that at PN 21 there is i) an increase 
in circulating CS, ii) a decrease in POMC mRNA levels, iii) a decrease in 
pituitary peptide stores and iv) a decrease in pituitary peptide plasma levels. 
Taken together, this suggests the emergence of negative CS feedback acting on 
the pituitary at the level of genomic transcription by PN 21 (Vazquez, 1998). 
Nonetheless, the emerging CS negative feedback by PN 21 has been shown to 
be a consequence of the inability of weanling rats to quickly terminate the 
adrenocortical response following exposure to stressful stimuli, due to a 
combination of adrenal developmental factors leading to a slow CS rise and 
pituitary and/or brain factors which result in decreased responsiveness to 
negative feedback, even when the rate of CS increase is high (Vazquez and 
Akil, 1993). In particular, it is of interest to note that, compared with adults, the 
exposure of weanling animals (aged about PN 22, on average) to a stressor like 
inhalation of ether vapor induces a robust CS peak but a slower return to resting 
CS levels. In this situation glucocorticoid concentrations are still significantly 
elevated 2 hours after the exposure to the stressor (Goldman, 1973; Vazquez 
and Akil, 1993).
Thus, to summarize what has been reported so far, it is clear that during 
development the HPA axis is different from the adult in both structure and 
function. The immediate postnatal period is characterized by a time-window 
(SHRP) in which the young animals show a relative insensitivity to 
environmental perturbations, followed by a peculiar pattern of stress 
responsiveness in weanling animals, which show an inability to quickly terminate 
glucocorticoid secretion. Indeed, experimental evidence has been accumulated
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in support of the notion that the mechanisms underlying normal HPA 
development and the mechanisms of adaptation are not necessarily those which 
the mature system would employ under those same challenges. Thus, during 
the first 2 weeks of life, pups respond to chronic intermittent stressors by 
increasing anterior pituitary POMC post-translational events, while adults are 
known to increase genomic events. At this developmental stage, although the 
increment of circulating ACTH concentration is minimal, the adrenocortical 
response to stress is already observable at PN 7, due to the augmented 
sensitivity of adrenal gland to circulating ACTH levels, and this responsiveness 
progressively increases during the following 2 weeks of life. It is relevant to note 
that in both the mature and PN 21 rat, the adrenocortical response to chronic 
intermittent stressful stimuli leads, eventually, to an increase of CS levels. 
However, the adult rat sustains this response by increasing the releasable pool 
of ACTH and reducing steroid feedback at the level of the pituitary. Conversely, 
the developing animal increases POMC molecule processing which leads to a 
minimal increase in circulating ACTH levels. Finally, levels of circulating CS in 
the immature rats in response to stressors have been shown to be long lasting 
as compared to adults.
I l l
1.4.4.3 Changes in mineralocorticoid and glucocorticoid
receptors in the developing hippocampus
Similar to other receptor systems, cytoplasmic receptors for CS also 
undergo a developmental change. Studies exploiting the in situ hybridization 
technique have shown that in almost every hippocampal subfield the mRNA for 
mineralocorticoid receptors increases with age, whereas the levels of transcript 
for glucocorticoid receptors decreases (Vazquez et al., 1996). Nonetheless, GR 
and MR protein expression generally increases from low levels on day 6 to adult 
levels by day 22, and between PN 22 and PN 45 both receptors reach the 
greatest absolute increase of protein levels, which then gradually decrease to 
adult levels (Vazquez et al., 1993). Binding studies have shown that the affinity 
of both corticoid receptors does not change with age. These findings suggest 
that the failure to terminate the stress response in young animals is neither due 
to a decrease in corticoid receptor numbers nor to a change in their affinity.
It is of interest to observe the sensitivity of both corticoid receptors in the 
early developmental stages of rat pups following an increase of circulating CS 
induced by stimulation of the HPA axis. Animals that underwent 24 hours of 
maternal deprivation clearly show an increase in CS levels which are 
significantly higher at PN 9 and PN 12. Moreover, this paradigm of stress was 
shown to prime the organism to increase its responsiveness to novel stressors 
that could be as mild as isotonic saline injection or inhalation of ether vapor 
(Rosenfeld et al., 1992). This feature was evident not only at PN 9 and PN 12 
but also at PN 6, which is during the SHRP time window.
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The mineralocorticoid and glucocorticoid receptor pattern in the 
hippocampus was evaluated in animals aged PN 6 , 9 and 12, challenged with 
24 hours of maternal deprivation. The mineralocorticoid receptor (MR) gene 
expression was shown to undergo a 25-35 % decrease in the CA1 area of the 
hippocampus at all ages, while significant changes in GRs mRNA levels 
appeared unaffected by maternal deprivation. Thus, the MR to GR ratio is 
influenced by the challenge of stressful stimuli. Unstressed animals usually 
showed a MR to GR ratio of about 1 at PN 6, 2 at PN 9 and 3 at PN 12, whereas 
rats which were challenged with 24 hours of maternal deprivation show a ratio of 
about 1 at PN 6 and PN 9, while the ratio increased to 2 at PN 12 (Vazquez et 
al., 1996).
It is largely accepted that MRs and GRs complement each other. The 
MRs appear to exert their tonic inhibition to the HPA axis as far as CS 
concentrations are low, whereas at high CS levels MRs saturate and the effects 
become mediated by GRs which are expected to restore the homeostasis. Thus, 
the dual action of these receptors in the hippocampus appears to be central for 
both basal modulation and stress regulation of the limbic-HPA axis. It is of 
interest to observe that the down-regulation of MRs in animals that underwent 
24 hours of maternal deprivation appears to be associated to an alteration of the 
tonic inhibition of the system which is manifested by an elevation of basal CS 
levels.
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1.4.4.4 Membrane mineralocorticoid receptors
Membrane mineralocorticoid receptors which mediate non-genomic 
actions of corticosteroids (Wehling et al., 1991; Schmidt et al., 2000) have been 
identified on several cell types, including synaptic membranes, and have been 
shown to be developmentally regulated (Sze et al., 1993). At present, little is 
known about their physiologic significance. In some cases, their function has 
been linked to alterations of electrolyte transport (intracellular Na+, K+, and Ca2+) 
and cell volume (Mihailidou et al., 1998; Wehling et al., 1991). Inherent to 
modulation of neuronal activity are experimental findings from 
electrophysiological measurements made in amphibian synaptic membrane 
preparations, which have shown that agonists of mineralocorticoid receptors 
cause a decline or cessation of firing in spontaneously active and sensory- 
responsive neurons (Rose et al., 1993).
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1.4.4.5 Mineralocorticoid receptors and modulation of 
seizure susceptibility
Indeed, a role of mineralocorticoid receptors in modulating seizure 
susceptibility has been established showing different effects in adult and infant 
rats. In adult rats, pre-treatment with a mineralocorticoid agonist enhances 
susceptibility to pentylenetetrazole and kainic acid seizures and these 
proconvulsant effects are blocked by antagonism of mineralocorticoid receptors 
(Roberts et al., 1994; Reddy et al., 2002). Glucocorticoid receptors appear to 
have little or no effect on seizure susceptibility in adult rats (Reddy et al., 2002). 
Conversely, in infant rats activation of mineralocorticoid receptors were shown to 
counteract seizure activity in a variety of seizure models and these 
anticonvulsant effects are blocked upon administration of an antagonist to 
mineralocorticoid receptors (Edwards et al., 2005; Edwards et al., 2002 (a, b)). 
Generally, two conclusions have emerged from these studies. Firstly, although 
the great majority of experiments were accomplished using PN 15 rats, the 
anticonvulsant properties triggered by mineralocorticoid receptor activation are 
age-dependent since they appear effective within the first four-five weeks of 
postnatal life. Secondly, the effects mediated by agonists to mineralocorticoid 
receptor, including corticosterone, have a short latency of occurrence (within 15 
min or less, depending on the agonist used) that is not compatible with the 
longer time required to elicit genomic effects by binding to nuclear receptors, 
hence suggesting an involvement of membrane mineralocorticoid receptors. 
However, available evidence about the mechanism of action of membrane 
corticosteroid receptors is too scarce to infer any reasonable explanation for
115
their age-dependent protective effect onto seizure susceptibility, although this 
property has been well documented.
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1.4.5. Activation of the HPA axis and the 
modulation of proinflammatory 
cytokines expression by PGE2
A molecule closely related to proinflammatory cytokines and the HPA axis 
activation and that may be relevant in the context of brain excitability and 
neurodegeneration at young ages is prostaglandin E2 (PGE2), the major 
enzymatic product of cyclooxygenase-2 (COX-2) activity (Brock et al., 1999).
Despite being formerly depicted as a strict proinflammatory molecules, 
PGE2 has been shown to significantly modulate the level of proinflammatory 
cytokines expression and the HPA axis activation by proinflammatory stimuli. 
Indeed, in rodents, PGE2 has anti-inflammatory effects in the CNS following 
brain injury and administration of LPS (Zhang and Rivest, 2001), while LPS- 
induced activation of the HPA axis has been shown to occur through the 
production of PGE2 (Zhang and Rivest, 2003; Turrin and Rivest, 2004 (b); Blais 
et al., 2005). At present, it is largely accepted that PGE2 may have a dual role in 
the CNS, being pro- or anti-inflammatory depending on the target cells and the 
type of insult. In particular, it has been shown that although PGE2 increases 
LPS-induced NF-kB activity and COX-2 transcription in vascular-associated 
elements, it significantly reduces microglial activation and TNF-a expression in 
the brain parenchyma. Intracerebral PGE2 infusion has been shown to largely 
prevent the expression of TNF-a and IL-1 (3 mRNA elicited by tissue injury 
(Zhang and Rivest, 2001).
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A reduction of microglial activation by PGE2 is supported by in vivo 
evidence (Caggiano and Kraig, 1996) and in vitro (Thery et al., 1994; Caggiano 
and Kraig, 1996; Caggiano and Kraig, 1998; Minghetti et al., 1997), showing that 
PGE2 can inhibit several microglial/macrophage functions, including the 
expression of major histocompatibility complex class II, NO production and 
synthesis of proinflammatory cytokines. The deactivating effect on microglial 
cells appears mediated by elevation of intracellular cAMP levels, and several 
studies suggest the involvement of the EP2 receptor subtype in this mechanism, 
although details of the cellular pathways involved are still lacking (Petrova et al., 
1999; Caggiano and Kraig, 1998; Caggiano and Kraig, 1999).
The following paragraphs describe findings related to COX-2 and PGE2 
expression and modulation in glial and neuronal cells.
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1.4.5.1 COX-2 and PGE2 expression and regulation in glial
cells
The COX-2 promoter contains binding sites for several transcription 
factors including NF-kB and CREB (Chun et al., 2004). However LPS-stimulated 
COX-2 expression in microglia occurs via several other pathways. Indeed, 
pathways related to p38 MAPK, p42/44 MAPKs and phosphocholine-specific 
phospholipase C (PC-PLC) appear to act in parallel without apparent cross-talk 
(Akundi et al., 2005), thus showing that overexpression of COX-2 might be a 
consequence of both increased transcription and enhanced mRNA stability. Of 
particular interest is the PC-PLC pathway which leads to activation of protein 
kinase C (PKC) by production of diacylglycerol (DAG). This kinase is able to 
activate NF-kB via phosphorylation of I-kB as well as p42/44 MAPKs through 
phosphorylation of Ras/Raf pathway (Sweatt, 2001). In microglia, PKC 
stimulates COX-2 transcription following LPS stimulation through a NF-kB as 
well as p42/44 MAPKs independent mechanism (Bauer et al., 1997; Akundi et 
al., 2005).
cAMP dependent modulation of LPS-induced COX-2 expression has 
been clearly shown in microglial cells (Minghetti et al., 1997). Interestingly, 
accumulation of cAMP by the adenylyl cyclase activator forskolin did not affect 
basal levels of COX-2 protein, but enhanced COX-2 protein levels following 
stimulation by LPS, or the cAMP analogue dibutyryl cAMP. This effect is 
mediated by protein kinase A (PKA) since its inactivation abolished the 
enhancing effect of LPS onto COX-2 protein expression. Importantly, PGE2 
release was shown to parallel the COX-2 pattern of expression following all
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treatments reported above. Thus, these experiments suggest that cAMP 
accumulation per se is not sufficient to induce COX-2 transcription and that 
another element is required to act in concert to modulate COX-2 expression. 
This element may be PKA, whose expression would be expected to be 
enhanced by LPS stimulation since basal levels of PKA are not enough to 
increase COX-2 transcription even in presence of an augmented cAMP 
availability (Minghetti et al., 1997).
Interestingly, exogenous PGE2 enhances the LPS-induced expression of 
COX-2 without affecting its basal levels (Minghetti et al., 1997). This effect is 
mediated by EP2 Gs-coupled receptors.
PKC regulates adenylyl cyclase activity differently in microglial cells and 
astrocytes. cAMP accumulation is quickly enhanced in astrocytes, peaking 
within a few minutes of exposure to PKC activators, but is unchanged in 
microglia, despite the phosphorilating activity of the kinase was increased 
(Patrizio et al., 1997). However, when microglia is stimulated with PGE2, 
phosphorylation of EP2 receptors by PKC results in a reduced accumulation of 
cAMP (Patrizio et al., 2000).
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1.4.5.2 COX-2 and PGE2 expression and regulation in
neuronal cells
Although microglial cells account for the majority of COX-2 production 
(Minghetti and Levi, 1998), seizure-activity perse enhances COX-2 and PGE2 
expression in neurons (Cole-Edwards and Bazan, 2005).
In the mature hippocampus, COX-2 has been shown to play a significant 
role in neuronal excitability and physiological phenomena such as LTP. COX-2 
is enriched in the dendritic spines of excitatory synapses (Kaufmann et al.,
1996) and constitutive levels of expression of COX-2 are regulated by synaptic 
activity and up-regulated by high-frequency stimulation associated with long­
term synaptic plasticity (Yamagata et al., 1993), a physiological feature which is 
particularly evident in brain structures such as the hippocampus.
A fundamental step in LTP induction is the spatiotemporal correlation of 
postsynaptic firing and excitatory postsynaptic potentials (Koester et al., 1998; 
Magee et al., 1997; Markram et al., 1997). A decrease in postsynaptic neuron 
membrane excitability, with a subsequent decrease of the number of 
postsynaptic action potentials during high-frequency stimulation of the 
presynaptic ending, diminishes the probability of LTP induction. Inhibition of 
constitutive COX-2 attenuates postsynaptic membrane excitability, thus 
decreasing the probability of LTP induction. Another important factor in LTP 
establishment is the active propagation of axonally generated action potentials 
back into the dendrites, where associated dendritic influx plays a significant role 
(Magee et al., 1997). Specifically, pharmacologic COX-2 blocking decreases
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back-propagating dendritic action potential-associated Ca2+ influx (Chen et al., 
2002).
Since PGE2 is the main product from the enzymatic conversion of 
arachidonic acid by COX-2 (Brock et al., 1999) and PGE2 receptors are 
expressed in the hippocampus (Zhu et al., 2005) then it is likely that PGE2 is the 
effector of COX-2 mediated activity-dependent synaptic plasticity (Chen et al., 
2002). Consistently, DG granule cells specific inhibition of COX-2 (but not COX- 
1) was shown to decrease the induction of LTP, whereas administration of PGE2 
(but not PGD2 or PGF2a) reversed COX-2 inhibitor-induced suppression of LTP 
(Chen et al., 2002). Interestingly, it has been shown that PGE2 acts as a 
retrograde messenger in excitatory synaptic transmission through a presynaptic 
EP2 receptor that increases the probability of glutamate release at hippocampal 
synapse (Sang et al., 2005). In particular, the increased COX-2 expression (at 
postsynaptic dendritic spines) causes enhanced production of PGE2 which in 
turn augments synaptic transmission via a presynaptic EP2-PKA pathway. Chen 
and Bazan (Chen and Bazan, 2005) showed that somatic and dendritic 
membrane excitability was significantly reduced when endogenous PGE2 was 
depleted using a selective COX-2 inhibitor (NS398). In addition, it was observed 
that exogenous application of PGE2 significantly increased the firing rate, 
excitatory postsynaptic potential amplitude, and temporal summation in slices 
treated with the COX-2 inhibitor. Interestingly, PGE2-induced enhancement of 
excitatory postsynaptic potentials was blocked by inhibiting both PKA and PKC 
activities (Chen and Bazan, 2005). Accordingly, PKA and PKC are involved in 
the modulation of K+ currents in dendrites of hippocampal CA1 pyramidal 
neurons (Hoffman et al., 1998). Indeed, the activation of either PKA or PKC
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significantly increase the amplitude of back-propagating action potentials in 
distal dendrites by down-regulation of transient K+ channels, thus supporting a 
prolonged cell excitability as shown by an increased amplitude of back- 
propagating action potentials upon either PKA or PKC stimulation (Hoffman et 
al., 1998).
Thus, these data suggest that PGE2 production and its interaction with its 
cognate receptors involve functional relationship among COX-2, PKA and PKC, 
possibly leading to relevant alteration of physiological phenomena such as LTP. 
In this regard, the developmental regulation of LTP induction is particularly 
relevant. In the adult hippocampus, one enzyme commonly implicated in LTP is 
Ca2+/calmodulin-dependent kinase II (CAMKII) (Lisman et al., 2002). In rats 
aged PN 7-18 it was shown that parallel kinase cascades are involved in the 
induction of LTP at hippocampal CA1 synapses (Wikstrdm et al., 2003). At this 
developmental stage, CAMKII participates in LTP induction, although its 
involvement is only manifest when either PKA or PKC is inhibited.
A stressful stimulus as mild neonatal isolation during the first postnatal 
week was shown to accelerate the developmental switch in the molecular 
mechanisms underlying hippocampal CA1 LTP from a PKA- to a CAMKII- 
dependent pattern (Huang et al., 2005). Importantly, the upregulation of CAMKII 
was mediated by CRH acting through CRF-R1, suggesting that activation of 
HPA axis could play an important role in modulation of neonatal LTP.
In the immature organism the role of PGE2 is not well established since 
often the available evidence comes from adult rodents. On the one hand, the 
accumulation of free arachidonic acid and the formation of prostaglandins and
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lipoxigenase reaction products in the brain during seizures is well established 
(Cole-Edwards and Bazan, 2005) and ibuprofen, a non-selective COX inhibitor, 
was shown to delay the onset of flurothyl-induced seizures in adult rats 
(Wallenstein and Mauss, 1984), suggesting a proconvulsant role of PGE2. On 
the other hand, by activating the HPA axis, PGE2 may exert an anticonvulsant 
action through the occupancy of membrane mineralocorticoid receptors by 
circulating corticosterone.
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2. Aims
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The available evidence shows that innate immune response, usually 
triggered in brain by systemic infection, involves proinflammatory signals 
which are also recruited by epileptic activity. The adaptive response to 
infection is rapid, reversible and aimed at eliminating pathogens from the 
host tissue. Conversely, chronic stimulation of proinflammatory signals by 
seizures, or a persistent proinflammatory situation in brain may contribute to 
the establishment of a pathological substrate (i.e. neurodegeneration, 
neuronal hyperexcitability, BBB damage, etc) playing a role in 
epileptogenesis and in the acute manifestation or reinforcement of seizures. 
In particular, it appears that the consequences of an increase in brain 
cytokines and related molecules on brain function depends on the extent 
and duration of these changes, on the subtype of cytokine receptors 
recruited and the pre-existing functional status of the cells exposed to 
cytokines.
In humans and in experimental models of epilepsy, seizure 
susceptibility and associated neuronal damage are age-dependent. The key 
determinants of this developmental occurrence are still unclear although 
evidence collected suggests that this is a multifactorial phenomenon.
Thus, in light of recent findings on inflammation and epilepsy, we 
hypothesized an age-dependent cause-effect relationship between 
proinflammatory molecules and seizure susceptibility and related 
neurodegeneration. Therefore, the goal of this thesis is to gain insights into 
this question. In particular, this work evaluates two hypothesis, i) the age- 
dependent changes in pro-inflammatory cytokines and their relation to
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seizure induced neuronal damage and ii) the effect of inflammatory 
challenge and possible molecular mechanisms.
In relation to the age-dependent changes in pro-inflammatory 
cytokines and their relation to seizure induced neuronal damage, 
experiments will investigate the hypothesis that activation of glia and 
subsequent production of proinflammatory molecules such as IL-1 p and 
TNF-a, as well as the naturally occurring anti-inflammatory molecule 
interleukin-1 receptor antagonist (IL-1Ra), are age-dependently involved in 
seizure-induced neuronal damage. In addition, as some proinflammatory 
molecules such as IL-1 p have been shown to modulate susceptibility to 
seizures and ictal activity in experimental models of SE in adults, a possible 
IL-1(3-induced age-dependent susceptibility to seizures will be also 
evaluated.
As it concerns the effect of inflammatory challenge at young ages 
and possible molecular mechanisms, experiments will investigate whether a 
pre-existing inflammatory state in the CNS may enhance the predisposition 
of rat pups to develop seizures. In this regard, these studies will use 
systemic administration of LPS in rat pups as a proinflammatory stimulus to 
investigate the relationship between IL-1 (3 and TNF-a mRNA levels and 
what the role of the HPA axis activation and COX-2 /PGE2 might be in the 
modulation of seizure susceptibility in this experimental paradigm.
If a link between inflammatory reactions in brain and 
epileptogenesis/ictogenesis were found, this novel information may open 
new therapeutic perspectives for the treatment of seizures or their 
prevention.
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3. Materials and methods 
- general procedures -
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In the following section, the general experimental procedures adopted in 
the experiments described in this thesis are provided. Further methodological 
details are given for each specific experiment before the presentation of the 
results.
Please note that the experiments involving seizure induction by flurothyl 
ether inhalation were run in collaboration with Dr. Jana Veliskova at the 
Laboratory of Pediatric Epilepsy; Albert Einstein College of Medicine, New York, 
USA.
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3.1 Experimental animals
3.1.1 Choice of experimental animals
To validate experimental results in terms of a meaningful comparison with 
human pathology, we should consider how the developing rat brain compares 
with human brain (Moshe, 1987; Holmes, 1986). Rats are known to be born in a 
premature state relative to humans, thus several factors must be taken into 
account to ensure the rats used are representative of specific stages of human 
development. The evaluation of some developmental parameters such as the 
length of gestation, the rate of brain growth, synaptogenesis, protein synthesis, 
myelination and cerebral glucose utilization have led to defined age-intervals of 
rat development that match stages of human development (Moshe, 1987; 
Nehlig, 1997; Avishai-Eliner et al., 2002; Romijn et al., 1991), as summarized in 
the following table 6:
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Table 6
Age-intervals of rat development that match stages of 
human development
Rat
(age-intervals)
Human 
(corresponding stages of 
development)
PN8-10 Full-term newborn
PN12-18
. . ■ ■ 
Infant/toddler
PN25-32 Peripubertal child
PN32-38 Onset of puberty
>PN60 Adult
Adapted from Haut et al., 2004
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Accordingly, experiments were performed using rats aged postnatal day 
(PN) 9, 15 and 21 since these age-intervals match human brain development 
from birth to peripuberty, thus embracing human ages at which susceptibility to 
neuronal injury is known to progressively increase. Concomitantly, rats in these 
age groups are known to be susceptible to seizure-induced brain injury in an 
age-dependent manner (Albala et al., 1984; Ben-Ari et al., 1984; Holmes and 
Thompson, 1988 (b); Nitecka et al., 1984).
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3.1.2 Animal care
Male Sprague-Dawley rats (Charles River, Calco, Italy) at PN 9, 15, and 
21 (with PN 0 defined as the day of birth) were used. All animals were used 
before weaning. Pups were housed with their dams at constant temperature 
(23°C) and relative humidity (60%) with a fixed 12 h light-dark cycle and free 
access to food and water. Procedures involving animals and their care were 
conducted in conformity with the institutional guidelines that are in compliance 
with national (D.L.n.116, G.U, suppl. 40, Feb. 18, 1992) and international laws 
and policies (EEC Council Directive 86/609, OJ L 358,1, Dec. 12,1987; Guide 
for the Care and Use of Laboratory Animals, U.S. National Research Council, 
1996).
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3.2 ‘In vivo’ models of seizures and status 
epilepticus
3.2.1 Induction of status epilepticus (SE) following 
systemic administration of kainic acid
Kainic-acid (KA) induced SE in rat is one of the widely accepted models 
of MTLE. KA acts specifically on the kainate receptor (one of the two ionotropic 
non-NMDA glutamate subtype receptors, the other being AMPA receptor). It is 
believed that induction of SE and the subsequent neurodegenerative pattern 
(see below) is triggered by activation of kainate receptors in the CA3 region of 
the hippocampus (Krnjevic et al., 1980), followed by release of the endogenous 
excitatory aminoacids glutamate and aspartate (Ferkany et al., 1982; Kohler et 
al., 1979) which in turn further activate all subtypes of glutamate receptors.
Typically, the progression to KA-induced SE consist of a sequence of 
stereotyped behaviours usually starting with staring and freezing within 5-15 min 
from administration. This is followed by mastication, head nodding, myoclonic 
twitches of the head and ‘wet dog’ shakes in the subsequent 15-30 min, lasting 
for about 30 min. Eventually, within 1 h of administration of KA, recurrent 
generalized tonic-clonic seizures develop (Sperk, 1994). The EEG dynamics 
correlate well with behavioural changes, clearly defining ictal and interictal 
events. Injection of KA also induces biphasic changes in body temperature, with 
hypothermia in the first 30-60 min, followed by hyperthermia lasting for several 
hours (Ahlenius et al., 2002).
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This experimental model of MTLE shows two relevant features. Firstly, 
after several hours SE ceases and a silent period follows during which 
epileptogenic mechanisms are believed to occur. This period lasts for weeks 
and, eventually, spontaneous seizures develop. Secondly, behavioural changes 
are followed by neurodegeneration which appears prominent in hippocampus, 
entorhinal and piriform cortex, thalamus and amygdala (Sperk et al., 1985). In 
particular, a typical pattern of neurodegeneration, similar to pathological findings 
in human MTLE, occurs in the hippocampus. Thus, cell loss mostly affects CA3 
pyramidal cells and interneurons in the dentate gyrus (Ben-Ari, 1985) followed 
by CA1 neurons (Sperk et al., 1985; Phelps et al., 1991), inducing cell death 
both through necrotic and apoptotic mechanisms (Ferrer et al., 1995; Simonian 
et al., 1996; Popescu et al., 2002). CA2 pyramidal neurons as well as granule 
cells are the most resistant to neurodegeneration. Structural alterations are 
reminiscent of human pathology, thus mossy fibre sprouting, astrocytosis and 
remodelling of GABAergic connections are known to take place.
This reproducible pattern of neurodegeneration can be induced by 
systemic, intrahippocampal, intra-amygdaloid or intracerebroventricular 
administration of KA, provided the generalized motor seizures are not 
terminated within about 20-60 min (Ben-Ari, 1985; Tanaka et al., 1992). 
Importantly, the onset of neuronal injury induced by KA administration has been 
shown to be age-dependent (Albala et al., 1984; Ben-Ari et al., 1984; Holmes 
and Thompson, 1988 (b); Nitecka et al., 1984). KA administration triggers 
behavioural SE at all ages, each manifesting its own motor pattern. In PN9 and 
PN15 rats SE is characterized by bilateral clonic seizures of all the extremities,
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whereas in PN21 rats, limbic motor seizures were characterized by continuous 
forelimb clonus (Albala et al., 1984; Friedman et al., 1997).
The preference of KA over pilocarpine for inducing SE in rats has also 
been driven by the consideration that the intensity of damage appears to be 
more severe in pilocarpine-treated rats (Covolan and Mello, 2000). In particular, 
pilocarpine administration can induce extensive damage to granule cells in the 
DG, whereas KA produces little damage (Covolan et al., 2000). Therefore, the 
neurodegenerative pattern induced by KA administration appears to be more 
similar to human MTLE-associated histopathological findings, since damage to 
granule cells in the DG accounts for no more than 5% of total neurodegenerative 
patterns occurring in MTLE sufferers. Finally, the human hippocampus is known 
to be vulnerable to excitotoxicity triggered by activation of kainate receptors. In 
1987 several Canadian patients were affected by domoic acid poisoning 
following ingestion of mussels. Neuropathological studies revealed lesions 
predominantly in the hippocampus and amygdala, resembling the pattern of 
neurodegeneration induced by administration of KA. Indeed, domoic acid is a 
structural analogue of KA, thus acting on kainate receptors, but its excitotoxicity 
is much higher as compared to KA itself. It was determined that the mussels had 
accumulated domoic acid, synthesized by the phytoplankton Nitzchia pungens 
(Teitelbaum et al., 1990). A further study (Cendes et al., 1995) described a 
patient responding with complex partial SE following acute intoxication of 
domoic acid. After a latent period of 1 year after the acute episode, the patient 
developed MTLE. MRI and post-mortem examinations showed a MTS pattern of 
neurodegeneration.
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3.2.2 Seizure induction by inhalation of flurothyl ether
Flurothyl (bis-2,2,2-trifluoroethyl ether, Flura Corp., USA) is a liquid 
convulsant which quickly evaporates, thus inducing seizures by inhalation. In our 
experimental setting, rat pups were placed in an air-tight chamber (9.38 I) and 
flurothyl was continuously delivered into this chamber via a precise 
microinfusion pump (WPI, Inc., USA).
The advantage of continuous flurothyl infusion is that seizures always 
occur. Two seizure types develop after flurothyl exposure: clonic and tonic-clonic 
seizures. Clonic seizures consist of clonic convulsion of head and forelimb 
muscles with preserved righting reflex. Tonic-clonic seizures are usually 
preceded by wild running followed by a loss of righting reflex. Then, there is a 
short tonic contraction of fore- and hindlimbs followed by long clonic convulsions 
of all four limbs. In rat pups, the first episode of clonic seizures is almost 
immediately followed by a tonic-clonic seizure.
In the case of SE induction, flurothyl was infused at 30 pl/min for the first 
10 min and then at 15 pl/min for the remaining time, and rat pups were left 
exposed to SE for 1 h.
In the case of seizure threshold testing, flurothyl was infused at 40 pl/min. 
We recorded the latency to the onset (measured from the beginning of flurothyl 
delivery) of the first clonic and first tonic-clonic seizure, with a limit of 20 min 
flurothyl exposure. Since flurothyl was infused at a constant rate, the latency to 
the onset of seizures allowed us to calculate the amount of infused flurothyl 
necessary to elicit seizures, i.e., the flurothyl seizure threshold for clonic or tonic- 
clonic seizures for our chamber size. The seizure threshold inversely reflects
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seizure susceptibility. Thus, the higher the seizure threshold, the lower the 
seizure susceptibility.
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3.3 Drugs
3.3.1 Butaprost, SC19220 and SC58125
In the rat, Butaprost (9-oxo-11a, 16S-dihydroxy-17-cyclobutyl-prost-13E- 
en-1— oic acid) is a selective EP2 receptor agonist and SC19220 (8-chloro- 
dibenz(b,f)(1,4) oxazepine-10(11H)-carboxy-(2-acetyl)hydrazide) is a selective 
EP1 receptor antagonist (Boye et al., 1997; Coleman et al., 1997). Doses and 
time of administration were chosen on studies based on functional studies 
exploiting subcutaneous or intraperitoneal injection as drug delivery method 
(Takeuchi et al., 2003; Pons et al., 1994; Pons et al., 1989; Barbieri et al., 1977). 
Butaprost and SC19220 (Cayman Chemicals, USA) were dissolved in 25% 
Tween 80 and injected subcutaneously (3 mg/kg, each). Their functional effects 
were evaluated 30 min after the administration. SC58125 (1-((4-
methylsulfonyl)phenyl)-3-tri-fluoromethyl-5-(-4-fluorophenyl)- pyrazole) is a 
selective inhibitor of COX-2 (Seibert et al., 1994; Kurumbail et al., 1996). The 
doses and the time of administration of SC58125 were selected on the basis of 
studies indicating i) the time the molecule requires to penetrate the blood-brain 
barrier (McCarthy et al., 2002) and ii) dose-response data showing significant 
inhibition of PGE2 levels in the brain parenchyma (Nakayama et al., 1998). 
SC58125 (Cayman chemicals, USA) was dissolved in 0.1 M PBS and injected 
intraperitoneally (3 mg/kg) and its functional effects were evaluated 30 min after 
the administration.
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3.3.2 Canrenoic acid and RU486
Canrenoic acid (the main metabolite of Spironolactone) and RU486 are 
selective antagonists of mineralocorticoid receptor and glucocorticoid receptor 
respectively. The doses of antagonists and timing of injections were chosen 
based on functional studies and binding assays demonstrating the time span 
necessary to allow proper passage of the drugs through the blood-brain barrier 
and their selective antagonism of mineralocorticoid and glucocorticoid receptors 
(Grupp et al., 1985; Semler et al., 1989; Baron et al., 1991; Herman and 
Spencer, 1998; Smriga et al., 1998; Koenig and Olive, 2004). Canrenoic acid 
(Sigma, USA) was dissolved in PBS 0.1 M and injected intraperitoneally (50 
mg/kg). RU486 (Sigma, USA) was dissolved in 25% Tween 80 and administered 
subcutaneously (8.5 mg/kg). The functional effects of Canrenoic acid and 
RU486 were evaluated 30 min after drug delivery.
r
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3.3.3 IL-1 (3
The doses and the time of administration of IL-1 p were selected on the 
basis of the studies indicating excitatory effects of these doses on seizure 
activity and neuron viability (Vezzani et al., 2000; Vezzani et al., 2002; Rothwell, 
1991; Morganti-Kossmann et al., 1992). Doses of IL-1 (3 administered were 5- 
100-200-500 ng/5 |jl PBS 0.1 M, icv (see protocol for icv injection below). The 
effect of cytokine on seizure threshold was tested 5 min after the icv 
administration.
3.3.4 Intracerebroventricular (icv) injections of IL-13
Rats were surgically implanted with cannulas under stereotaxic guidance 
as previously described (Vezzani et al., 1999). Briefly, rats were deeply 
anesthetized by administration of Equithesin (1% Phenobarbital and 4% chloral 
hydrate, 3 ml/kg i.p.). Bilateral stainless-steel guide cannulas (5 mm length) 
were implanted 1 mm above the lateral ventricles (AP, 0.2-0.3 mm caudal from 
bregma; L, ± 1.6 mm; V, 3.3 mm from the skull surface). The cannulas were 
secured with fast-curing dental acrylic. Bilateral icv infusion of IL-1 (3 was 
performed by using stainless-steel internal cannulas (6 mm length), each 
connected by a polyethylene tube to a 10-pl Hamilton syringe.
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3.4 Immunohistochemistry, Western blotting and 
Fluoro-Jade staining
3.4.1 Immunohistochemical detection of microglia and 
astrocytes
For immunohistochemical analysis of microglia and astrocytes, 
experimental rats and their controls (n = 5-10 each group) were killed 4 and 24 h 
after SE onset. At these time points we previously found significant glial cell 
activation by SE in adult rat brain (Vezzani et al., 1999; De Simoni et al., 2000). 
Rats were deeply anaesthetized using Equithesin [1% pentobarbital/4% (v/v) 
chloral hydrate; 3.5 ml/kg, i.p.] and transcardially perfused with 0.05 M PBS (pH
7.4) followed by 4% paraformaldehyde in PBS. Brains were postfixed in fixative 
for 4 h then cryoprotected in 20% sucrose in PBS overnight and rapidly frozen at 
—25°C.
Serial horizontal 40pm forebrain sections were cryosectioned at —  20°C. 
The sections encompassed the whole septotemporal aspect of the 
hippocampus. Adjacent slices were used in each brain for detection of microglia 
and astrocytes using specific markers, complement receptor type 3 (OX-42) and 
glia fibrillary acidic protein (GFAP) respectively and for detection of neuronal 
injury using Fluoro-Jade (Schmued et al., 1997).
Slices were incubated at 4°C for 30 min in 0.4% Triton X-100 in PBS 
followed by a 15-min incubation in 3% fetal bovine serum (FBS) in 0.1% Triton 
X-100 in PBS. They were subsequently incubated overnight at 4°C with the
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primary antibodies: mouse monoclonal antibody against OX-42 (Serotec Ltd, 
Oxford, UK, 1:100) or GFAP (Chemicon Int. Inc., Temecula, USA, 1:2500) in 3% 
FBS in 0.1% Triton X-100 in PBS. Immunoreactivity was tested by the avidin- 
biotin-peroxidase technique (Vectastain ABC kit, Vector Labs, USA). Sections 
were then reacted by incubation with 3',3'-diamino-benzidine (Sigma, Milan, 
Italy), mounted onto gelatine-coated slides, dehydrated in graded alcohols, and 
coversliped.
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3.4.2 Detection of degenerating neurons by Fluoro-Jade 
staining
Fluoro-Jade is an anionic tribasic fluorescein derivative with an emission 
peak at 550 nm and excitation peaks at 362 and 390 nm respectively. Fluoro- 
Jade staining was carried out as originally described by Schmued et al., 
(Schmued et al., 1997).
Brain sections were mounted with distilled water onto gelatine coated 
slides and dried on a slide warmer at 45° C. Dried tissue was then immersed in 
100% ethanol for 3 min followed by a 1 min change in 70% ethanol and a 1 min 
change in distilled water. The slides were then transferred to a solution of 0.06% 
potassium permanganate for 15 min and were gently shaken on a rotating 
platform. Then, the slides were rinsed for 1 min in distilled water and transferred 
to the Fluoro-Jade staining solution (0.001% Fluoro-Jade and 0.1% acetic acid, 
in distilled water), where they were gently agitated for 30 min. After staining, the 
sections were rinsed with three 1 min changes of distilled water. Excess water 
was drained off, and the slides were air dried on a slide warmer. When dry, the 
slides were immersed in xylene and then coversliped.
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3.4.3 Western blotting
Rats were decapitated 4 h after the SE onset. Both hippocampi were 
dissected out at 4°C, pooled, and homogenized in 20 mM Tris-HCI buffer (pH =
7.4) containing 1 mM EDTA, 5 mM EGTA, 1 mM Na-vanadate, 2 pg/pl aprotinin, 
1 pg/pl pepstatin, and 2 pg/pl leupeptin (30 mg tissue/100 pi homogenization 
buffer).
Total proteins were measured in each sample using the Bio-Rad Protein 
Assay (Bio-Rad Labs, Munchen, Germany). Twenty-five micrograms of total 
proteins per lane were analyzed using SDS-PAGE, 10% acrylamide, and each 
sample was run in duplicate in two different gels. Proteins were transferred to 
Hybond nitrocellulose membrane by electroblotting.
For immunoblotting, we used a mouse monoclonal antibody against 
GFAP (Clone G-A-5, 1:5000; Chemicon Int Inc.). This antibody has been 
previously characterized in detail (Debus et al., 1983) and it recognizes in 
Western blot a specific band of — 50 kDa corresponding to GFAP. It shows no 
cross-reactivity with other intermediate filament proteins. Immunoreactivity was 
visualized with enhanced chemiluminescence (ECL, Amersham, UK), using 
peroxidase-conjugated goat antimouse IgG (1:2000; Sigma-Aldrich, St. Louis, 
MO, USA) as secondary antibody. Densitometry was used to quantify the 
changes in protein levels in the immunoblots (AIS image analyzer, Imaging 
Research Inc., Ontario, Canada). Values obtained for each sample run in 
duplicate in two different gels were averaged to take into account variability due 
to protein loading. Assay variability in each sample was <10%. Film exposures
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with maximal signals below the photographic saturation point were used in the 
densitometric analysis.
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3.5 Evaluation of gene expression
3.5.1 Total RNA extraction and DNase I treatment
Rats were killed by decapitation at selected timepoints. Brains were 
removed and both hippocampi were dissected out at 4°C and rapidly frozen to 
— 70°C until assayed. Total RNA was isolated from tissue samples according to 
the acid guanidium-phenol-chloroform method (Chomczynski and Sacchi, 1987). 
The samples were digested by a denaturing solution containing 4 M guanidium 
thiocyanate, 25 mM sodium citrate, 0.5% sarcosyl, 0.1 M 2-mercaptoethanol, pH 
7.0. The lysate was extracted with a mixture of 2 M sodium acetate, pH 
4.0/phenol/chloroform-isoamyl alcohol (49:1), with relative ratios of 1:10:2 
respectively, and nucleic acids were precipitated with equal volumes of isopropyl 
alcohol. Total RNA was quantified by spectrophotometer whilst an aliquot was 
loaded onto 1 % agarose gel in order to visually check for RNA integrity. Before 
performing RNA reverse transcription to cDNA an aliquot of each sample (1-2 
pg) was treated with 1-2 U/pl of DNase I (Invitrogen, S. Giuliano Milanese, Italy) 
in order to minimize genomic DNA contaminants.
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3.5.2 Synthesis of cDNA by total RNA reverse transcription
The preferred method to generate cDNA was reverse transcription of total 
RNA with a Moloney murine leukaemia virus reverse transcriptase (MMLV-RT) 
using random primers. The use of random hexamers produces the least bias in 
the resulting cDNA and is amenable to both relative and standard-curve 
quantification methods (see below). Moreover, the use of random primers 
maximizes the number of mRNA molecules that can be analyzed from a small 
sample of RNA.
Practically, 1-2 pg of DNase-treated total RNA from each sample was 
used as a substrate for single-stranded cDNA synthesis using murine leukemia 
virus reverse transcriptase (50 U/pl; Perkin-Elmer, Emeryville, CA, USA), 
random hexamers (2.5 pM), and deoxyNTP mix (1.25 mM each) in a final 
volume of 20 pi. The mixture was stored at room temperature for 10 min, then 
incubation was performed in a thermocycler (Omn-E; Hybaid, Ashford, UK) at 
42°C for 15 min, at 99°C for 5 min, and at 5°C for 5 min.
For sample processing (i.e. real-time quantitative PCR) it was noticed 
that a two-step RT-PCR approach, in which the reverse-transcription reaction is 
performed in a separate tube to that of the PCR, was preferred to a one-step 
RT-PCR reaction, in which both reactions are performed in the same tube. 
Primarily, the two-step method produces cDNA that can be used in many 
experiments with several different genes and with less handling of the RNA, 
which can lead to degradation.
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3.5.3 Measurement of gene expression by real-time PCR
The levels of expression of mRNAs were determined by real-time 
quantitative PCR, performed with 5700 SDS instrumentation (Applied 
Biosystems), exploiting SYBR Green I as fluorescent dye. The specificity of 
SYBR Green I dye to a specific DNA target is entirely determined by primers, 
since this dye binds any double stranded nucleotide sequence.
In order to reach high efficiency rate of amplification most of the steps to 
optimize the reaction of amplification were accomplished according to the 
manufacturer of the real-time PCR instrument. Indeed, amplicon and primer 
design were accomplished by Primer Express software (Applied Biosystems) set 
with default parameters. Thus, the annealing temperature of each primer was 
restricted to 58-60°C, which corresponds to the optimal working conditions for 
the used DNA polymerase enzyme (AmpliTaq Gold, Applied Biosystems), 
General conditions for primer design were also followed, i.e., to keep the G/C 
content in the 20-80% range, to avoid runs of an identical nucleotide (especially 
for guanine) and, when possible, no more than two G and/or C bases at 3' end. 
Software allowed to check for hairpins, loops and potential primer-dimers thus 
permitting a finer tuning of primer pair selection.
Primers were not designed on different exons or intron-exon boundaries. 
To avoid co-amplification of contaminating genomic DNA, all RNA samples were 
treated with RNAse-free DNAse (see paragraph 3.4.2).
After primer design, the concentrations of each pair of forward and 
reverse primers that provide optimal assay performance (lowest threshold cycle, 
Ct, with highest efficiency) was identified.
149
Since the incorporation of SYBR Green I into real-time PCR allows the 
detection of any double-strand DNA generated during PCR, a dissociation curve 
analysis (analysis of melting temperature profiles) was performed upon 
completion of each PCR run. Dissociation curve analysis is equivalent to 
agarose gel analysis in order to assure for amplification of specific products and 
the lack of any spurious band due to non-specific amplification.
The following tables 7 and 8 summarize the operative conditions we used 
for measurement of gene expression by real-time PCR and list the primer pairs 
used for each specific gene of interest.
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Table 7. Summary of the operative conditions used for measurement 
of gene expression by real-time PCR
Real-time PCR operative conditions
> Replicate number for each sample loaded on reaction plate: 4
> Reagents and reaction buffer: SYBR Green 1 PCR Master Mix (ABI)
> Amplification Instrument: GeneAmp 5700 Sequence Detection 
System (ABI)
> Amplification Instrument operative conditions:
• 2 min at 50 °C
• 10 min at 95 °C
■>
• 5 sec at 95 °C
• 1 min at 60 °C
>- 40 cycles
> Dissociation Curve (melting temperature profile): starting at 60 °C to
90 °C
> Quantification Method: standard scale
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4. Experimental section
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4.1 Evaluation of glia activation and cytokine 
expression in the rat hippocampus by 
kainic acid-induced status epilepticus 
during postnatal development
The key determinants of the age-dependent occurrence of seizure- 
induced injury are still unclear. The present investigation starts by testing the 
hypothesis that activation of glia and the subsequent production of inflammatory 
molecules are involved in seizure-induced neuronal damage. To test this, we 
used rats of different ages [postnatal days (PN) 9, 15, and 21] known to have 
distinct susceptibility to seizures and neuronal injury. We studied (i) whether 
microglia and astrocytes are activated after SE induced by kainic acid, because 
these cells represent the major source of cytokine synthesis in mature rodent 
brain (Allan and Rothwell, 2001); (ii) whether proinflammatory (IL-1 p, IL-6, and 
TNF-a) and anti-inflammatory (IL-1Ra) cytokines are induced by SE in immature 
rat brain; and (iii) if there is a relationship between SE-induced cytokine changes 
in immature brain and the occurrence of neuronal cell injury.
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4.1.1 Materials and methods
4.1.1.1 Induction of status epilepticus
Different doses of intraperitoneal kainic acid (1.3, 5, and 7.5 mg/kg) were 
injected in PN9, PN15, and PN21 rats respectively because the seizure 
threshold to kainic acid is age-dependent (Cherubini et al., 1983; Albala et al., 
1984; Veliskova et al., 1988). As previously described in the chapter ‘Materials 
and methods -  general procedures’, we choose this model because it is well- 
established that SE induced by kainic acid is associated with age-dependent 
onset of neuronal injury (Albala et al., 1984; Ben-Ari et al., 1984; Holmes and 
Thompson, 1988 (a)). Controls were age-matched rats injected with an 
equivalent volume of phosphate-buffered saline (PBS, pH 7.4). Rats were 
monitored for about 3 h after kainic acid injection for behavioural manifestation 
of SE.
Kainic acid induced behavioural SE at all ages, with an average onset of 
30 min and duration of at least 3 h. As previously described in detail (Albala et 
al., 1984; Friedman et al., 1997), in PN9 and PN15 rats SE was characterized 
by bilateral clonic seizures of all extremities, whereas in PN21 rats, limbic motor 
seizures were characterized by continuous forelimb clonus.
Rats were returned to the lactating mother until sacrificed.
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4.1.1.2 Immunohistochemistry and Fluoro-Jade staining
Technical details related to immunohistochemical detection of OX-42 and 
GFAP as well as Fluoro-Jade staining have already been reported in ‘Materials 
and methods -  general procedures’.
157
4.1.2 Results
4.1.2.1 Glia activation by SE during postnatal development
Kainic-acid induced SE age-dependently increased OX-42 and GFAP 
immunostaining mainly in the hippocampus with no differences between 
individual hippocampal regions examined (CA1, CA3, dentate gyrus).
4.1.2.2 Changes of OX-42 immunostaining
Figure 7 shows OX-42 immunostaining in area CA3 of hippocampi from 
representative PN 9, PN 15, and PN 21 rats, 4 h and 24 h after SE onset, and 
their respective controls (n = 5-10 rats each group). Faint immunoreactivity was 
found in control sections at all postnatal ages. High magnification analysis of cell 
morphology at PN 9 (Fig. 6, control panel) revealed the presence of primitive 
ramified microglia, i.e., microglia with an oval, slightly elongated shape and 
scantly developed processes, whereas at PN 15 (Fig. 6, control panel) reactive­
like microglia (i.e., round to oval shape and coarse processes) was also 
observed (Dalmau et al., 1998). At PN 21, OX-42 staining in control sections 
(Fig. 6, control panel) was too faint to allow clear definition of cell morphology. 
This corresponds to the adult immunoreactivity pattern previously reported 
(Vezzani et al., 1999). SE induced little activation of microglia in PN 9 rats at 
either time points. OX-42 immunostaining was enhanced by seizures in PN 15
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and PN 21 rats (Fig. 6, 4 and 24 h panels) since strongly immunoreactive cells 
resembling reactive and ameboid microglia (Kreutzberg, 1996) were observed at 
both postnatal ages (Fig. 6, high magnification panels). In PN 15 rats, staining of 
microglia was enhanced also in the subiculum, whereas in 40% of PN 21 rats, 
microglia staining was increased also in the amygdala, entorhinal cortex, 
external layers of the temporal cortex, and periventricular thalamic nuclei (not 
shown).
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Control 4h 24h
PN 9
PN 15
PN 21
Representative photomicrographs of horizontal sections of the ventral 
hippocampus showing OX-42-positive microglia, 4 and 24 h after the 
onset of kainic acid-induced SE in PN 9, PN 15, and PN 21 rats. CA3, 
pyramidal layer; h, hilus. Scale bar, 100 pm.
Fig. 6
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4.1.2.3 Changes of GFAP immunostaining
GFAP staining was diffusely low in control sections at all postnatal ages 
(Fig. 7). High-magnification analysis of control sections showed stellate-shaped 
astrocytes with more pronounced arborization at PN 21. GFAP immunostaining 
was slightly enhanced by SE in PN 9 rats, 4 h and 24 h after SE onset as 
depicted in area CA3 of the hippocampus.
In PN 15 and PN 21 rats, a pronounced increase in GFAP signal was 
observed at both time points. GFAP-positive cells showed markedly enlarged 
cell bodies and thickening of processes, typical features of an activated 
phenotype. In PN 15 and PN 21 rats, the pattern of astrocyte activation in other 
forebrain areas was overlapping with that described for microglia.
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Control 4h 24h
PN 9
PN 15
PN 21
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Representative photomicrographs of horizontal sections of CA3 area of 
the ventral hippocampus showing GFAP-positive astrocytes, 4 and 24 h 
after the onset of kainic acid-induced SE in PN 9, PN 15, and PN 21 rats. 
CA3, pyramidal layer; h, hilus. Scale bar, 100 pm.
Fig. 7
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4.1.2.4 Western blot analysis of GFAP activation
Fig. 8, panel A, shows a Western blot analysis of GFAP from hippocampi of 
PN 9, PN 15, and PN 21 rats, 4 h after the onset of KA-induced SE, versus 
respective controls, accomplished in order to provide a semi-quantitative 
measure of reactive astrocytosis. Bargram depicts mean ± SEM (n = 4) of the 
optical density (OD) of the 50-kDa band corresponding to GFAP expressed as a 
percentage of respective control values.
A densitometric analysis of protein bands (fig. 8, panel B) showed a 
significant age-dependent increase in GFAP concentration in the hippocampus 
of control rats. At PN 15, GFAP concentration in the hippocampus was 26 ± 
1.5% (p < 0.05) higher than at PN 9. At PN 21, GFAP concentration was 60 ± 
3% higher than at PN 9 (p < 0.01) and 34 ± 1.5% higher than at PN 15 (p < 
0.01). Four hours after SE, GFAP levels did not change at PN 9, whereas they 
increased by 35% on average at PN 15 and PN 21. An attempt of measuring 
microglia activation by Western blot using the antibodies OX-42 and ED-1 
(Serotec, Oxford, UK) both labelling microglia in immunocytochemistry was 
unsuccessful since both antibodies did not recognize their specific antigens 
when using brain homogenates under denaturized conditions.
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a Western blot analysis of GFAP in the hippocampus of PN 9, 
PN 15 and PN 21 rats 4 hours after the onset of KA-induced 
status epilepticus
□ Control
□ Kainic acid
PN 9 PN 15 PN 21
B
-----  ------ -
1 2 3 4 5 6
Panel A. Western blot analysis of GFAP in the hippocampus, 4 h 
after the onset of kainic acid-induced SE in PN 9, PN 15, and PN 21 
rats. Panel B. Representative Western blots showing the increase in 
the GFAP band after seizures at PN 15 (lane 4) and PN 21 (lane 6) 
versus respective controls (lanes 3 and 5). No changes in GFAP 
were found after seizures at PN 9 (lane 2) versus control (lane 1).
*p < 0.05, **p < 0.01 vs control by Mann-Whitney.
Fig. 8
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4.1.2.5 Cytokine mRNA expression
The mRNA expression of the various cytokines was evaluated in the 
hippocampus of PN 9, PN 15, and PN 21 rats, 4 h after the onset of KA-induced 
SE (Fig. 9). Data are the mean ± SEM, (n = 6-10 rats) and are expressed as 
percentage of basal values of each cytokine. The amount of mRNA was 
calculated as the ratio of densitometric measurement of the cytokine samples to 
the corresponding internal standard (P-actin). Cytokine mRNA expression was 
unaffected by SE at PN 9, whereas in PN 15 rats, only IL-ip mRNA was 
increased by 2.2-fold (p <0.01). In PN 21 rats, all cytokines were increased. 
Thus, IL-ip and IL-6 mRNA expression was augmented by 3.6-fold above 
control (p < 0.01) and TNF-a and IL-1Ra by 1.5-fold on average (p < 0.05, p < 
0.01). IL-1p mRNA was induced to a significantly larger extent in PN 21 
compared to PN 15 rats (p < 0.05). A more detailed time-course of changes in 
PN 15 rats (2, 4, 18, and 24 h after the onset of SE) showed that IL-1 (3 mRNA 
expression was not modified at 2 h. The expression of IL-1 p was significantly 
increased over basal levels at 4 h. This increment was transient and returned to 
control values by 18 h. The expression of the other cytokines did not change at 
anytime point tested (fig. 10).
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mRNA expression of IL-1 beta, IL-1Ra, TNF-alpha and 
IL-6 in the hippocampus of PN 9, PN 15 and PN 21 
rats 4 hours after SE induced by KA
500.0
400.0
S 300,0 c
°  200,0
------------------i- • • I
* *
T”
IL-1 beta IL-1 Ra TNF-alpha IL-6
□ PN CO
PN 15
□ PN 21
Densitometric analysis of cytokine mRNA expression in rat 
hippocampus 4 h after SE induced by kainic acid in PN 9, PN 15, 
and PN 21 rats. *p < 0.05, **p < 0.01 vs respective age-matched 
controls by Mann-Whitney. IL-1 (3 mRNA levels after SE at PN 21 
were significantly higher than at PN 15 (p < 0.05)
Fig. 9
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Time-courseof IL-lbeta mRNA expression after 
KA-induced seizures in PN 15 rats
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□ KA4h
EDKA 18h
■ KA24h
Densitometric analysis of IL-1 (3 mRNA expression 2, 4, 18, and 24 
h after the onset of KA-induced SE in the hippocampus of PN 15 
rats. *p < 0.05 vs control group by Kruskal Wallis.
Fig. 10
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4.1.2.6 Evaluation of neuronal cell injury by Fluoro-Jade 
staining
Neuronal cell injury was not observed in the hippocampus of PN 9 rats (n = 
5-6) (fig. 11, panel A) or in any forebrain area, 4 and 24 h after SE onset. 
Evidence of Fluoro-Jade-positive neurons was found only 24 h after the SE 
onset in PN 15 and PN 21 rats. At PN 15 (n = 7), scattered positive pyramidal 
CA3 neurons were found in the most temporal aspect of the ventral 
hippocampus (fig. 11, panel B). At this age, few Fluoro-Jade-positive neurons 
were also detected in the dorsal part of the subiculum (fig. 11, panel C) but not 
in other forebrain areas. At PN 21 (n = 10), various pyramidal neurons in CA1 
(not shown) and in CA3 (fig. 11, panel D) were labelled in the ventral and dorsal 
hippocampus. At this age, 40% of rats showed Fluoro-Jade-positive neurons in 
the basolateral amygdala (fig. 11, panel E), entorhinal and temporal cortices, 
and periventricular thalamic nuclei. In PN 15 and PN 21 rats, consistent glia 
activation was found in the same brain areas showing injured neurons (not 
shown).
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Fluoro-Jade labelling of hippocampal neurons in horizontal section of the 
forebrain, 24 h after kainic acid-induced SE in PN 9, PN 15, and PN 21 
rats. CA3, pyramidal layer; si, stratum lacunosum-moleculare; so, stratum 
oriens; h, hilus. Scale bar, 100 pm.
Fig. 11
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4.1.3 Discussion
Results obtained in this experimental section show that activation of 
microglia and astrocytes, major sources of cytokines in the brain, as well as 
cytokine neosynthesis induced by SE, are age-dependent. Thus, at PN9 little 
activation of glia occurs and cytokines are not synthesized despite severe 
seizure activity. At PN15 and PN21 glia is strongly activated; IL-1 (3 mRNA only 
is induced at PN15, whereas the profile of cytokine mRNAs induction at PN21 is 
similar to adult rat brain (De Simoni et al., 2000).
The limited sensitivity of ELISA methods and lack of specific signal in 
immunocytochemistry with available antibodies in immature brains did not make 
the measure of cytokine proteins possible. In this regard, it is relevant to observe 
that the interpretation of our experimental data relies on the assumption that 
upon mRNA increasing a corresponding protein synthesis occurs. Nonetheless, 
several evidence has shown that transcription can be an isolated event from 
translation. A variety of stimuli, including LPS, IL-1 p and TNF-a, were shown to 
increase IL-1 (3 transcription without affecting translation, depending on the 
system under investigation (Fenton, 1992; Chantry et al., 1989; Sung and 
Walters, 1991; Knudsen et al., 1986; Dinarello, 1992). Indeed, both positive 
and negative regulation of translation occur at multiple sites of modulation along 
the translation pathway (Watkins et al., 1999; Fenton, 1992). Among several 
factors involved in the regulation of translation, relevant roles were shown to be 
played by the modulation of the percentage of mRNA sequestered in a 
functionally inactive state within structures called messenger ribonucleoprotein 
particles (Hershey, 1991), the modulatory effect mediated by proteins binding at
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specific regulatory sites within the 5’ UTR (Jansen et al., 1995) and the 
interactions between this region and the poly(A) tail which is also associated 
with specific binding proteins (Jackson, 1993). Additionally, the presence of AU 
rich element in the 3’ UTR is known to modulate translation (Kruys and Huez,
1994). In particular, the AU rich elements were shown to modulate the 
translation stability both by tonically decreasing the efficiency with which protein 
is formed and by expression of binding sites for proteins that can enhance or 
suppress the effect mediated by the same AU rich elements (Pain, 1996; Kruys 
and Huez 1994; Kruys et al., 1989). In this regard, the AU rich elements found in 
cytokines mRNAs are thought to tonically suppress translation via binding of a 
constitutive repressor protein.
In principle, the complexity of gene transcription modulation of molecules 
such as proinflammatory cytokines and the immaturity of the organism under 
investigation make the possible dissociation between transcription and 
translation a conceivable hypothesis. Indeed, it cannot be ruled out that the 
production of several modulators potentially relevant for bridging the gap 
between transcription and translation may not be appropriately entered into play 
at young ages, maybe due to the immaturity of signalling pathways and 
transcriptional/translational machineries.
By comparing the developmental patterns of cytokine induction in the hip­
pocampus with the appearance of Fluoro-Jade-positive neurons, it was evident 
that de novo cytokine synthesis, and in particular that of IL-1 p closely parallels 
the age-dependent profile of SE-induced cell injury. Noteworthy, IL-1 (3 mRNA at 
PN15 and PN21 increased in the hippocampus 4 h after SE onset, thus before 
the appearance of injured neurons (i.e., 24 h after seizures). The increased
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expression was more pronounced in PN21 rats in which a greater degree of 
injury was observed.
At PN15 only IL-1 (B is synthesized after SE, whereas the entire variety of 
proinflammatory cytokines is produced at PN21 as in adult brain (De Simoni et 
al., 2000). It is therefore possible that IL-1 (3 needs to work in concert with other 
cytokines in order to contribute to the occurrence of significant neuronal 
damage. Accordingly, IL-1 (3 and TNF-a in combination have been shown to 
cause marked neuronal injury in neuronal cell cultures although neither cytokine 
alone was toxic (Chao et al., 1995).
The possibility that the absence, or limited, cytokine induction within the 
first three postnatal weeks might be due to lack of hippocampal involvement in 
paroxysmal activity can be excluded, since it has been established that kainic 
acid induces strong metabolic activation and electrocorticographic seizures in 
the hippocampus of immature rats by PN9 (Albala et al., 1984; Ben-Ari et al., 
1984; Stafstrom et al., 1992).
Thus, the age-dependent profiles of mRNA induction appear to play a 
pivotal role in favour of the hypothesis that neurodegeneration might occur when 
seizures are able to induce the genome transcription of TNF-a and, in particular, 
IL-1 p.
It is of interest to observe that the ontogeny of physiological as well as 
KA-induced activity of nuclear regulatory elements that govern the gene 
transcription of proinflammatory cytokines in the rat hippocampus might 
contribute to describe our results.
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4.1.3.1 Ontogeny of KA-induced AP-1 mRNAs, proteins
and DNA binding activity in the rat hippocampus
The activator protein-1 (AP-1) represents a family of transcription factors 
which bind to AP-1 regulatory site (TGACTCA) located in the promoter region of 
target genes hence modulating transcriptional activity. This protein family 
includes c-fos and fos-related antigens (fra) as well as the jun-related factors. 
The AP-1 DNA binding complex is usually composed of a fra:jun heterodimer, 
although jun proteins can also form homodimers or dimers with other jun family 
members. Chemical agents, such as kainate, or hilar lesions that lead to seizure 
activity are known to induce the expression of AP-1 transcription factors in the 
adult hippocampus (Dragunow and Robertson, 1987; Morgan et al., 1987; 
Sonnenberg et al., 1989 (a, b); Simonato et al., 1991). Indeed, within 1.5 hours 
of kainate administration, changes in fra-immunoreactivity occur in entorhinal 
cortex and dentate gyrus, whereas fra-immunoreactivity in CA subfields of the 
hippocampus requires about 3-4 hours to become significantly different 
(Popovici et al., 1990).
The pattern of fra activation is significantly different when mRNA 
expression of transcription factors was evaluated in young rats aged PN7, PN14 
and PN21 at 1 and 6 hours after kainate treatment (Pennypacker et al., 1994). 
Despite seizure activity induced by KA administration at all ages, none of the 
transcripts encoding for c-fos, fos B, c-jun, jun B and jun D were overexpressed 
in PN7 rat hippocampus at 1 or 6 hours, while in the hippocampus of PN14 rats 
the mRNA for all of the transcription factors was significantly induced 6 h after 
KA administration with the important exception of c-jun and jun D which
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remained at basal levels. At PN21, rats exhibited an increase of mRNA 
expression for all transcription factors at 6 hours, reaching patterns of induction 
similar to that observed in adult rats.
The same group of investigators also assessed the AP-1 DNA binding 
activity and immunoreactivity for fos and c-jun proteins. Interestingly, PN7 rats, 
show elevated basal AP-1 DNA binding activity, despite a lack of KA-induced 
gene expression of AP-1 constitutive elements. The binding activity was indeed 
the highest as compared to what measured in PN14, PN21 and even adult rats, 
clearly showing that AP-1 DNA binding activity decreases markedly during 
ontogeny (Pennypacker et al., 1994). No KA-induced AP-1 DNA binding activity 
was evident until the second postnatal week of life. Consistent with these 
findings, both fra and c-jun immunoreactive proteins were not increased in the 
hippocampus following KA administration until PN14, where induction occurs 
later (4 h) compared to PN21 (1.5 h, similar to what occurs in adult rats). The c- 
jun protein in the rat hippocampus was not induced by KA administration at PN7 
although high basal level of c-jun protein was observed at this developmental 
stage as compared to PN14, PN21 and adult rats. Kainate was able to increase 
the expression of c-jun protein at PN14 as well as PN21, although at PN14 the 
increment takes longer to be evident (about 4 h) as compared to PN21 (1.5 h, 
similarly to adults).
This evidence is consistent with findings by other groups of investigators. 
For instance, c-fos protein has been shown not to be induced by KA 
administration in the mouse hippocampus until PN20 (Sakaurai-Yamashita et 
al., 1991), whereas prolonged seizures caused by high doses of 
pentylenetetrazole induce c-fos protein immunostaining in the mouse
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hippocampus which appears delayed until 4 h after drug administration (Jensen 
et al., 1993). Schreiber et al., (Schreiber et al., 1992) showed that KA 
administration was able to increase c-fos mRNA in the rat hippocampus only at 
PN13 (Dugich-Djordjevic et al., 1992).
Recently, a more detailed study based on immunohistochemistry 
technique (Silveira et al., 2002) has shown that fra immunoreactivity was 
increased in CA3 hippocampal subfield already at PN 7, 2-4 h after induction of 
seizures by KA administration. In older rats (aged PN 13 and PN 20) the 
induction of fra proteins was extended to all hippocampal subfields and DG, 
showing a significant increase 1 h after seizure onset which remained 
significantly elevated above basal level even after 24 h (PN 20 and adult rats) 
from seizure onset. These results are not in contradiction with those reported 
above since the discrepancy concerning pups at younger ages is likely due to 
the loss of sensitivity that affect measurements accomplished on whole tissue 
(as it is by electrophoretic mobility shift assay, EMSA) as compared to local 
evaluation of protein expression (as it is by immunohistochemistry).
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4.1.3.2 Ontogeny of physiological DNA binding activity of
CREB transcription factors in the rat hippocampus
It is of interest to observe that AP-1 transcription factors are usually 
composed of a fra:jun heterodimer formed through a leucine zipper to confer 
DNA binding activity. Nonetheless, jun proteins can also form homodimers or 
dimers with other jun family members. Differences in the individual components 
of AP-1 are known to affect the specificity as respect to canonical consensus 
sequences, hence giving rise to the possibility for AP-1 to bind to other 
sequences with similarities to the AP-1 site. Pennypacker et al., (Pennypacker et 
al., 1994; Pennypacker et al., 1995) showed that fra immunoreactivity in AP-1 
complexes in the rat hippocampus during the first three weeks of development is 
very low or undetectable. Indeed, the same group of investigators evidenced 
that CREB antibodies reacted with the AP-1 DNA binding complex at PN7, 
PN14 and PN21 thus indicating that CREB protein is a component of the basal 
AP-1 DNA binding activity during the early postnatal development (Pennypacker 
et al., 1995), just opposite to what encountered in adult animals where AP-1 
DNA binding complex contains fra and little or no CREB. Moreover, probably 
due to the similarity between the AP-1 sequence (TGACTCA) and CREB 
sequence (TGACGTCA), it was demonstrated that factors in the CREB DNA 
binding complex are able to recognize both the CRE and AP-1 elements, 
implying that genes with either of these promoter elements could be modulated 
by this transcription factor. This CREB containing complex was also shown to be 
recognized by antibodies reacting with jun-related factors. Since i) c-jun protein 
is also expressed at high basal levels during early development, ii) fra protein
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immunoreactivity is low during the same period and iii) c-jun expression is 
correlated with AP-1 DNA binding activity, then it is conceivable that the early 
postnatal AP-1 transcription factor might be composed of a CREB:c-jun dimer 
(Pennypacker et al., 1995).
These findings could suggest that during early developmental stages the 
transcription of genes containing binding element for AP-1 and CREB is 
favoured, and signalling pathways leading to jun protein transcription and 
activation might play a more relevant role during early postnatal life, maybe due 
to the constitutive commonality of this element with both transcription factors. 
Also, it appears that CREB could have a broader influence on gene transcription 
since it could bind to both CRE and AP-1 DNA binding site (Pennypacker et al.,
1995).
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4.1.3.3 Ontogeny of KA-induced NF-kB binding activity in
the rat hippocampus
Of interest is also the profile of induction of NF-kB following KA-induced 
SE in the rat hippocampus at different ages. Adult (PN 50) and young rats (PN 
15) were compared in their seizure-induced pattern of activation of nuclear 
factors such as NF-kB, and AP-1 (Rong et al., 1996). Besides confirming 
previous observations of AP-1 induction at young ages, as reported above, it 
was shown that following SE induced by kainate administration the transcription 
factor NF-kB was significantly induced in adult rats at 4 hours from KA injection, 
reaching the maximal increase at 8-16 hours after treatment and then 
decreasing to basal levels within 5 days. Conversely, no significant changes in 
NF-kB binding activity were observed after KA injection in PN 15 rats. Although 
not directly proven, it is conceivable that the lack of induction of NF-kB following 
KA-induced seizures might hold true also for younger pups such as those aged 
PN 7- 9.
Thus, it appears that changes related to SE induced by KA administration 
as well as some physiological features of young pups could account for the age- 
dependent pattern of both the expression of proinflammatory cytokines and the 
ontogenetic profiles of some transcription factors which are relevant to IL-1(3 and 
TNF-a expression. Interestingly, it could be observed the accordance of time 
course of induction of AP-1 by KA administration in PN 14 and PN 21 with the 
time course of transcription of IL-1(3 mRNA at comparable ages. Thus, IL-1 p 
transcript is transiently increased at 4 h after KA administration in PN 15 rats,
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while it is expressed at long-lasting high levels in PN 21 rats, similar to what 
occurs in adulthood.
The following table 9 aims to show the good accordance between the 
ontogenetic profile of KA-induced nuclear transcription factors for 
proinflammatory cytokines and their mRNAs as evidenced in this experimental 
section.
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In relation to seizure-induced neuronal damage that affect the limbic 
system, all temporal profiles of proinflammatory cytokines and related 
molecules, as evidenced so far, clearly show how the first two weeks of 
development mark a significant border-line beyond which some relevant 
phenomena linked to maturational aspects might come into play. Indeed, 
physiological events such as synapse formation, maturation of mossy fibres 
pathway, dendrite formation and innervation from the entorhinal cortex are 
expected to have a relevant role into the age-dependent occurrence of 
neurodegeneration.
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4.1.3.4 Induction of proinflammatory cytokines and
potential mediators of neurodegeneration
The limited activation of microglia and astrocytes after SE in the 
hippocampus and the lack of cytokine transcription at PN9 appear to be specific 
to seizures, as it was shown that microglia, astrocytes, and cytokines are 
activated at PN9 in other pathological conditions, such as hypoxia/ischemia 
(Szaflarski et al., 1995; Hagberg et al., 1996; Bona et al., 1999).
A general thought supports the hypothesis that if the induction of 
inflammatory processes by sustained seizures plays a role in age-dependent 
neuronal death, at least three pathways linked to cytokine-activated signal 
transduction may be involved, namely induction of iNOS, COX-2, and NMDA 
receptor subunit phosphorylation. Indeed, the pattern of induction of these 
potential mediators of neurodegeneration appears to be in good agreement with 
the time course of induction of proinflammatory cytokine mRNAs.
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4.1.3.4.1 Proinflammatory cytokines and iNOS
Proinflammatory cytokines are potent activators of iNOS, thus leading to 
the production of reactive nitrogen species (Chao et al., 1995; Romero et al., 
1996). Activation of iNOS in astrocytes by IL-ip potentiates NMDA-mediated 
neurotoxicity in mixed cortical cultures (Hewett et al., 1994). In addition, 
astrocytes exposed to IL-ip release measurable quantities of peroxide 
(Robinson et al., 1999), likely by activation of membrane-bound NADPH 
oxidase. Overproduction of free radicals, both oxygen and nitrogen species, 
during seizures has been suggested to play a pivotal role in neuronal cell injury 
(Koprowski et al., 1993; Ishida et al., 2001; Takei et al., 2001). As already 
mentioned (see paragraph 1.3.3) recent evidence has indeed shown that 
prolonged seizures in immature rats do not increase reactive oxygen species 
(ROS) as they do in adults (Li and Patel, 2002; Sullivan et al., 2003). Thus, IL- 
1P induced production of reactive nitrogen species and ROS may be 
developmentally regulated and contribute to age-dependent onset of irreversible 
cell injury.
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4.1.3.4.2 Proinflammatory cytokines and COX-2
The role of IL-ip in seizure-induced neuronal damage at PN15 and PN21 
may also involve its ability to stimulate COX-2 activity (Cao et al., 1995; Tocco et 
al., 1997). Constitutive expression of COX-2 in brain increases markedly in 
hippocampal neurons between PN7 and PN14, reaching adult levels at PN21 
(Tocco et al., 1997). Despite intense kainic acid-induced seizures, no COX-2 
induction was found before PN14 (Tocco et al., 1997). COX-2 mRNA induction 
in adult rat brain parallels temporally and spatially with the appearance of 
apoptotic cells in the hippocampus and other limbic areas (Tocco et al., 1997).
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4.1.3.4.3 Proinflammatory cytokines and NMDA
receptor
It was recently found that IL-1p induces Src kinases family-mediated 
tyrosine phosphorylation of the NR2A/B subunit of the NMDA receptor (Viviani et 
al., 2003). This is known to mediate upregulation of NMDA activity by increasing 
its channel gating properties (AH and Salter, 2001). The NR2A subunit sharply 
increases on pyramidal hippocampal cells after the first postnatal week (Monyer 
et al., 1994; Zhong et al., 1995). Thus, the age-dependent induction of IL-1 (3 
during seizures may contribute to the occurrence of neuronal damage by 
inducing post-translational modifications in the NR2 subunit. Interestingly, 
although NMDA receptors are operative in immature hippocampi, the reactivity 
of pyramidal cell apical dendrites to NMDA increases from PN5-9 to PN 12-30 
(Hamon and Heinemann, 1988), suggesting age-dependent modifications in 
receptor responsiveness to endogenous agonists.
The low reactivity of NMDA receptors at PN 5-9 itself might represents a 
control mechanism for the up-regulation of gene transcription for 
proinflammatory cytokines such as IL-1 (3 and TNF-a, whose induction could 
potentially become self-inducing by the involvement of this subtype of glutamate 
receptor. NMDA receptors have been shown to be physiologically and age- 
dependently coupled with CREB. Indeed, it is known that calcium influx through 
postsynaptic NMDA receptors can stimulate neuronal gene expression via 
signalling pathways such as the Ras-MAPK and the induction of CREB. It has 
been shown, in vitro, that the duration of CREB phosphorylation induced by 
NMDA receptor activation depends on the developmental maturity of cultured
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hippocampal neurons (Sala et al., 2000). A long-lasting (2 hours) increase in 
phosphorylated CREB was shown to occur at 7 days in vitro, whereas at 14 
days in vitro and older a strong stimulation of NMDA receptors only yielded a 
transient and short-lasting increase (< 30 minutes) in phosphorylated CREB. 
This feature appears to be specific for NMDA receptors since other stimuli, such 
as depolarization induced by high concentration of KCI, were shown to induce 
the same prolonged CREB phosphorylation in young and mature cultures. 
These observations suggest that NMDA receptors become coupled to a specific 
CREB phosphatase activity as neurons mature. Indeed, it was shown that PP-1 
is the major phosphatase involved in CREB dephosphorylation (Hagiwara et al., 
1992; Sala etal., 2000).
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4.1.4 A few observations on the hypothesis 
so far formulated
Evidence and arguments mentioned so far support the hypothesis that 
neuronal damage could be age-dependently linked to the overproduction of 
proinflammatory cytokines and related molecules.
Nonetheless, some issues arise. The experimental results obtained so far 
do not fully harmonize with the physiological and SE-induced developmental 
patterns as reported above.
Indeed, a look at the promoter region of genes for proinflammatory 
cytokines and mediators such as IL-1(3, TNF-a, COX-2 and iNOS, clearly shows 
that DNA binding sites for transcription factors such as AP-1, CREB and NF-kB 
are common to all those genes. The high levels of c-jun protein during early 
stages of life (despite low levels of its mRNA), together with a prolonged NMDA- 
mediated activation of CREB as well as formation of CREB:c-jun dimers which 
are able to also recognize AP-1 DNA binding sites, should increase the 
probability that gene transcription could be induced at earlier developmental 
stages of life (such as PN 9), in particular after induction of SE which leads to a 
prolonged stimulation of glutamate receptors. Genes responsive to CREB are 
known to be activated only when phosphorylation of CREB is prolonged (Bito et 
al., 1996; Sala et al., 2000), as occurs during long-lasting synaptic stimulation 
(e.g. during seizure activity) and, in light of findings mentioned above, it should 
be age-dependent, showing the strongest induction of CREB only at earlier 
developmental stages.
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Thus, apparently, it seems that at early postnatal stages of life, there are 
two opposite routes involved in the induction of gene transcription for 
proinflammatory cytokines such as IL-1 p and TNF-a, as well as proinflammatory 
mediators such as COX-2. An age-dependent AP-1 activation would account for 
the pattern of induction for IL-1 p, TNF-a and COX-2. In opposition, a prolonged 
activation of CREB following NMDA receptor stimulation, a physiological age- 
dependent feature which is particularly pronounced in the early postnatal 
development, represents a potential inductor of IL-1 p, TNF-a and COX-2 gene 
transcription. Such a gene transcription induction would be accomplished by 
binding to CRE DNA site as well as to AP-1 DNA site since it should be kept in 
mind that CREB also represents, together with c-jun protein, a constitutive 
element of AP-1 transcription factors in young pups. At present, there is no 
explanation for this issue.
However, it should be also observed that the great majority of studies on 
the induction of nuclear transcription factors relies on techniques such as the 
‘electrophoretic mobility shift assay’ (EMSA) which are mainly designed to 
determine any change in levels of such factors, leaving unanswered the 
question whether binding to chromatin and induction of target gene transcription 
actually occurs. It is known that the activation of a transcription factor and its 
subsequent translocation into the nucleus does not necessary mean that gene 
transcription is actually induced, as it has been shown for CREB (Gilty, 1997). 
Indeed, genomic advances have clearly shown that eukaryotic gene expression 
is mediated by interlinked regulatory mechanisms raising up through the 
interactions among nucleotide sequences, chromatin structure and 3D spatial 
organization of the genome inside the cell nucleus (van Driel et al., 2003). Thus
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it cannot be excluded that the age-dependent patterns of induction, as 
evidenced so far, might also be better explained in terms of ontogenetic 
changes of the complex dynamics governing the genome structure.
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4.2 Induction of cytokine expression in the 
hippocampus of PN 9 rats by flurothyl- 
induced status epilepticus
At the present step of discussion, it is relevant to ascertain if the pattern 
of expression of proinflammatory cytokines mRNAs by seizures induced by KA 
administration is a peculiarity of ictal activity itself or it could be related to the 
proconvulsant agent specifically used in the animal model under investigation. 
As the most relevant results occurred at PN 9, rat pups at this age underwent a 
protocol of SE induced by inhalation of flurothyl and mRNA expression for IL-1 p, 
IL-1Ra and TNF-a was evaluated at 4 and 24 hours after seizure onset. These 
measurements were also accompanied by histochemical evaluation of neuronal 
damage in the hippocampus by Fluoro-Jade staining, since it has been shown 
that also for flurothyl model of SE the induction of neurodegeneration is age- 
dependent (Sperber et al., 1999).
190
4.2.1 Materials and methods
4.2.1.1 Flurothyl-induced status epilepticus and evaluation 
of gene expression
Technical details related to:
• Flurothyl-induced status epilepticus;
• total RNA extraction;
• reverse transcription of total RNA;
• quantitative evaluation of gene expression by real-time PCR
• Fluoro-Jade staining
have already been reported in ‘Materials and methods -  general procedures’ 
For the assessment of neurodegeneration, Fluoro-Jade positive cells 
evaluation was accomplished 24h after seizure-onset. For each rat, 5 to 6 
40pm-thick slices were analysed.
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4.2.2 Results
The effect of 1 hour duration of flurothyl-induced SE on the mRNA 
expression of IL-1 (3, IL-1Ra and TNF-a was evaluated in the hippocampus of PN 
9 rats, 4 and 24 hours after the onset of seizures.
Results are depicted in fig. 12. Differently from that observed in PN 9 pups 
who underwent KA-induced seizures, statistically significant differences of 
mRNA expression were detected for both IL-1 (3 (12.3-fold increase) and TNF-a 
(6.7-fold increase) 4 hours after the onset of flurothyl-induced seizures as 
compared to control values, whereas the level of transcript of IL-1Ra was 
unaffected.
Table 10 shows that 1h flurothyl-induced SE does not affect neuronal 
viability 24 h after seizure-onset in PN 9 rats.
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Fig. 12
mRNA expression of IL-1 beta, IL-1Ra and TNF-alpha in the 
hippocampus of PN 9 rats sacrificed after 4 h and 24 h from 
the onset of flurothyl-induced seizures
□  Control
□  4 h
□  24 h
IL-1 beta IL-1Ra TNF-alpha
Data are the means ± SEM (n=6). * p<0.05 ** p<0.01 versus control 
group; § p<0.05 §§ p<0.01 vs 4 h group by Kruskal-Wallis test
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4.2.3 Discussion
The mRNAs for IL-1 (3 and TNF-a (fig. 12) are considerably expressed by 
flurothyl-induced SE 4 hours after the onset of ictal activity in rat pups aged as 
young as PN 9, with the exception of mRNA for IL-1Ra. The induction of IL-1 (3 
mRNA was still significantly higher when compared to basal levels 24 hours 
after the onset of flurothyl-induced seizures. We checked for neurodegeneration 
by Fluoro-Jade staining in the hippocampus of PN 9 rats which underwent 
flurothyl-induced SE and then sacrificed 24 h after seizure-onset (table 10, 
compare PBS group vs PBS+Flurothyl group). Clearly, there was a lack of 
degenerating neurons as assessed by Fluoro-Jade staining.
These findings confirm and extend results indicating the age-dependency 
of neurodegeneration induced by SE triggered by inhalation of flurothyl (Sperber 
et al., 1999). These authors showed that rat pups at PN 9 are preserved from 
neuronal damage in this model of SE, as in the KA model. Nonetheless, the 
expression of mRNA for proinflammatory cytokines, such as IL-1 (3 and TNF-a, is 
strongly induced 4 hours post treatment in rat pups aged PN 9, which is different 
from what occurs in the KA model of SE.
Studies investigating flurothyl-induced ontogenetic profiles of induction of 
either transcriptional factors or constituent molecules have been poorly 
investigated so far, probably because of the high cost of flurothyl, hence it is 
hard to attempt a plausible explanation for the pattern of expression of 
proinflammatory cytokines at PN 9 as it was done for the KA model of status 
epilepticus. At present, available evidence is mainly focused on c-fos and fra 
mRNA and protein expressions in young rats as compared to adults. Thus, c-fos
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protein was shown to be mildly induced in rat pups at PN 10-11 following single 
or brief flurothyl-induced seizures (Liu et al., 1999; Jensen et al., 1993), whereas 
a more pronounced immunostaining in DG and hippocampus occurs with more 
prolonged seizures (Jensen et al., 1993). A mild pattern of induction has been 
shown to occur at PN 23 following single seizures (Liu et al., 1999) while at PN 
19 the levels of c-fos mRNA expression were shown to be variable, being 
elevated in DG and CA3 hippocampal subfield in four animals out of ten (Szot et 
al., 2001).
However, these data, although similar to those found in the KA model as 
reported above, are not useful for the interpretation of the experimental results 
obtained, in particular because c-fos and fra in rat pups at young ages appear 
not to be so relevant as in older rats as respect to their contribution as 
constituent elements in nuclear transcription factors potentially involved in 
transcriptional activation of genes coding for proinflammatory cytokines and 
related molecules.
Generally, the model of flurothyl-induced SE seems not to support the 
hypothesis that neurodegeneration is preceded by an increase of transcription 
levels of proinflammatory cytokines. It might be that mRNAs production for IL-1 p 
and TNF-a does not yield significant levels of respective proteins in order to give 
raise to an inflammatory state that could affect the viability of neuronal 
populations in PN 9 rats. In vitro, the ability of proinflammatory cytokines to 
affect neuronal survival to an excitotoxic insult has been shown to depend on 
the concentration of the cytokines. For instance, it has been recently shown that 
a relatively high concentration of mouse recombinant TNF-a (10 ng/ml) 
enhances excitotoxicity in organotypic hippocampal slice cultures when
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simultaneously exposed to AMPA and to this cytokine. Conversely, a 10-times 
lower concentration of TNF-a (1 ng/ml) was shown to protect the cultures 
against AMPA-induced neuronal death (Bernardino et al., 2005).
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4.3 Effect of icv administration of IL-1 (3 
on flurothyl-induced seizure-onset 
and neurodegeneration following 1h 
flurothyl-induced SE in PN 9 rats
The possibility that IL-1 (3 levels might not be sufficient to induce 
neurodegeneration in PN 9 rats prompted us to evaluate the effect of the icv 
administration of a high dose of IL-1 (3 on neuronal viability after flurothyl-induced 
SE. We also investigated the dose-response of the icv administration of IL-1 (3 on 
flurothyl-induced clonic and tonic-clonic seizure-onset in PN 9 rats.
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4.3.1 Materials and methods
Technical details related to:
• Flurothyl-induced status epilepticus;
• Fluoro-Jade staining
have already been reported in ‘Materials and methods -  general procedures’. 
Each group of rats injected with a dose of IL-1 (3 was matched with a control 
group (indicated in the bargram’s legend as “PBS”). Independently from the 
dose of IL-1 p used, rat pups of the control group were always injected icv with 
0.1 % BSA dissolved in PBS. Seizure threshold was tested 5 min after the icv 
administration of IL-1 p. For the assessment of neurodegeneration, Fluoro-Jade 
positive cells evaluation was accomplished 24h after seizure-onset. For each 
rat, 5 to 6 40pm-thick slices were analysed.
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4.3.2 Results
Table 11 shows the effect of IL-1 p on neuronal viability after 1h SE 
induced by flurothyl. Evaluation was accomplished 24h after the onset of 
seizure. For a direct comparison, Table 11 also includes data of Table 10. The 
increment of the number of degenerating neurons in animals treated with icv 
injection of the cytokine ranges from 2 to 4 fold, on average.
Figure 13 depicts the dose-response of the icv administration of IL-1 (3 on 
clonic and tonic-clonic seizure onset flowing flurothyl inhalation. None of the 
doses administered was able to affect seizure susceptibility in PN 9 rats.
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Fig. 13
Dose-response of icv administration of IL-1 beta on 
flurothyl-induced seizures in PN 9 rats
Onset to clonic seizures
140
120
100
o
coo
40
□ PBS
□ IL-1 beta 5 ng
□ PBS
□ IL-1 beta 100 ng
LsJ r D o
□ IL-1 beta 200 ng
L-J r D o
□ IL-1 beta 500 ng
Onset to tonic-clonic seizures
□ PBS
□ IL-1 beta 5 ng
□ PBS
□ IL-1 beta 100 ng
□ PBS
□ IL-1 beta 200 ng
□ PBS
□ IL-1 beta 500 ng
Data are the mean ± SEM (n=8-12). No statistically significant 
differences occurred by Mann-Whitney test
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4.3.3 Discussion
Our findings support the hypothesis that the lack of neurodegeneration 
following SE at PN 9 may be ascribed at least in part to the lack of sufficient 
production of hippocampal IL-1 p. Thus, the administration of IL-1 p induces cell 
damage at PN 9 when exogenously applied before the induction of SE. 
Noteworthy, IL-1 p does not affect seizure in immature rat brain differently from 
adult rats. It should be observed, however, that testing for seizure threshold was 
performed shortly after the administration of cytokine (5 minutes, since this time 
interval was shown to be sufficient for IL-1 (S to affect seizure threshold in adult 
rats). Therefore, it might be that longer exposure time to cytokines is required to 
induce any effect on seizure susceptibility at young ages. We investigated this 
hypothesis in the next experimental section.
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4.4 Effect of LPS on the susceptibility to 
seizures induced by flurothyl inhalation 
in PN 9 rats
4.4.1 Introduction
As shown in the previous experimental section, the icv administration of 
IL-1 p in rat pups at PN 9 does not affect seizure susceptibility, differently from 
what reported in adult animals (fig. 13). This might be due to an insufficient 
concentration of IL-ip in the brain parenchyma to affect seizure susceptibility as 
in adult rats, although a high dose of the cytokine was injected. The possible 
requirement of a longer exposure time to cytokines to induce any effect on 
seizure susceptibility at young ages is indeed relevant. Clinical and experimental 
studies have shown that perinatal exposure to proinflammatory cytokines such 
as IL-1 p and TNF-a can be associated to neonatal brain damage which might 
constitute a pathological substrate priming the brain to develop enhanced 
seizure susceptibility and epilepsy later in life. During the last decade it has been 
suggested that maternal or placental infection (as well as early postnatal 
exposure to infections) may cause neonatal brain damage such as white matter 
disease (periventricular leukomalacia), and that induction of proinflammatory 
cytokines such as IL-1 p and TNF-a owing to maternal infectious diseases may 
be a mechanism mediating this and several other neurological disorders. In
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support of this hypothesis it has been shown that the occurrence of 
periventricular leukomalacia, which often leads to cerebral palsy, is frequently 
associated with increased concentrations of proinflammatory cytokines in the 
infant brain (Deguchi et al., 1996; Deguchi et al., 1997; Yoon et al., 1997), in the 
cord blood (Yoon et al., 1996) or in the amniotic fluid (Yoon et al., 1997). 
Additionally, a variety of maternal infections during pregnancy have been 
associated with an increased incidence of several pathologies such as 
schizophrenia in offspring, bronchopneumonia and other respiratory infections 
and varicella zoster (Gilmore and Jarskog, 1997; Watson et al., 1984; Torrey et 
al., 1988; O’Callaghan et al., 1994; Brown et al., 2000).
However, although increasing evidence has demonstrated the link 
between inflammatory cytokines and brain injury induced by 
infection/inflammation or hypoxia-ischemia (Dammann et al., 1997; Leviton, 
1993), the detailed role of cytokines in mediating neuronal cell death and white 
matter injury is still elusive and often controversial. Indeed, neurological 
alterations that frequently accompany white matter injury such as ventricle 
dilation, white matter rarefaction, reactive astrogliosis as well as decreased 
levels of myelin binding protein in the brain of neonates appear to be differently 
affected by proinflammatory cytokines such as IL-1 p and TNF-a. Thus, whereas 
administration of IL-1Ra has been shown to significantly attenuate LPS-induced 
white matter injury as well as LPS-induced elevation of caspase-3 activity in the 
rat brain, administration of TNF-a antibody was shown not to affect caspase-3 
activity nor significantly counteract white matter injury elicited in the same 
experimental conditions although a significant reduction of LPS-induced
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increase of IL-1 (3 protein levels in the neonatal rat brain was observed (Cai et 
al., 2003).
Generally, cytokines are known to regulate normal brain maturation and 
have been implicated in abnormal brain development (Merrill, 1992; Mehler et 
al., 1995; Mehler and Kessler, 1997). Moreover, proinflammatory cytokines have 
been shown to be neurotoxic to a variety of developing neurons in vitro. For 
instance, IL-1 p, TNF-a and IL-6 decrease survival of dopaminergic and 
serotonergic neurons (Jarskog et al., 1997). Also, IL-1 (3 decreases neuron 
survival in primary cultures of embryonic rat hippocampus (Arajujo and Cotman, 
1995; Viviani et al., 2003) and TNF-a potentiates glutamate excitotoxicity in 
cultures of fetal cortical neurons (Chao and Hu, 1994) and in organotypic slice 
cultures (Bernardino et al., 2005).
Therefore, it is conceivable that alterations of neuronal and glial 
populations and brain circuitries due to hypomyelinated neuronal connections 
might prime the neonatal CNS to increase the likelihood of seizures and/or 
epilepsy to occur during later stages of life.
In light of the aforementioned findings, we investigated the effect of 
inducing an inflammatory response in PN 9 rats on seizure susceptibility. LPS 
administration was used as the proinflammatory stimulus and seizure threshold 
was tested 2 hours after the endotoxin challenge. As a measure of the ongoing 
proinflammatory response IL-113 and TNF-a mRNAs were evaluated by RT-real 
time PCR.
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4.4.2 Materials and methods
LPS (Lipopolysaccharides from Escherichia coli, serotype 055:B5, Sigma, 
St. Louis, Mo, USA) was dissolved in 0.1 M Phosphate-buffered saline (PBS, 0.1 
M, pH 7.4 - 0.154 M NaCI; 0.016 M NaH2P 0 4 2H20\ 0.089 M Na2H P 04 2H20) 
and administered intraperitoneally 120 min before flurothyl delivery.
Technical details related to:
• seizure-threshold testing by flurothyl inhalation;
• mRNA extraction;
• reverse transcription;
• quantitative evaluation of gene expression by real-time PCR 
have already been reported in ‘Materials and methods - general procedures’.
For seizure susceptibility testing, drugs were administered 
intraperitoneally 2 hours before flurothyl delivery. For the evaluation of 
hippocampal levels of IL-1 [3 and TNF-a mRNA expression, rats were sacrificed 2 
hours after drugs administration.
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4.4.3 Results
Fig. 14 (A, B) depicts the dose-response effect of lipopolysaccharide 
(LPS) on flurothyl-induced seizures in PN 9 rats. Data are the mean ± SEM (n = 
12-16 pups) expressed as % of control (PBS-injected) group. The ordinate axis 
represents the latency times to onset of clonic (A) and tonic-clonic (B) seizures 
(the total volume in pi of flurothyl required to induce convulsions). Statistically 
significant delays of seizure-onset were achieved for all the doses of LPS 
administered, with the exception of the highest ones (2.0 and 4.0 mg/kg) for 
clonic seizures and 0.4 mg/kg for tonic-clonic seizures. The most effective dose 
of LPS in delaying seizure-onset for both clonic and tonic-clonic seizures was 
0.1 mg/kg, which showed, on average, 40% increase of latency to ictal events vs 
PBS-injected controls (p<0.01).
Herein we will refer to any dose of LPS that was shown to delay seizure- 
onset as being ‘protective’.
Fig. 15 (A, B) shows the level of mRNA of IL-1 [3 and TNF-a in the 
hippocampus induced by the administration of LPS, at protective (0.1 mg/kg and
1.0 mg/kg) and non-protective (4.0 mg/kg) doses. Measurements were done 2 
hours after the LPS administration, i.e. at the time of flurothyl delivery, thus, 
before the challenge with flurothyl-inhalation. The ordinate axis represents the 
level of mRNA expression as % of control (PBS-injected) group, assessed by 
quantitative RT-PCR.
The most protective dose of LPS (0.1 mg/kg) induced 235.2 ± 5.5 % 
level of expression of IL-1 (3 mRNA as compared to PBS-treated rats (p<0.01), 
whereas 10 times-higher concentration of LPS (1.0 mg/kg) triggered 145.5 ± 4.5
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%, p<0.01 vs basal levels of expression (fig. 15, panel A). A similar pattern 
occurred also for TNF-a (fig. 15, panel B). Thus, 0.1 mg/kg LPS induced a 362.7 
± 8.5 % level of expression of TNF-a mRNA as compared to PBS-treated rats 
(p<0.001), whereas 1.0 mg/kg LPS triggered 271.6 ± 15.5 %, p<0.001 vs basal 
levels of expression.
After administration of a non-protective dose of LPS (4.0 mg/kg), the 
levels of transcript of IL-1 p were similar to those elicited by 1.0 mg/kg LPS, 
whereas the TNF-a mRNA expression was markedly increased, 425.0 ± 27.3 %, 
p<0.01 vs basal levels of expression (fig. 15, panel B).
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Fig. 14
Dose-response curve of LPS administration on 
flurothyl-induced clonic (panel A) and tonic- 
clonic (panel B) seizure-onset in PN 9 rat pups.
Onset to clonic seizures
#
□ PBS
■ LPS 0.1 mg/kg
□ LPS 0.3 mg/kg
□ LPS 1.0 mg/kg
□ LPS 1.5 mg/kg
□ LPS 2.0 mg/kg
□ LPS 4.0 mg/kg
O nset to tonic-clonic seizures
&
□  PBS
■  LPS 0.1 mg/kg
□  LPS 0.3 mg/kg
□  LPS 1.0 mg/kg
□  LPS 1.5 mg/kg
□  LPS 2.0 mg/kg
□  LPS 4.0 mg/kg
Data are the mean ± SEM (n=12-16). * p<0.05 ** p<0.01 vs PBS; 
§ p<0.05 vs LPS 1.0 mg/kg and LPS 1.5 mg/kg; # p<0.01 vs LPS
2.0 mg/kg and LPS 4.0 mg/kg; ° p<0.01 vs LPS 4.0 mg/kg; 00
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p<0.01 vs LPS 2.0 mg/kg; A p<0.05 vs LPS 4.0 mg/kg; AA p<0.01 
vs LPS 2.0 mg/kg by Kruskal-Wallis test
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Fig. 15
mRNA expression of IL-1 (3 (panel A) and TNF-a 
(panel B) following the administration of 
different doses of LPS in PN 9 rats
IL-1 (3 mRNA expression
200 □ PBS
■ LPS 0.1 mg/kg
□ LPS 1.0 mg/kg
□ LPS 4.0 mg/kg
B
TNF-a mRNA expression
o 200
□ PBS
mLPS 0.1 mg/kg
□ LPS 1.0 mg/kg
□ LPS 4.0 mg/kg
Data are the mean ± SEM (n=6). * p<0.05 ** p<0.01 vs PBS; 
§ p<0.05 §§ p < 0.01 vs LPS 0.1 mg/kg; # p<0.01 vs LPS
1.0 mg/kg by Kruskal-Wallis test
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4.4.4 Discussion
Our findings suggest that the delaying effect of LPS on seizure-onset is 
not related to the pattern of induction of proinflammatory cytokines. Thus, the 
most pronounced increase in cytokines was provoked by the low protective dose 
of LPS. On the bases of the literature evidence it is expected that increasing 
doses of LPS induce increasing levels of proinflammatory cytokines transcripts.
Since this is not the case in our experimental conditions, a candidate 
mechanism which may explain our results is the activation of the hypothalamic- 
pituitary-adrenal axis (HPA). As already mentioned, unlike in adult animals 
which respond to most stimuli by increasing circulating corticosterone levels, rat 
pups are known to undergo a period (SHRP) characterized by adrenal 
insensitivity to direct stimulation with ACTH, minimal corticosterone elevations in 
response to most stressors, and a failure of mild stimuli to elicit ACTH response. 
Nonetheless, the limited response of the immature HPA system during the 
SHRP is not absolute and appears to be stimulus-specific and depends on 
which component of the HPA axis is considered. LPS, which is known to 
potently activate HPA axis in adult rats, acts similarly in rat pups at very young 
ages (such as PN 1-2) even during the SHRP (Witek-Janusek, 1988; Dent et al., 
1999). Indeed, the HPA axis response to intraperitoneal LPS administration in 
rat pups was determined at the beginning (PN 6), at the nadir (PN 12) and 
outside (PN 18) the SHRP. At all three ages, ACTH levels were robust with 
highest concentrations reached at PN 12, whereas the highest concentrations of 
corticosterone were reached at PN 18, as shown in fig 17. It is of interest to 
observe the temporal profile of circulating corticosterone at each age, which
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actually parallels the ACTH variations. At PN 6 and PN 12, after 4 hours from 
LPS administration, the concentration of corticosterone still tends to increase, 
although at PN 12 the absolute levels are lower than those measured at PN 6. 
These findings are fully compatible with i) a lack of an effective inhibitory 
feedback mechanism acting onto the HPA axis in young animals and ii) a 
decreased sensitivity of adrenal glands to circulating ACTH at PN 12. This is 
known to occur around this stage of postnatal life, leading to a reduced release 
of corticosterone into the circulation. Conversely, at PN 18, the levels of both 
ACTH and corticosterone tends to decrease after 4 hours from LPS 
administration, thus revealing operative negative feedback mechanisms (Dent et 
al., 1999).
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Adapted from Dent et al., 1999
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Thus, increasing doses of LPS in PN 9 rats may progressively stimulate 
the HPA axis to release corticosterone. Subsequently, this hormone would exert 
its well known anti-inflammatory action at genomic level by inhibiting 
transcriptional activation of molecules such as IL-1 p and TNF-a.
Interestingly, our results may have some relevance in relation to the 
phenomenon known as ‘preconditioning’ or ‘tolerance’. Generally, this term 
describes an event, usually a short insult, that once occurred in the brain is able 
to confer a transient resistance of brain tissue to a subsequent deleterious insult. 
For instance, it is known well that a brief exposure to ischemia provides robust 
protection against injury from subsequent prolonged ischemia (ischemic 
preconditioning) (Simon et al., 1993). This has been shown in animal models of 
stroke, whereas an analogous process has been suggested in humans wherein 
previous transient ischemic attacks are associated with improved clinical 
outcome and reduced infarction size from subsequent stroke (Weih et al., 1999; 
Wegener et al., 2004; Johnston, 2004). Although tolerance has mostly been 
described for ischemic insults, it has been reported also for other types of 
insults, including brain trauma and epilepsy (Dirnagl et al., 2003; Rejdak et al.,
2001). Indeed, epileptic tolerance is met in several animal models of seizures 
where, often, the preconditioning stimulus consists of noninjurious epileptic 
episode such as that induced by normal or rapid hippocampal kindling (Kelly and 
McIntyre, 1994; Penner et al., 2001), kainic acid-induced seizures (El Bahh et 
al., 1997; El Bahh et al., 2001; Lere et al., 2002; Najm et al., 1998), bicuculline- 
induced seizures (Sasahira et al., 1995), or electroshock (Kondratyev, 2001). 
Usually, the positive effects of preconditioning over prolonged epileptic episodes
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are related to a significantly reduced extension of neuronal damage as well as to 
an increased seizure-threshold to proconvulsant stimuli.
Interestingly, ischemic preconditioning or hypoxia inhibits the lethal 
effects of subsequent sustained severe seizures on neurons of various regions 
of brain (Plamondon et al., 1999; Emerson et al., 1999; Emerson et al., 2000; 
Rejdak et al., 2000; Rejdak et al., 2000), whereas preconditioning seizures 
partially inhibit neuronal death associated with severe ischemia (Plamondon et 
al., 1999). This evidence suggests that ischemic preconditioning and epileptic 
tolerance may share common mechanisms of action. Generally, preconditioning 
stimuli have been shown to generate a wide variety of metabolites and ligands 
that may be involved in the tolerance phenomenon (Blondeau et al., 2000; 
Dirnagl et al., 2003; Rejdak et al., 2001; Emerson et al., 2000; Leker and 
Neufeld, 2003; Nvue et al., 2004; Plamondon et al., 1999; Xu et al., 2002). In 
relation to our results, it is of interest to note that ischemia, seizures and LPS 
are usually expected to enhance gene expression and protein synthesis of 
proinflammatory molecules. Indeed, the activation of the transcription factor NF- 
kB and signalling pathways involving p38 MAPK were shown to be crucial steps 
underlying the development of brain seizure and ischemia tolerance (Blondeau 
et al., 2001; Jiang et al., 2005). These molecules play a pivotal role in the 
induction of transcription and mRNA stabilization of immediate early genes 
products such as inflammatory mediators, thus making the involvement of 
proinflammatory molecules in preconditioning phenomenon a conceivable 
hypothesis. In this regard, it has recently shown that within a short time window 
of 3 hours ischemic preconditioning followed by stroke strongly up-regulates 
genes related to inflammation and stress responses as compared to stroke
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alone. This pattern of gene induction at 3 hours turned to a significant down- 
regulation as compared to stroke alone when evaluated within a longer time 
window as 24 hours (Stenzel-Poore et al., 2004). It could be argued that our 
results show an inhibition of gene expression of LPS-induced proinflammatory 
markers such as IL-1 |S and TNF-a. In this regard, it is of interest to note that NF- 
kB and p38 MAPK have been shown to enhance the transcription of COX-2 
mRNA, leading to a subsequent increase of PGE2 production (Akundi et al., 
2005; Rhee and Hwang, 2000) which could actually account for the diminished 
expression of IL-1 p and TNF-a mRNA, being PGE2 shown to down-regulate the 
gene transcription of these cytokines. Accordingly, an indirect confirmation of 
increased PGE2 levels in our experimental system may be inferred by 
considering that LPS-induced activation of the HPA axis has been shown to 
involve PGE2 (see paragraph 1.4.5). In principle, although the anticonvulsant 
effect of LPS are expected to be mediated by the occupancy of membrane 
mineralocorticoid receptors by corticosterone, it cannot be ruled out an 
anticonvulsant role of PGE2. Several evidence from literature has shown the 
potential anticonvulsive and neuroprotective properties of endogenous 
prostaglandins in animal models of seizures. So, apparently, it might be that a 
possible phenomenon of preconditioning in our experimental system could be 
potentially mediated by corticosterone and PGE2. Nonetheless, a role of PGE2 
per se as a protective agent over seizure susceptibility may not be consistent 
with our experimental results. Indeed, our data show that the more the dose of 
LPS increases, the lower the seizure-threshold. Since several evidence from 
literature shows that PGE2 production is dose-dependently related to LPS, the 
less protective doses of LPS (i.e. the highest doses administered) are expected
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to be associated with high levels of PGE2 production, hence the exclusion of a 
protective role of PGE2 over seizure susceptibility.
In light of the present results, the exploitation of a proinflammatory 
stimulus such as LPS as a tool for seizure preconditioning needs substantial 
information which cannot be inferred from our data. A relevant parameter to be 
established is the duration of the protective effect over seizure susceptibility. 
Usually, the temporal scale within which the preconditioning shows its efficacy 
ranges from days to weeks. In our experimental system we detected the effect 
of LPS on seizure threshold within a time window as short as 2 hours, an 
interval which would suggest LPS administration as an efficacious 
‘pretreatment’ rather than a useful tool for ‘seizure preconditioning’. However, it 
is worth reminding that due to the immaturity of negative feedbacks involved in 
the HPA axis activation in rat pups, the increase over basal levels of LPS- 
induced corticosterone in the circulation was shown to be a long lasting 
phenomenon. Thus, elevation of corticosterone levels may represent a potential 
preconditioning stimulus, whereas the effect of PGE2 may be limited to the HPA 
axis activation with a possible affection of IL-1 (3 and TNF-a gene transcription. 
However, it is also conceivable that the down-regulation of 1L-1(3 and TNF-a 
gene expression might be ascribed to the conventional anti-inflammatory effect 
mediated by corticosteroids. This effect, in light of IL-1 (3 as a potential 
proconvulsant stimulus, may strengthen the resistance of the organism to 
develop seizures and should be a long lasting effect, being the translation of IL- 
1p protein down-regulated.
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Thus, to sum up, at this step of the investigation it is possible to speculate 
that the activation of the HPA axis by the systemic LPS administration and the 
subsequent involvement of the membrane mineralocorticoid receptors could 
represent a possible explanation of the LPS-induced delayed onset of flurothyl- 
induced seizures in rat pups.
The assessment of this working hypothesis is the target of the next 
experimental section.
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4.5 Involvement of corticosteroid receptors 
in the LPS modulation of flurothyl- 
induced seizures in PN 9 rats
4.5.1 Introduction
We tested the hypothesis that the delaying effect of LPS administration 
on flurothyl-induced seizure onset is mediated by an interaction of circulating 
corticosterone with membrane mineralocorticoid receptors. However, since our 
evaluation of seizure susceptibility and mRNAs expression of proinflammatory 
cytokines were made 2 hours after endotoxin administration it is possible that 
some genomic effects of corticosterone may have occurred, possibly 
contributing to modulate seizure susceptibility. Genomic effects of corticoids 
include the transcription of molecules which have been shown to be involved, at 
least in adulthood, in neurodegenerative phenomena such as IL-1 (3, TNF-a, 
COX-2, iNOS. All these molecules are characterized by a NF-kB consensus 
sequence in their promoter region. Any significant modulation of corticoids on 
these molecules might contribute to alter developing neuronal circuitries, 
producing a priming of the immature brain to show a predisposition to elicit ictal 
events and related neurodegeneration later in life.
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To verify the influence of corticosterone on seizure-threshold in our 
experimental conditions, canrenoic acid and RU486 were used as selective 
antagonists to mineralocorticoid and glucocorticoid receptors respectively. Drug 
delivery and testing of seizure susceptibility were accomplished in rat pups at 
PN 9.
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4.5.2 Materials and methods
Technical details related to seizure-threshold testing by flurothyl 
inhalation have already been reported in ‘Materials and methods - general 
procedures’.
The concentration of LPS used was 0.1 mg/kg and flurothyl delivery 
always occurred 2 h after the endotoxin challenge.
Canrenoic acid (Sigma, USA) was dissolved in PBS 0.1 M and injected 
intraperitoneally (50 mg/kg) 30 min before flurothyl delivery (i.e. 90 min after the 
systemic LPS administration).
RU486 (Sigma, USA) was dissolved in 25% Tween 80 and administered 
subcutaneously (8.5 mg/kg) 30 min before flurothyl delivery. Controls were rat 
pups treated with 0.1 mg/kg LPS and then administered with PBS or 25% 
Tween 80 30 min before flurothyl delivery.
223
4.5.3 Results
Figure 17, (A, B) depicts the effect of corticosteroid receptors on LPS- 
induced delay of seizure onset following flurothyl inhalation. The administration 
of canrenoic acid per se did not affect the susceptibility to seizures, but it 
abolished the delay of seizure onset induced by a protective dose of LPS (0.1 
mg/kg).
Figure 17, (C, D) shows the effect of the glucocorticoid receptor 
antagonist RU486 on the LPS-induced delay of seizure onset following flurothyl 
inhalation. The vehicle used to dissolve RU486 (25% Tween 80) significantly 
affected the onset to flurothyl-induced seizure when administered alone by 
increasing by 25% the latency to clonic seizures.
A further 30 % increase above Tween-injected rats (p<0.01) in the latency 
to both clonic (panel C) and tonic-clonic (panel D) seizures was induced by 
RU486. There were not statistically significant differences between the RU486 
alone and the LPS + RU486 administered group (panels C and D).
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Fig. 17
Effect of canrenoic acid (panels A and B) and 
RU486 (panels C and D) on LPS-induced delay of 
flurothyl-induced seizures in PN 9 rats
Onset to clonic seizures
□  PBS
□  Canrenoic acid
■  LPS 0.1 mg/kg
■  Canrenoic acid+LPS
Onset to tonic-clonic seizures
□  PBS
□  Canrenoic acid
■  LPS 0.1 mg/kg
■  Canrenoic acid+LPS
SplS
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Fig. 17 - (continued)
C
Onset to clonic seizures
□ PBS
■ LPS 0.1 mg/kg
□ 25% Tween 80
□ LPS 0.1 mg/kg (25% Tween 80)
□ RU486
□ LPS+RU486
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□ 25% Tween 80
□ LPS 0.1 mg/kg (25% Tween 80)
□ RU486
□ LPS+RU486
Data are the mean ± SEM (n=9-12 for panels A and B; n=6-10 for panels 
C and D). * p<0.05 ** p<0.01 vs PBS; § p<0.01 vs LPS 0.1 mg/kg; # 
p<0.01 ## p<0.001 vs 25% Tween 80 and LPS 0.1 mg/kg (25% Tween 
80) by Kruskal-Wallis test
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4.5.4 Discussion
These experiments show that seizure susceptibility is modulated by 
corticosterone. In particular, corticosterone receptors appear to mediate 
opposite effects since antagonism of mineralocorticoid receptors blocks the 
protective effect of LPS whereas antagonism of glucocorticoid receptors 
enhances seizure threshold perse but does not affect the LPS effect.
Thus, corticoid receptors appear to play a dual role on seizure 
susceptibility. A protective effect mediated by mineralocorticoid receptors, and a 
proconvulsant effect mediated by glucocorticoid receptor.
A relevant role for mineralocorticoid receptors in our experimental 
conditions is in line with the ontogenetic profile of these receptors. Protein levels 
of mineralocorticoid receptors are similar to adults by PN 7 and are much more 
abundant when compared to glucocorticoid receptors. Moreover, 
mineralocorticoid receptors show affinity an order of magnitude higher to the 
endogenous ligand corticosterone than glucocorticoid receptors after birth and 
during brain maturation (Bohn et al., 1994; Sarrieau et al., 1988; Vazquez et al., 
1998).
As far as glucocorticoid receptors are concerned, there is no evidence in 
the literature to support a proconvulsant effect emerging from the specific 
activation of these receptors in rat pups. Indeed, these receptors were shown 
not to modulate the occurrence of ictal events at young ages (Edwards et al.,
2002). In our experiments RU486 affects seizure susceptibility despite the effect 
of vehicle alone (25% Tween 80) (panels C, D). In particular, the delaying effect 
of RU486 on seizure onset is present in rats treated with this antagonist alone.
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The lack of a statistically significant difference between the RU486 administered 
group and the LPS + RU486 group (panels C and D) suggests a plateau effect 
when RU486 is administered in rats that cannot be further increased by 
endotoxin.
It cannot be excluded that antagonism to glucocorticoid receptors results 
in an enhancement of the anticonvulsant effect of circulating corticosterone 
acting on mineralocorticoid receptors. Glucocorticoid receptors are expressed to 
a much lesser extent than mineralocorticoid receptors and their affinity to 
corticosterone binding is 10 times lower. Additionally, although binding to 
glucocorticoid receptors by RU486 has been shown to translocate the 
receptorial complex into the nucleus, there is a substantial lack of a specific 
binding to GRE consensus sequences as demonstrated by the random 
distribution of the receptorial complex inside the nucleus (Htun et al., 1996). 
Therefore, it is likely that blockade of glucocorticoid receptors increases the 
probability of free corticosterone to significantly augment the percentage of 
cytoplasmic and membrane mineralocorticoid receptors occupancy.
In summary, HPA axis activation seems effective in modulating seizure 
susceptibility in LPS challenged animals, presumably through activation of 
membrane mineralocorticoid receptors. It is likely that cytoplasmic corticosteroid 
receptors exert also their classical genomic action, hence giving support to the 
hypothesis of a corticosterone-mediated modulation of IL-1(3 and TNF-a mRNA 
expression following systemic LPS administration in PN 9 rats. Therefore, it is 
conceivable that, in PN 9 rats, increasing doses of LPS progressively tend to 
increase mRNA levels of proinflammatory cytokines while at the same time 
stimulate the HPA axis to release corticosterone. Subsequently, this hormone
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would exert its well known anti-inflammatory action at genomic level by inhibiting 
transcriptional activation of molecules such as IL-113 and TNF-a.
It is of interest to observe that the activation of the HPA axis may be 
ascribed as a possible mechanism affecting the age-dependent expression of 
proinflammatory cytokines after KA and flurothyl administration. Excitatory 
aminoacids have been shown to activate the HPA axis not only in adults but 
also in rat pups, even during the stress hyporesponsive period (SHRP) (Bardgett 
et al., 1992; Chautard et al., 1993). In the study by Kent (Kent et al., 1996) 
experiments were accomplished in rat pups at PN 6 (near the beginning of 
SHRP), PN 12 (at the nadir of responsiveness) and PN 18 (after the end of 
SHRP). The pattern of induction of ACTH and corticosterone clearly shows that 
KA is a potent activator of the HPA axis in rat pups. The temporal profile of 
induction are very similar to those shown following LPS administration (Kent et 
al., 1996). The release of ACTH, which stimulates the release of corticosterone, 
is induced by KA at a greater extent at earlier ages (PN 6 and PN 12) and it 
appears even stronger than that induced by LPS. Similarly to endotoxin 
administration, negative feedback starts only at PN 18; thus, at earlier ages, 
corticosterone release by the adrenal glands stimulated by ACTH induces 
feedback inhibitory control. Interestingly, the authors showed that the elevation 
of levels of circulating hormones following KA administration was not due to ictal 
activity, since the raise of ACTH and corticosterone concentrations in animals 
who experienced SE was found long before the onset of any behavioural 
manifestation, and was similar to that found in animals that did not show any 
abnormal behaviour (Kent et al.,1996). These observations suggest that the lack 
or limited induction of mRNAs for cytokines at earlier ages (PN 9 and PN 15)
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following KA-induced SE might be a consequence of the anti-inflammatory effect 
of high levels of corticosterone triggered by KA administration itself. At PN 21, 
the raise of cytokines would be affected by the negative feedback mechanism 
acting on HPA axis, hence limiting elevation of corticosterone with a subsequent 
decrease of anti-inflammatory effect and resulting in a pronounced elevation of 
transcripts for proinflammatory cytokines.
In regard to the activation of the HPA axis following the administration of 
flurothyl, inhalation of ether vapor at PN 9 has been shown to be ineffective or 
mildly stimulating corticosterone levels (Suchecki et al., 1995; Walker et al., 
1993). This evidence may explain why rat pups exposed to flurothyl-induced SE 
showed elevation of transcripts for IL-1 p and TNF-a (fig. 12).
It should be mentioned, however, that a major limitation of data obtained 
in this experimental section is in that the interpretation of results relies on the 
assumption that the pattern of induction of corticosterone levels in our 
experimental conditions is similar to that reported in the literature for similar 
experimental paradigms. Indeed, our experimental system and the experimental 
paradigms share common features such as age, gender and treatment. 
However, the accordance of basal and LPS-induced levels of corticosterone and 
ACTH in our experimental system to those reported in the literature should be 
confirmed and extended. Two parameters, in particular, would be amenable of 
attention, i) the temporal profile of corticosterone induction shortly after the 
administration of a protective dose of the endotoxin and ii) the pattern of 
induction of corticosterone levels induced by a non-protective dose of LPS. As it 
regards the first parameter, the evaluation of corticosterone levels at time-points 
as short as 15-30 minutes after LPS administration would allow to verify the
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hypothesis of the involvement of membrane mineralocorticoid receptors in the 
quick modulation of seizure susceptibility in our experimental system, being this 
time-window hardly compatible with effects mediated by an action of 
corticosteroids at genomic level. As it concerns the second parameter, i.e. the 
induction of corticosterone by a non-protective dose of LPS, it cannot be ruled 
out that the lack of a protective effect of the highest doses of LPS might be 
ascribed to an inadequate amount of corticosterone due to an inefficient 
machinery of the immature HPA axis when facing an intense stimulation, as 
shown to occur in regard to the ACTH levels in young pups (Vazquez, 1998).
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4.6 LPS-induced IL-1p and TNF-a mRNA 
expression in the hippocampus of PN 9 
rats and its modulation by corticosteroid 
receptors
4.6.1 Introduction
Our data indicate that corticosterone released by the LPS-induced HPA 
axis activation modulates seizure susceptibility by activation of membrane 
mineralocorticoid receptors. Gene transcription of proinflammatory cytokines 
such as IL-1 p and TNF-a is NF-xB-dependent and susceptible to modulation by 
steroid hormones. Thus, it cannot be excluded that antagonism to 
mineralocorticoid receptor by canrenoic acid affects mRNA levels of these 
proinflammatory cytokines. It is possible that the effect of canrenoic acid 
administration on LPS-induced decrease in seizure susceptibility in PN 9 rats, is 
due to an enhancement of transcription of proinflammatory cytokines. In 
particular, IL-1 p has been shown to increase seizure susceptibility in adult 
rodents. It could be argued that we showed IL-1 (3 not to affect seizure 
susceptibility in PN 9 rats (fig. 13, paragraph 4.3.2) and we hypothesized it might 
be due to an insufficient increase in the brain parenchyma of IL-1 (3 levels, mainly 
because of the short interval between the icv administration of IL-1 p and seizure 
induction (5 min). However, the experimental protocol we used for testing
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seizure susceptibility was aimed to evaluate the levels of proinflammatory 
cytokines 2h after the administration of LPS. Moreover, the involvement of 
cerebral vascular system due the systemic administration of LPS is expected to 
induce an ubiquitous production of proinflammatory cytokines in the brain 
parenchyma. In principle, this widely distributed induction of IL-1 (3 may actually 
affect seizure susceptibility negatively, as it occurs in adult rodents.
Thus, we investigated the pattern of LPS-induced gene expression of IL- 
1p and TNF-a and its modulation by antagonists of corticosteroid receptors in 
our experimental system.
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4.6.2 Materials and methods
Technical details related to mRNA extraction, reverse transcription and 
evaluation of gene expression by real-time PCR have already been reported in 
‘Materials and methods - general procedures’.
The concentration of LPS used was 0.1 mg/kg. The experimental animals 
were sacrificed 2 h after the PBS or LPS injection for the subsequent evaluation 
of levels of transcripts in hippocampal tissue.
Canrenoic acid (Sigma, USA) was dissolved in PBS 0.1 M and injected 
intraperitoneally (50 mg/kg) alone or 90 min after the systemic LPS.
RU486 (Sigma, USA) was dissolved in 25% Tween 80 and administered 
subcutaneously (8.5 mg/kg) alone or 90 min after the systemic LPS
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4.6.3 Results
Figure 18, (A-D), depicts the effect of systemic administration of 
canrenoic acid and RU486 on the LPS-induced IL-1 (3 and TNF-a mRNA 
expression in PN 9 rats.
Effect of canrenoic acid
Systemic administration of 0.1 mg/kg LPS induced a 12-fold increase of 
IL-1 p and a 25-fold increase of TNF-a above basal levels (p<0.01).
Antagonism of mineralocorticoid receptors by canrenoic acid alone did 
not affect the mRNA expression of IL-ip and TNF-a. Conversely, canrenoic acid 
administration markedly diminished the LPS-induced expression of IL-1 p and 
TNF-a by 68% (p<0.05, panel A) and 60% (p<0.05, panel B) respectively.
Effect of RU486
Antagonist of glucocorticoid receptors by RU486 alone, or its vehicle, did 
not alter cytokine transcripts. Conversely, RU486 administration markedly 
diminished the LPS-induced expression of IL-1 (3 and TNF-a by 78% (p<0.05, 
panel C) and 84% (p<0.001, panel D).
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Fig. 18
Effect of canrenoic acid and RU486 administration 
on LPS-induced IL-1 (3 (panels A and C) and TNF-a 
(panels B and D) mRNAs expression in PN 9 rats
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Fig. 18 -  (continued)
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4.6.4 Discussion
The basal levels of mRNA expression of IL-1 (3 and TNF-a were not 
modified by either canrenoic acid or RU486. As expected, LPS administration 
increased the mRNA expression of these cytokines and this effect was strongly 
reduced following treatment with either canrenoic acid or RU486.
Our results show that the inhibitory effects of canrenoic acid and RU486 
on LPS-induced levels of IL-1 (3 and TNF-a are independent on the effects of 
these drugs on seizure susceptibility. These data support previous evidence that 
these cytokines are unlikely to play a role in the susceptibility to seizures in PN 9 
rats differently from adult rodents. In addition, our results show that the classical 
anti-inflammatory effect mediated by corticosteroids is not operative since 
antagonists of corticosterone receptors decrease LPS-induced IL-1 (S and TNF-a 
mRNA expression.
As a possible explanation of our findings, it is worth considering that, 
however, the production of proinflammatory mediators by glial cells is expected 
to be accompanied by production of regulators which limit in space and time the 
action of such inflammatory mediators. Among these regulators are IL-10 and 
IL-4, often referred to as anti-inflammatory cytokines. In peripheral tissues, these 
cytokines can be produced by a variety of immune cells (e.g. T cells and 
macrophages) and are known to suppress the secretion of proinflammatory 
cytokines and NO by activated macrophages. In the CNS, anti-inflammatory 
cytokines are produced by microglial and astroglial cells under various 
pathological conditions, including multiple sclerosis (Cannella and Raine, 1995; 
Peress et al., 1996), experimental allergic encephalomyelitis (EAE) (Jander et
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al., 1998; Kiefer et al., 1998; Laman et al., 1998), ischemia (Knuckey et al., 
1996; Lehrmann et al., 1998), AIDS (Johnson and Gold, 1996; Wahl et al., 
1991), and Alzheimer’s disease (Flanders et al., 1995; Peress and Perillo, 
1995). Since their production is associated with lesions or affected sites in the 
brain, IL-10 and IL-4 may have anti-inflammatory actions in the CNS similar to 
those in the periphery, i.e. inhibition of the production of inflammatory mediators.
As already discussed in the introductory part of the thesis, another 
candidate mechanism that could account for our results involves PGE2. It is 
worth reminding that PGE2 was shown to reduce microglia activation in vivo 
(Caggiano and Kraig, 1996) and in vitro (Thery et al., 1994; Caggiano and Kraig, 
1996; Caggiano and Kraig, 1998; Minghetti et al., 1997) by down-regulating the 
expression of major histocompatibility complex class II and the synthesis of 
proinflammatory cytokines. In particular, PGE2 was shown to largely prevent the 
expression of IL-1 (3 and TNF-a mRNA elicited by tissue injury (Zhang and 
Rivest, 2001).
Therefore, in the following two experimental sections we investigated the 
involvement of anti-inflammatory cytokines and PGE2 as possible candidate 
mechanisms capable to account for our findings.
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4.7 LPS-induced IL-4, IL-10, iNOS and 
IL-1Ra mRNAs expression in the 
hippocampus of PN 9 rats and their 
modulation by corticosteroid 
receptors
4.7.1 Introduction
As mentioned in the previous section, in the present experimental 
investigation we turn our attention to the levels of gene expression of anti­
inflammatory cytokines such as IL-4 and IL-10 in the same samples processed 
for IL-1 (3 and TNF-a evaluation. Indeed, it cannot be ruled out that the pattern of 
expression of IL-1 p and TNF-a mRNAs as shown in the previous experimental 
section might be ascribed to the induction of anti-inflammatory cytokines such as 
IL-10 and IL-4.
Biologically active IL-10 is a homodimers that affects many aspects of 
inflammatory and immune responses and acts on both haematopoietic and non- 
haematopoietic cells. Studies accomplished by cultures of microglia, co-cultures 
of rat astroglial and microglial cells and by in vivo administration of IL-10 have 
shown that exogenous IL-10 suppressed the LPS-induced production of NO, IL- 
6, IL-1 p and TNF-a at level of both proteins production and gene expression,
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whereas antibody to IL-10 yielded the opposite results (Kremlev and Palmer, 
2005; Ledeboer et al., 2000; Ledeboer et al., 2002; Di Santo et al., 1995). IL-10 
was also shown to enhance production of IL-1Ra by delaying mRNA 
degradation (Cassatella et al., 1994; Jenkins et al., 1994; de Waal Malefyt et al., 
1991). Interestingly, IL-10 inhibits its own mRNA expression, thus indicating an 
autoregulatory loop for IL-10 (Ledeboer et al., 2002). Computer-assisted studies 
inherent to the identification of consensus sequences for nuclear transcription 
factors have shown that the gene of IL-10 possesses putative AP-1 binding 
sites, glucocorticoid response element (GRE) and a cAMP response element 
(CRE) which appears to be functional, as agents that raise intracellular cAMP 
levels enhance the expression of IL-10 in monocytes. Interestingly, IL-10 was 
shown to inhibit PGE2 production induced by LPS-stimulated monocytes (Niiro 
et al 1994). This latter observation seems to suggest a regulatory loop between 
IL-10 and PGE2 since, on the one hand, IL-10 gene expression is up-regulated 
by cAMP elevating agents (such as PGE2 itself), while, on the other hand, IL-10 
inhibits PGE2 production following LPS stimulation.
Also IL-4 is an anti-inflammatory cytokine capable to reduce the 
production of inflammatory mediators, including IL-1 (3, TNF-a, iNOS, COX-2 
induced by activated microglia in vivo and in vitro (Furlan et al., 2000; Ledeboer 
et al., 2000). IL-4 production is controlled post-transcriptionally through 
stabilization of IL-4 mRNA (Dokter et al., 1993). Interestingly, in activated human 
T lymphocytes, accumulation of IL-4 mRNA is down-regulated by PGE2 and 
cAMP-dependent pathways, thus indicating the activation of PKA as a negative 
regulatory mechanism in IL-4 expression (Borger et al., 1996).
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Evidence shown above prompted us to associate the evaluation of IL-4 
and IL-10 gene expression with the measurement of transcription levels of IL- 
1Ra and iNOS, both molecules being relevant in the context of a 
proinflammatory state. We will take advantage from the evidence that these 
molecules are affected by the protein levels of IL-4 and IL-10, thus their 
modulation could be exploited as a marker of the functional involvement of the 
two anti-inflammatory cytokines.
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4.7.2 Materials and methods
Technical details related to mRNA extraction, reverse transcription and 
evaluation of gene expression by real-time PCR have already been reported in 
‘Materials and methods - general procedures’.
The concentration of LPS used was 0.1 mg/kg. The experimental animals 
were sacrificed 2 h after the PBS or LPS injection for the subsequent evaluation 
of levels of transcripts in hippocampal tissue.
Canrenoic acid (Sigma, USA) was dissolved in PBS 0.1 M and injected 
intraperitoneally (50 mg/kg) alone or 90 min after the systemic LPS.
RU486 (Sigma, USA) was dissolved in 25% Tween 80 and administered 
subcutaneously (8.5 mg/kg) alone or 90 min after the systemic LPS
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4.7.3 Results
Figure 19, (A-F), depicts the effect of systemic administration of canrenoic 
acid and RU486 on the LPS-induced IL-10, IL-1Ra and iNOS mRNAs 
expression in PN 9 rats. Likely due to the paucity of expression of IL-4 mRNA, 
RT-PCR did not yield any amplification for this cytokine. Indeed, the samples 
fluorescence was never significantly different from no-template controls (data 
not shown).
Effect of canrenoic acid
Panel A
Systemic administration of 0.1 mg/kg LPS induced a 2-fold increase of 
IL-10 vs PBS injected group (p<0.01) whereas canrenoic acid +LPS induced a 
2.5-fold increase of IL-10 above basal levels (p<0.01). The experimental groups 
treated with LPS and canrenoic acid + LPS were not statistically different. 
Canrenoic acid perse did not affected the basal levels of expression of IL-10.
Panel B
The administration of 0.1 mg/kg LPS induced a 2.2-fold increase of IL- 
1Ra vs PBS injected group (p<0.01) whereas canrenoic acid +LPS induced a 
1.7-fold increase of IL-1Ra above basal levels (p<0.01). The expression of IL- 
1Ra in the experimental group treated with canrenoic acid + LPS was
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significantly reduce by 21% as respect to the experimental group treated with 
LPS alone (p<0.01). Canrenoic acid per se did not affect the basal levels of 
expression of IL-1Ra.
Panel C
LPS administration (0.1 mg/kg) induced a 4-fold increase of iNOS vs PBS 
injected group (p<0.01) whereas canrenoic acid +LPS induced a 3.4-fold 
increase of iNOS above basal levels (p<0.01). The experimental groups treated 
with LPS and canrenoic acid + LPS were not statistically different. Canrenoic 
acid perse did not affected the basal levels of expression of iNOS.
Effect of RU486
Panel D
Systemic administration of 0.1 mg/kg LPS induced a 2-fold increase of 
IL-10 vs PBS injected group (p<0.05) whereas RU486 +LPS induced a 2.7-fold 
increase of IL-10 above basal levels (p<0.01). RU486 per se and RU+LPS 
induced a significant increase of the basal levels of expression of IL-10 (230% 
p<0.01, 170% p<0.01, respectively). The increments of levels of IL-10 mRNA 
induced by RU486 and RU486+LPS were also statistically different from that 
induced by LPS (p<0.01, p<0.05 respectively). The experimental groups treated 
with LPS and RU486 + LPS were not statistically different.
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Panel E
The administration of 0.1 mg/kg LPS induced a 2-fold increase of IL-1Ra 
vs PBS injected group (p<0.01) whereas RU486 +LPS induced a 4-fold increase 
of IL-1Ra above basal levels (p<0.01). The levels of IL-1Ra mRNA induced by 
RU486+LPS were significantly higher than those induced by LPS (p<0.01). 
RU486 perse did not affect the basal levels of expression of IL-1 Ra.
Panel F
LPS administration (0.1 mg/kg) induced a 4-fold increase of iNOS vs PBS 
injected group (p<0.05) whereas RU486 +LPS induced a 13-fold increase of 
iNOS above basal levels (p<0.01). The levels of iNOS mRNA of experimental 
groups administered with LPS and RU486+LPS were statistically different 
(p<0.01). RU486 perse did not affect the basal levels of expression of iNOS.
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Fig. 19
Effect of the administration of Canrenoic Acid 
(panels A, B, C) and RU486 (panels D, E, F) on LPS- 
induced IL-10, IL-1Ra and iNOS mRNAs expression 
in PN 9 rats
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Fig. 19 -  (continued)
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Fig. 19 -  (continued)
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4.7.4 Discussion
One of the immediate conclusions coming from our results is the 
irrelevant influence of IL-4. The amount of IL-4 mRNA expression is so low, 
even after stimulation by LPS, that a sensible technique such as real-time PCR 
cannot detect a significant amount of transcript in any of the experimental 
groups. This result is not surprising since other investigators have met 
undetectable amount of IL-4 both in terms of mRNA expression and protein 
synthesis, suggesting that in several experimental systems IL-4 cannot be 
readily produced in functionally relevant concentrations (Xiao et al., 1996; Brodie 
et al., 1998; Suzumura et al., 1994; Ledeboer et al., 2000), despite several 
studies indicate that IL-4 can be expressed by both microglial and astroglial cells 
in neuropathological conditions such as multiple sclerosis and EAE (Cannella 
and Raine, 1995; Laman et al., 1998; Ledtke et al., 1998). It cannot be ruled out 
that the short time-window of our testing, together with undetermined age- 
dependent feature of hippocampal tissue, may account for the low pattern of 
expression of IL-4 transcript.
Additionally, these results suggest that also IL-10 is not relevant in 
governing our experimental system. A few observations and several evidence 
from the literature support this conclusion. The first trivial observation is that the 
pattern of LPS-induced IL-1p and TNF-a mRNA expression modulated by CA 
and RU486 is always toward a decrease of transcript levels. If such a decrease 
was ascribed to the modulation of IL-10 than it is expected a similar pattern of 
LPS-induced IL-10 mRNA induction modulated by either corticosteroid receptors
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antagonists. This is not the case, as the administration of CA does not affect IL- 
10 mRNA expression, whereas RU486 perse  increases the levels of transcript 
of this anti-inflammatory cytokine. Indeed, this effect seems to be maximal for 
the system since LPS administration does not further increase the levels of IL-10 
transcripts. A second relevant consideration comes from the experimental 
observation that following LPS-administration both IL-10 gene expression and 
IL-10 protein synthesis takes much longer to be induced than those of IL-1 p and 
TNF-a. In principle, this observation does not rule out that a significant amount 
of IL-10 protein is synthesized, hence leading to a subsequent decrease of the 
expression of proinflammatory cytokines. Nonetheless, in co-cultures of rat 
microglial and astroglial cells, although LPS induces an up-regulation of IL-10 
mRNA expression, several hours are required for IL-10 protein to become 
apparent in the medium (Ledeboer et al., 2002). A similar slow onset of IL-10 
mRNA and protein responses has been reported for human monocytes (de 
Waal Malefyt et al., 1991; Donnelly et al., 1995) and microglial cells (Sheng et 
al., 1995; Williams et al., 1996; Kitamura et al., 2000). Indeed, the relatively 
delayed increase of IL-10 production after LPS activation is markedly different 
from the early onset of production of proinflammatory cytokines such as IL-1 (3 
and TNF-a, whose secretion was shown already detectable at 2h (Ledeboer et 
al., 2002; Sheng et al., 1995; Chao et al., 1995). For that reason the delayed 
production of IL-10 as compared to that of IL-1 (3 and TNF-a is consistent with 
the concept of a modulating role of IL-10 in the late phase of the inflammatory 
cascade (Zhai et al., 1997). Thus, it is hardly conceivable that our experimental 
system is facing a relevant amount of IL-10 sufficient to account for a strong 
down-regulation of IL-1 p and TNF-a gene expression, despite an increased level
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of IL-10 mRNA as shown following RU486 administration. It is of interest to 
observe that another confirmation of the lack of significant amount of IL-10 
protein production in our system may come from the increased expression of 
LPS-induced iNOS gene expression following RU486 administration. This 
finding is inconsistent with evidence from literature showing that IL-10 is likely to 
down-regulate the iNOS levels of transcript in cultures of rat microglia (Minghetti 
et al., 1998). However, it could be argued that IL-10 was shown to induce the 
production of IL-1Ra and our data with RU486 seems to support this finding. 
Nonetheless, in our opinion, the evidence supporting the lack of functionally 
relevant levels of IL-10 protein in our experimental conditions makes this 
presumed direct induction of IL-1Ra by IL-10 unlikely.
The evaluation of IL-1Ra as a potential anti-inflammatory modulator in our 
experimental system seems to suggest two different patterns of expression 
modulated by either corticosteroid receptors antagonists, being IL-1Ra gene 
expression enhanced when corticosterone is prevented to act on glucocorticoid 
receptors by RU486, whereas mineralocorticoid receptors appear to tonically 
sustain the expression of IL-1Ra mRNA. Clearly, these different patterns of IL- 
1Ra expression are not compatible with the down-regulation of LPS-induced 
gene expression of IL-1 p and TNF-a which is a common feature observed 
following the administration of either corticosteroid receptors antagonists. 
Interestingly, dexamethasone (an agonist of glucocorticoid receptors) was 
shown to inhibit IL-1Ra macrophage mRNA expression in LPS-treated rats 
(Ulich et al., 1992). Similar results were also obtained in LPS-stimulated human 
monocytes (Arzt et al., 1994). The effect was reversed by blocking the 
glucocorticoid receptors with the antagonist RU486. Indeed, this paper showed
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that inhibition by dexamethasone concomitantly affected both mRNA expression 
and protein levels of IL-1Ra, thus suggesting that IL-1Ra gene expression is 
regulated by glucocorticoid receptors (Arzt et al., 1994). This evidence may 
explain the decrease of LPS-induced IL-1Ra mRNA expression mediated by CA 
administration, as shown in our experiments. The occupancy of the abundant 
population of mineralocorticoid receptors by CA could increase the amount of 
corticosterone available to bind to glucocorticoid receptors, hence the decrease 
of IL-1Ra gene expression as shown following stimulation of this type of 
corticosteroid receptor. However, such an explanation may account for the 
down-regulation of LPS-induced IL-1Ra mRNA modulated by CA, but cannot be 
used as a possible explanation for the enhanced transcription of LPS-induced 
IL-1Ra mRNA following the administration of RU486. Indeed, RU486 was shown 
to counteract the effect of dexamethasone but not to increase the IL-1Ra gene 
expression when administered alone (Arzt et al., 1994).
Thus, the patterns of expression of conventional anti-inflammatory 
molecules such as IL-4, IL-10 and IL-1Ra lead to exclude a role for any of these 
molecules in mediating the down-regulation of LPS-induced IL-1 p and TNF-a 
mRNA expression following the administration of CA and RU486, as shown in 
our experimental conditions.
As far as the iNOS gene expression in concerned, it is not surprising to 
observe an insensitivity of this proinflammatory molecule to modulation by 
mineralocorticoid receptors, being iNOS mainly produced by glial cells. The 
antagonism of glucocorticoid receptors by RU486 enhances the LPS-induced 
gene expression of iNOS, apparently suggesting a conventional anti­
inflammatory role of glucocorticoid receptors. Thus, from this point of view, it is
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expected that blockade of glucocorticoid receptors by RU486 increases the 
expression of NF-xB-dependent inflammatory molecules such as iNOS. 
However, this hypothesis does not account for the down-regulation of LPS- 
induced IL-1 p and TNF-a mRNA expression following the administration of CA 
and RU486, as shown in our experimental conditions. According to evidence 
from literature, this result may be due to the insensitivity of microglia to 
circulating corticosterone, an insensitivity which seems not to affect iNOS 
production. Indeed, our data accentuate the discrepancy among the different 
patterns of gene expression of IL-1 (3, TNF-a and iNOS following the 
administration of either corticosteroid receptors antagonists, being all of them 
NF-xB-dependent immediate early genes. Thus, our data further exclude that 
corticosteroid receptors antagonists might be directly involved in the induction of 
patterns of gene expression so different from each other. Rather, CA and 
RU486 are expected to induce the production of a common mediator which 
should account for the majority (if not the whole) patterns of gene expression 
seen in our experimental conditions. Such a common mediator, as suggested by 
our evaluations, does not belong to the category of conventional anti­
inflammatory cytokines such as IL-4, IL-10 and IL-1Ra.
It is of interest to note that a quick survey on present data allows a 
distinction of the functional involvement of neuronal and glial cell populations, in 
that mineralocorticoid receptors are located on neurons whereas glucocorticoid 
receptors are mainly located on glial cells. Thus, it is not surprising to find out a 
substantial lack of effect of canrenoic acid as respect to the effects modulated 
by RU486, being IL-10, iNOS and IL-1Ra molecules originating from glial cells 
mainly. In this respect, it could be argued that also the patterns of inhibition of
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LPS-induced IL-1 (3 and TNF-a mRNA expression modulated by CA and RU486 
appear similar to each other, thus potentially suggestive of an irrelevant role of 
mineralocorticoid receptors. Nonetheless, the similarity is limited to the 
qualitative pattern since the relative amount of the inhibition of IL-113 and TNF-a 
mRNA expression by RU486 is much more pronounced as respect to the 
inhibition induced by CA, thus suggesting a specific involvement of RU486 
whose effect might sum to or synergize with a presently unknown factor.
According to evidence from literature, we formerly proposed also PGE2 as 
a candidate mediator of the down-regulation of proinflamatory cytokines 
expression, and our recent results keep this hypothesis conceivable. Indeed, 
COX-2 and iNOS are immediate early genes whose products of translation 
(PGE2 and NO, respectively) are promptly synthesized in LPS-stimulated glial 
cells. NO was shown to enhance the enzymatic activity of COX-2, without 
affecting the levels of its mRNA expression (Salvemini et al, 1993). Therefore, 
PGE2 production under a proinflammatory stimulus such as LPS appears to be 
favoured also in our experimental conditions. However, such a mechanism 
would only account for the mechanism of action of RU486, since CA does not 
affect iNOS mRNA expression. Nonetheless, our experimental system shows 
that both corticosteroid receptors antagonists down-regulate the IL-1 (3 and TNF- 
a mRNA expressions. Thus, it may be that CA and RU486 lead to an 
enhancement of prostanoid production through the involvement of different 
pathways, as the receptors upon which they act are localized on distinct cellular 
populations, that is neurons (mineralocorticoid) and glia (glucocorticoid).
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4.8 Modulation of LPS-induced COX-2 
mRNA expression by canrenoic acid 
and RU486 in the hippocampus of 
PN 9 rat
In this experimental section we focused on the involvement of PGE2 in 
the modulation of IL-1 p and TNF-a mRNA expression as shown in our 
experimental findings. Specifically, we evaluated the hypothesis that CA and 
RU486 would enhance PGE2 production by up-regulating the COX-2 gene 
expression. Such a hypothesis is indeed conceivable since gene transcription of 
COX-2 is NF-KB-dependent. Therefore, inhibition of corticosterone action by 
antagonists is expected to boost the expression of NF-xB-dependent genes. 
From this point of view, this is an intriguing issue since in our experimental 
system the expression of IL-1 (S and TNF-a mRNAs seems not to be affected by 
a direct action of corticosterone, although gene transcription of both of these 
proinflammatory cytokines is NF-xB-dependent.
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4.8.1 Materials and methods
Technical details related to mRNA extraction, reverse transcription and 
evaluation of gene expression by real-time PCR have already been reported in 
‘Materials and methods - general procedures’.
The concentration of LPS used was 0.1 mg/kg and after drug delivery the 
PN 9 rats were always sacrificed 2 hours after the endotoxin challenge for the 
successive evaluation of levels of transcripts in hippocampal tissue.
Canrenoic acid (Sigma, USA) was dissolved in PBS 0.1 M and injected 
intraperitoneally (50 mg/kg) 30 minutes before sacrifice (i.e. 90 minutes after the 
systemic LPS administration).
RU486 (Sigma, USA) was dissolved in 25% Tween 80 and administered 
subcutaneously (8.5 mg/kg) 30 minutes before sacrifice.
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4.8.2 Results
Fig. 20 depicts the effect of canrenoic acid administration on LPS-induced 
COX-2 mRNA expression in PN 9 rats. Data are the mean ± SE (n = 6 pups) 
The ordinate axis represents the level of mRNA expression as percentage of the 
control (PBS-injected) group, assessed by quantitative RT-PCR.
The protective dose of LPS (0.1 mg/kg) significantly increased the 
expression of COX-2 mRNA (303.1 ± 15.4) %, p<0.01 vs PBS-injected control 
group). This increment was not affected by the systemic administration of 
canrenoic acid, a mineralocorticoid receptor antagonist (406.4 ± 54.0) %). 
Canrenoic acid did not affected the basal level of COX-2 mRNA expression 
when administered alone.
Fig. 21 shows the effect of systemic administration of the glucocorticoid 
receptor antagonist RU486 on LPS-induced COX-2 mRNA expression in PN 9 
rats. As above, data are the mean ± SE (n = 6 pups) and the ordinate axis 
represents the level of mRNA expression as a percentage of control (PBS- 
injected) group, assessed by quantitative RT-PCR. The vehicle used to dissolve 
RU486 (25% Tween 80) did not affect the levels of COX-2 transcripts when 
administered alone and when injected 90 minutes after 0.1 mg/kg LPS.
The systemic administration of RU486 appeared to not affect the basal 
and LPS-induced expression of COX-2 mRNA. The only statistically significant 
differences were strictly related to the LPS-induced increment of COX-2 
transcription vs respective control groups, i.e. 280.1 ± 29.2 % vs 100.0 ± 7.3 % 
(p<0.05).
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Fig. 20
Effect of Canrenoic acid administration on LPS- 
induced COX-2 mRNA expression in PN 9 rats
□  PBS
□  Canrenoic Acid 
■ LPS 0.1 mg/kg
□  Canrenoic acid + LPS 0.1 
mg/kg
Data are the mean ± SE (n=6). * p<0.01 ** p<0.001 vs PBS; # p<0.01 
## p<0.001 vs Canrenoic acid. Kruskal-Wallis followed by Dunns 
multiple comparison test
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Fig. 21
Effect of RU486 administration on LPS-induced COX-2 
mRNA expression in PN 9 rats
□  PBS
■  LPS 0.1 mg/kg
 □  25% Tween 80
  □  LPS 0.1 mg/kg (25% Tween 80)
□  RU486
□  LPS+RU486
Data are the mean ± SE (n=6). * p<0.05 ** p<0.01 vs PBS group; § 
p<0.05 ° p<0.01 vs 25% Tween 80 and RU486 groups. Kruskal-Wallis 
followed by Dunns multiple comparison test
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4.8.3 Discussion
Systemic LPS administration induces COX-2 mRNA expression in the rat 
hippocampus at PN 9 but this effect appears to be insensitive to modulation by 
corticosterone. Since LPS is expected to activate gene transcription by NF-kB 
pathway, such insensitivity might suggest an apparent NF-xB-independent 
mechanism. Nonetheless, it is difficult to reasonably exclude an NF-xB- 
dependent mechanism of expression for COX-2, in particular when mediated by 
LPS administration, as several papers have demonstrated (Lacroix and Rivest, 
1998; Laflamme and Rivest, 1999; Laflamme et al., 1999; Zhang and Rivest, 
2001). Moreover, the inhibitory effect of glucocorticoids onto microglial COX-2 
expression has been clearly shown in vitro (Bauer et al., 1997).
Nonetheless, it is important to note that, in spite of a high responsiveness 
to glucocorticoids in vitro, microglia were shown not to readily respond to 
manipulation of glucocorticoid levels in vivo (Castano et al., 1996). According to 
available studies, this could be due to the density of corticosteroid receptors in 
microglia in vivo which is negligible in comparison with that found in neuronal 
cells and astrocytes, where they have been mainly localized (Aronsson et al., 
1988; Chou et al., 1991; Cintra et al., 1994). In addition, in vivo microglial 
glucocorticoid receptors appear to be down-regulated (Minghetti and Levi, 
1998).
If it is assumed that, in our experimental system, COX-2 expression is 
mainly of microglial origin and that its transcript is indeed NF-xB-dependent, our 
data are in agreement with a manifest insensitivity to circulating corticosterone
261
of microglia in vivo. Indeed, the similarity of pattern of induction of COX-2 
following administration of either type I or type II corticosteroid receptor 
antagonists supports this hypothesis.
The insensitivity of COX-2 expression and, presumably, PGE2 production 
to circulating corticosterone, increases the probability that the proconvulsant 
effect following the administration of canrenoic acid might be exclusively due to 
the lack of occupancy of membrane mineralocorticoid receptors, apparently 
without a significant contribution of PGE2.
Nonetheless, although PGE2 does not appear directly involved in the 
modulation of the effect of canrenoic acid administration on the LPS-induced 
delay of seizure-onset in rat pups, in adult animals the increase of its levels has 
been shown as a fundamental step for the activation of the HPA axis following 
the injection of a proinflammatory stimulus. It is conceivable that also in rat pups 
the increase of PGE2 following LPS administration could activate the HPA axis, 
thus leading to the age-dependent anticonvulsant effect of corticosterone.
So, on the one hand, PGE2 could play an indirect anticonvulsant role 
through the activation of the HPA axis, while, on the other hand, evidence from 
literature shows that (in adult rats) the administration of a COX-2 inhibitor 
delayed flurothyl-induced seizure-onset, hence supporting a proconvulsant role 
of PGE2. In the next experimental section we went on investigating on the 
possibility of a functional involvement of PGE2 in our experimental system. We 
focused our attention on alternative mechanisms capable to boost PGE2 
production despite unchanged levels of expression of COX-2 mRNA.
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4.9 Modulation of the expression of the PKA 
regulatory subunit Rllp and PKC-y by 
corticosteroid receptors
4.9.1 Introduction
Our experimental results suggest that despite the insensitivity of 
microglia to circulating corticosterone, canrenoic acid and RU486 
administration somehow modulate the down-regulation of IL-1 p and TNF-a 
expression (fig. 18). This modulation is likely to involve an effector originating 
from neurons and/or astrocytes following blockade of corticosterone action.
We speculated that, despite unchanged levels of COX-2 expression, the 
treatment with canrenoic acid or RU486 could lead to an increase of PGE2 
production from non-microglial cells. This would lead to the decreased 
expression of proinflammatory cytokines resulting from the deactivating role of 
PGE2 over microglia.
Therefore, we wondered whether corticosteroids might affect the gene 
expression of some proteins usually involved in the modulation of the 
functionality of the COX-2 /PGE2 system, leading to an overexpression of PGE2 
production, in particular in non-microglial cells.
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As discussed in the introductory section (see paragraphs 1.4.5.1 and 
1.4.5.2), the expression and functionality of COX-2 and PGE2 are strictly 
interrelated with the activity of two relevant kinases, PKA and PKC. Therefore, 
as a working hypothesis, we wondered whether antagonists to corticosteroid 
receptors could affect the expression of these two enzymes and therefore 
account for the postulated overproduction of PGE2 observed, in spite of the 
unchanged level of expression of COX-2 mRNA.
As PKA and PKC are characterized by several isoforms and variations 
of constitutive regulatory and catalytic subunits, it is of interest to ascertain 
whether specific isozymes as well as subunits might be of particular relevance 
in order to target their mRNA expression.
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4.9.1.1 PKA: a relevant role of the regulatory subunit 
Rll(3
In the absence of cAMP, PKA is an enzymatically inactive tetrameric 
holoenzyme consisting of two catalytic subunits (C) bound to a dimer which 
constitute the regulatory subunit (R). Activation of PKA occurs when four 
molecules of cAMP bind to the R subunit dimer, two to each subunit, in a 
positive cooperative fashion. As a consequence of cAMP binding, the R 
subunits adopt a configuration with low affinity for the C subunits and the 
holoenzyme dissociates. Active C subunits then phosphorylate serine and 
threonine residues on specific substrate proteins (Skalhegg et al., 2000). The 
two major forms of PKA are termed type I and II as they were shown to contain 
C subunits associated with two different R subunits, termed Rl and RlI.Cloning 
of cDNAs for regulatory subunits have identified for each R subunit two 
isoforms termed a and p, hence giving rise to Rla, Rip, Rlla and Rlip. 
Generally, PKA type I is soluble and preferentially located in the cytosol 
whereas type II preferentially binds to the particulate fraction (Meinkoth et al., 
1990). The tissue distribution of regulatory subunits is such that Rla and Rlla 
are present ubiquitously, whereas Rip is present in the brain. However, the 
predominant isoform and principal mediators of cAMP-induced activity in 
mammalian CNS is Rllp, which shows a high affinity for specific proteins 
located on membranes of intracellular structures such as the Golgi complex 
and perinuclear area. These proteins are generally named A-kinase anchoring 
proteins, and are required to mediate specific, localized effects of cAMP to
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subcellular domains (Sarkar et al., 1984). In cortical cells, Rllp was shown 
abundant in neurons and astrocytes (Stein et al., 1987).
Interesting observations have been made on investigation of the 
differential response of PKA to cAMP in discrete brain areas in relation to the 
abundance of Rlip mRNA expression (Ventra et al., 1996 J). Indeed, the 
investigators pointed out that cerebral areas with high levels of membrane- 
bound PKA and low levels of cytosolic catalytic subunit also have high levels of 
Rllp expression, suggesting that areas containing membrane-bound PKA 
maintain PKA prevalently undissociated, thus showing a correlation between 
Rllp mRNA level measurements and PKA intracellular distribution. In 
comparison with cerebral areas such as neocortex and corpus striatum, the 
hippocampus expresses low levels of Rlip mRNA in terms of relative ratio to 
the other R subunits, Rla and Rlla. Nonetheless, this limbic area shows a very 
high level of PKA catalytic activity in the cytosol, activity which is the highest 
among all the cerebral areas investigated (Ventra et al., 1996 J). Furthermore, 
the same paper showed a relevant differential feature between cerebral areas 
with low levels of Rllp mRNA expression (such as cerebellum) and those 
expressing high levels (such as neocortex), in that although PKA 
responsiveness to cAMP-stimulation of areas with lower Rllp mRNA is highly 
sensitive, there is a substantial lack of translocation of catalytic subunits into 
the nucleus, as also confirmed by immunoblot analysis aimed to evaluate the 
amount of nuclear phosphorilated-CREB. Conversely, high Rllp mRNA 
expressing areas were shown poorly sensitive to cAMP-stimulation, leaving 
PKA mainly in the undissociated state. However, despite the low degree of 
PKA dissociation, the response in terms of nuclear translocation of catalytic
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subunits is quick and sustained, as confirmed by the consistent levels of 
phosphorylated-CREB (Ventra et al. 1996).
Regarding the gene expression of PKA regulatory subunits, the lack of 
DNA-binding sites sensitive to direct or indirect modulation of Rlip gene 
expression by glucocorticoids (GRE, NF-kB, AP-1) would apparently suggest a 
weak relationship between corticosteroids and PKA. Nonetheless, several 
studies have suggested that glucocorticoids can up- or down-regulate adenylyl 
cyclase activity depending on the type of neurotransmitter receptors affected 
(Mobley et al., 1983; Harrelson et al., 1987; Gannon et al., 1990; Duman et al., 
1989; Johnson et al., 1983; Saito et al., 1989). Of interest to our purposes, in 
the cortex and hippocampus of adult rats, it was shown that removal of 
corticosterone by adrenalectomy increased PKA activity and cAMP binding 
sites to PKA, along with an increase of protein expression for the specific 
subunits Rla and Rlip as well as catalytic subunit p (Dwivedi et al., 2000). 
These increments were preventable by simultaneous treatment with 
corticosterone, which caused just the opposite effect on administration to intact 
animals.
It is worth noting that the relationship between the catalytic activity of 
PKA and Rllp might be relevant in view of the modulating role of the PKA C 
subunit upon both transcriptional activity of NF-kB and cross-repression by NF- 
kB and the glucocorticoid receptor (Zhong et al., 1997; Doucas et al., 2000).
The majority of available data comes from studies accomplished in adult 
animals which underwent prolonged treatment with corticosteroids, thus 
dealing with experimental protocols which are substantially different from our 
experimental conditions. Nonetheless, they show that glucocorticoids can
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modulate the cAMP-PKA system, including the expression of regulatory and 
catalytic subunits of the kinase. However, these studies would suggest an 
indirect effect of glucocorticoids since interactions between the HPA axis and 
cAMP-PKA system become significantly relevant only on chronic treatments 
with augmented or abolished levels of circulating corticosterone, as, for 
instance, in the case of corticosterone-supplemented naive animals or 
adrenalectomized animals.
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4.9.1.2 PKC: a relevant role of the isoform y
Generally, protein kinase C is a serine/threonine protein kinase 
ubiquitously found in a variety of animal tissues and shown to be encoded by a 
family of closely related genes, hence giving rise to several PKC isoforms. 
Structurally, PKC consists of a regulatory domain and a catalytic domain 
(Nishizuka et al., 1991). To date, at least 12 PKC isozymes are known and 
have been classified as conventional (a, pi, (311 and y), novel (5, e, q. 0 and p), 
or atypical (£, A and i). Novel PKCs differ from conventional ones because they 
do not require Ca2+ for activation whereas atypical PKCs, besides being Ca2+ - 
independent, are also insensitive to DAG and to phorbol ester activation 
(Dwivedi et al., 1999). Each PKC isozyme differs in its distribution, biochemical 
characteristics and substrate specificity. PKC isozymes a, 5 and ? are present 
in nearly all tissues, whereas PKC e, rj and 0 are restricted to a few tissues, 
and PKC y is present only in the brain and spinal cord (Nishizuka, 1988; 
Nishizuka et al., 1991; Casabona, 1997). The PKC y-isoform, which is 
exclusively located in neuronal cells and totally absent in microglia and 
astrocytes (Gott et al., 1994; Roisin et al., 1997; Masliah et al., 1991; Slepko 
et al., 1999), is highly concentrated in cerebellum, hippocampus, amygdala and 
cerebral cortex (Huang et al., 1987). During the rat brain development this 
kinase was shown to be expressed at a low level in the neonate one-week after 
birth, whereas a rapid synthesis occurs between two and three weeks of age 
(Yoshida et al., 1988), a period which correlates with commencement of 
synaptogenesis and myelination. In keep with the aforementioned observation, 
it has been suggested that the PKC-y gene might be developmentally regulated
in that a specific binding motif in the 5-flanking region is targeted by nuclear 
proteins whose levels of expression are evident in PN 3 -  6 rats but much less 
expressed at PN 14, and by the third week of age become undetectable. As the 
decrease of binding proteins to such a specific site in developing rats is 
inversely associated to the expression of PKC-y, it was speculated that these 
binding proteins possess a negative regulatory function (Chen et al., 1993).
Several studies have pointed out the relevant role of PKC-y in the brain, 
especially in cerebral areas into which neuronal plasticity occurs, as in the 
hippocampus where PKC-y is particularly abundant in pyramidal cells (Saito et 
al., 1988). At the cellular level, PKC-y, differently from the other isoforms, is 
nearly exclusively localized postsynaptically (Kose et al., 1990) and it is present 
abundantly in dendritic spines (Kose et al., 1990; Tsujino et al., 1990). This 
specific localization is indeed supportive of pharmacological and 
electrophysiological evidence showing that several neuronal functions such as 
long-term potentiation (LTP) are specifically PKC-y-dependent (Angenstein et 
al., 1994; Akers et al., 1986; Bliss et al., 1993).
Several studies, spanning different models of epileptogenesis as well as 
status epilepticus, have described how PKC-y can be modulated by seizures, 
without showing any peculiar pattern of variation for this PKC isoform (Tang et 
al., 2004; Guglielmetti et al., 1997; Chen, 1994; Beldhuis et al., 1992), probably 
owing to the different triggering stimuli and experimental protocols adopted. 
However, the available data usually deal with measurement of PKC-y levels 
after convulsive phenomena and refer to experiments in adult animals, usually 
rodents. Nonetheless, in a different paper (McNamara et al., 1999), it was
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reported that following KA administration a transient increase of PKC-y was 
shown to precede seizure activity.
As far as modulation of PKC by corticosterone is concerned, repeated 
administration of dexamethasone was shown to up-regulate the protein levels 
of isoform y in the cortex and the hippocampus of adult rats, whereas a single 
administration did not produced any effect (Dwivedi et al., 1999). These data 
are supportive of an indirect effect of glucocorticoids on PKC expression since 
only repeated administrations were able to induce significant changes. This 
finding is compatible with the observation that the promoter region of PKC-y 
lack of DNA-binding sites sensitive to direct or indirect modulation of gene 
expression by glucocorticoids (GRE, NF-kB, AP-1), whereas a consensus 
sequence for AP-2 and Sp1 has been identified (Chen et al., 1990; Chen et 
al., 1993; Takanaga et al., 1995).
Thus, owing to the aforementioned evidence, we were interested to 
ascertain in rat pups at PN 9 whether i) the protective endotoxin challenge was 
able to modulate mRNA expression of the PKA Rllp subunit and PKC-y isoform 
by itself and ii) the effect on such modulation of antagonists on both corticoid 
receptor subtypes.
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4.9.2 Materials and methods
Technical details related to mRNA extraction, reverse transcription and 
evaluation of gene expression by real-time PCR have already been reported in 
‘Materials and methods - general procedures’.
The concentration of LPS used was 0.1 mg/kg. The experimental 
animals were sacrificed 2 hours after the PBS or LPS injection for the 
successive evaluation of levels of transcripts in hippocampal tissue.
Canrenoic acid (Sigma, USA) was dissolved in PBS 0.1 M and injected 
intraperitoneally (50 mg/kg) alone or 90 minutes after the systemic LPS 
administration, depending on the experimental group.
RU486 (Sigma, USA) was dissolved in 25% Tween 80 and 
administered subcutaneously (8.5 mg/kg) alone or 90 minutes after the 
systemic LPS administration, depending on the experimental group.
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4.9.3 Results
Figures 22-25 show the effect of the systemic administration of 
canrenoic acid and RU486 on the LPS-induced Rlip and PKC-y mRNA 
expression in PN 9 rats. Measurements were made 2 hours after the endotoxin 
challenge. Data are the mean ± SE (n = 6 pups). In each bargram the ordinate 
axis represents the level of mRNA expression as the percentage of control 
(PBS-injected) group, assessed by quantitative RT-PCR.
Effect of canrenoic acid
Canrenoic acid did not affect the basal and 0.1 mg/kg LPS-induced 
mRNA expression of the PKA regulatory subunit Rllp (fig. 22). Indeed, the 
amount of transcript elicited by LPS (171.0 ± 10.5 % vs PBS-injected controls, 
p<0.05) was left unchanged in the presence of the mineralocorticoid receptor 
antagonist (208.0 ± 23.1 % vs PBS-injected controls, p<0.01).
Conversely, the systemic administration of canrenoic acid markedly 
increased the mRNA expression of PKC-y in the presence of the endotoxin 
stimulus (0.1 mg/kg), despite the fact that the administration of LPS alone did 
not induce variations in the level of PKC-y transcript (fig. 23). The PKC-y 
mRNA expression induced by canrenoic acid in the presence of the endotoxin 
was 332.6 ±19.1 % (p<0.001) compared with PBS-injected controls as well as 
LPS and canrenoic acid both individually injected (fig. 23).
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Effect of RU486
The vehicle used to dissolve RU486 (25% Tween 80) did not show any 
effect on basal and LPS-induced expression of Rlip mRNA (fig. 24). Also the 
systemic administration of RU486 alone left the levels of transcript unchanged. 
Conversely, the RU486 administration markedly diminished the LPS-induced 
expression of Rlip mRNA, even to below the basal level of PBS-injected 
controls. Indeed, the extent of reduction was, on average, 39% (p<0.001) 
compared with 0.1 mg/kg LPS (25% Tween 80), and 29% (p<0.001) compared 
with PBS-injected controls.
Fig. 25 shows the lack of any modulating effect of the systemic 
administration of RU486 onto PKC-y mRNA expression, both when 
administered alone and in the presence of the LPS challenge. Indeed, the 
levels of transcript in all the experimental groups were not statistically different 
from those of PBS-injected controls.
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Fig. 22
Effect o f C anrenoic  acid adm inistration on LP S - 
induced RIIbeta m R N A  in PN 9 rats
□ PBS
■ LPS 0.1 mg/kg
□ Canrenoic acid
□ Canrenoic acid+LPS
Data are the mean ± SE (n=6). * p<0.05 ** p<0.01 vs PBS; § p<0.05 vs 
Canrenoic acid. Kruskal-Wallis followed by Dunns multiple comparison 
test.
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Fig. 23
E ffect o f C anreno ic  acid adm in istration  on L P S - 
induced P K C -gam m a m R N A  in PN 9 rats
##
□ PBS
■ LPS 0.1 mg/kg
□ Canrenoic acid
□  Canrenoic acid+LPS
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Data are the mean ± SE (n=6). ** p<0.001 vs PBS; §§ p<0.001 vs 
Canrenoic acid; ## p<0.001 vs LPS 0.1 mg/kg. Kruskal-Wallis followed 
by Dunns multiple comparison test.
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Fig. 24
Effect of RU486 administration on LPS-induced Rll-beta 
mRNA expression in PN 9 rats
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□  PBS
■  LPS 0.1 mg/kg
□  25%  Tw een 80
□  LPS 0.1 mg/kg (25%  Tw een  
80)
□  R U 486
□  L P S +R U 486
Data are the mean ± SE (n=6). * p<0.05 ** p<0.001 vs PBS; §§ 
p<0.001 vs 25% Tween 80, RU486, LPS+RU486; ## p<0.001 vs 
25% Tween 80, RU486, LPS+RU486. Kruskal-Wallis followed by 
Dunns multiple comparison test.
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Fig. 25
Effect of RU486 administration on LPS-induced PKC-gamma 
mRNA expression in PN 9 rats
□  2 5 %  Tw een 80
□  LPS 0.1 m g/kg (2 5 %  Tw een  
80)
□  R U 4 8 6
□  L P S + R U 4 8 6
Data are the mean ± SE (n=6). No statistically significant differences. 
Kruskal-Wallis test.
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4.9.4 Discussion
The administration of LPS induces transcriptional activation of the PKA 
Rlip subunit, whereas PKC-y isoform mRNA expression is left steady at basal 
levels. Interestingly, selective antagonists to corticosterone receptors appear to 
delineate two differential patterns of mRNA expression, one for each specific 
receptor subtype. Mineralocorticoid receptors seem to exert an inhibitory tone 
on PKC-y isozyme transcriptional activation, leaving Rlip levels unaltered, 
whereas glucocorticoid receptors appear to sustain the expression of Rlip 
mRNA without affecting the expression of the PKC-y isoform.
It could be observed that PKC-y is exclusively modulated by 
mineralocorticoid receptors, hence supporting the neuronal location of the type 
I receptor, whereas data related to Rlip expression point to astrocytes as an 
exclusive target of modulation by type II receptors. Type I receptors are mainly 
localized in neuronal cells, as our results confirm by showing the modulation of 
gene expression of neuron-specific PKC-y. Type I receptors do not modulate 
Rlip mRNA expression, whereas type II receptors, also distributed in glial cells, 
are shown to affect transcription levels. Since, in vivo, microglia seems to be 
insensitive to corticosterone (as also supported by our results) then astrocytes 
appear to be the main target for modulation of Rlip subunit by corticosterone.
In regard to the modulation of 1L-1 p and TNF-a mRNA expression by 
canrenoic acid and RU486, we hypothesized that such an effect could be 
mediated by an increase of PGE2, despite unchanged levels of COX-2 mRNA 
following LPS injection after canrenoic acid or RU486 administration. In
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addition, we hypothesized that the de novo synthesis of PGE2 should occur in 
non-microglial cells.
In our opinion, the pattern of induction of PKC-y and Rlip following the 
administration of type I and type II corticosteroid receptor antagonists could 
support our hypothesis.
The enhancement of PKC-y expression by blockade of type I receptors 
would lead to an increase of synaptic strength by LTP induction, which 
implicates a long-lasting elevation of intracellular Ca2+ levels on synapse 
activation. Owing to the prolonged increase of intracellular calcium 
concentration, an enhancement of translocation of cPLA2 to neuronal 
membranes occurs and, subsequently, levels of free arachidonic acid increase, 
leading to an overproduction of PGE2 via the enzymatic activity of neuronal 
COX-2. Then, extracellularly transported PGE2 would act on neighbouring 
microglial cells leading to a down-regulation of IL-1p and TNF-a expression.
As far as the type II receptor is concerned, a comparison between the 
patterns of induction of Rlip mRNA by antagonists to both corticosteroid 
receptor subtypes suggest that the modulation of this PKA subunit mostly, if not 
exclusively, occurs in astrocytes. Astrocytes are the main source of arachidonic 
acid in the brain (Moore et al., 1991). Once synthesized, arachidonic acid is 
released in the extracellular fluids and then taken-up by neurons where it is 
very quickly incorporated into the endoplasmic reticulum, plasma and 
mitochondrial membranes (Katsuki et al., 1995). Importantly, the release of 
arachidonic acid from primary astrocyte cultures was shown to be PKA- 
dependent in that it is significantly reduced by PKA inhibitors (Strokin et al., 
2003). This finding could help explaining how RU486 contributes to increased
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PGE2 production without affecting COX-2 expression. The levels of Rlip mRNA 
expression were shown to be inversely correlated to the amount of PKA 
catalytic subunits in the cytoplasm (see paragraph “PKA: a relevant role of the 
regulatory subunit Rlip”). Thus, on the decrease of Rlip mRNA expression, the 
subsequent increase of dissociated PKA catalytic subunits is expected to 
enhance the release of arachidonic acid from astrocytes. This should lead to 
an increase in levels of arachidonic acid incorporated into the membrane 
phospholipids of both neurons and microglial cells, hence increasing the 
availability of substrates for cPLA2- Elevation of PGE2 production then ensues, 
due to an elevation of intracellular arachidonic acid. Then, PGE2 of microglial 
as well as neuronal origin should act in autocrine and paracrine fashion yielding 
a down-regulation of IL-1 p and TNF-a mRNAs expression.
Thus, the aforementioned hypotheses do not require a further increment 
of COX-2 expression in order to achieve an enhancement of PGE2 production.
These results show that CA and RU486 can modulate LPS-induced IL- 
1p and TNF-a mRNA expression through different mechanisms, yielding, 
however, the same effect, that is an enhancement of PGE2 production. 
Obviously, any mechanism affecting, for instance, the efficiency of enzymatic 
activity of COX-2, the rate of cAMP production or the sensitivity of EP2 receptor 
to PGE2 itself as well as to its coupling with down-stream signalling could be 
evoked as a possible explanation for an enhanced PGE2 production. 
Nonetheless, any direct modulation of these mechanisms by blockade of both 
corticosteroid receptors should be excluded since it would require an action of 
corticosterone directly onto microglial cells.
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It is worth speculating on the different amount of inhibition of LPS- 
induced IL-1 (3 and TNF-a gene expression when comparing the effect of CA as 
respect to RU486, being the down-regulation of proinflammatory cytokines 
much more pronounced with the latter antagonist. Evidence from the literature 
suggests a few mechanisms that may contribute to explain this feature. We 
already observed an increment of the LPS-induced immediate early gene iNOS 
following RU486 administration and this makes conceivable the hypothesis that 
production of NO enhances the enzymatic activity of COX-2 without affecting 
its mRNA expression. However, one more mechanisms is worth to be 
mentioned. Glucocorticoid receptors have been shown to mediate a tonic anti­
inflammatory effect by inhibiting the formation of lipocortin-1 (also known as 
annexin-1), a molecule capable to enhance the activity of PLA2 and, 
subsequently, to increase the release of arachidonic acid. Thus, upon RU486 
administration, it is expected an increment of lipocortin-1 production and, 
eventually, an increment of PGE2 production mediated by an enhanced release 
of arachidonic acid.
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4.10 Dose-response of LPS-induced COX-2 
mRNA expression in PN 9 rats
4.10.1 Introduction
Starting from this experimental section we investigated the role of PGE2 
in our experimental system as a modulator of susceptibility to seizures. At this 
step of investigation our experimental data indirectly support the role of PGE2 as 
a down-regulator of proinflammatory cytokines expression also in rat pups. 
However, there are no clear indications concerning the role of PGE2 on seizure 
susceptibility in rat pups. Indeed, it is of interest to observe the pattern of LPS- 
induced seizure-threshold to flurothyl inhalation (fig. 14). The more the dose of 
LPS increases, the less the LPS administration delays the seizure onset. The 
highest doses do not show any protective effect over seizure susceptibility. 
Generally, it is expected that increasing amounts of the endotoxin dose- 
dependently stimulate the mRNA expression of NF-xB-dependent genes such 
as COX-2, hence promoting the PGE2 production in a dose-dependent manner. 
Therefore, it is conceivable to hypothesize that the increasing amount of PGE2 
in our experimental system might be responsible for the dose-dependent 
reduction of the protective effect of LPS administration. Therefore, from this 
point of view, it cannot be excluded that PGE2 might preserve its own
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proconvulsant effect as shown in adult rats but this effect would be partially 
masked by the concomitant activation of the HPA axis by the prostaglandin 
itself. Upon a strong increase of PGE2 production (as it is expected to occur at 
high doses of LPS) the proconvulsant effect of PGE2 would prevail over the 
anticonvulsant effect mediated by the HPA axis activation.
We started investigating the validity of such working hypothesis by testing 
whether the levels of COX-2 transcript were dose-dependently increased by 
LPS. The assay was done using the same samples where levels of IL-113 and 
TNF-a transcripts were measured after LPS (fig. 15, panels A and B).
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4.10.2 Materials and methods
Technical details related to mRNA extraction, reverse transcription and 
evaluation of gene expression by real-time PCR have already been reported in 
‘Materials and methods - general procedures’.
The concentrations of intraperitoneally administered LPS (dissolved in 0.1 
M PBS) were 0.1 -  1.0 -  4.0 mg/kg. The experimental animals were sacrificed 2 
h after the PBS or LPS injections for the subsequent evaluation of COX-2 level 
of transcript in hippocampal tissue.
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4.10.3 Results
Figure 26 depicts the pattern of COX-2 mRNA induction following the 
systemic administration of three doses of LPS, two of which were shown 
protective (0.1 mg/kg and 1.0 mg/kg) whereas the highest dose (4.0 mg/kg) was 
ineffective on seizure threshold (fig. 14, panels A and B).
LPS induced a dose-dependent increase of COX-2 mRNA ranging 
approximately from 90% to 220% above control levels at 0.1 and 4.0 mg/kg 
respectively.
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Fig. 26
mRNA expression of COX-2 following the administration of 
increasing doses of LPS in PN 9 rats
COX-2 mRNA expression
□  PBS
■  LPS 0.1 mg/kg
□  LPS 1.0 mg/kg
□  LPS 4.0 mg/kg
Data are the mean ± SEM (n=6). ** p<0.01 vs PBS; §§ p<0.01 vs LPS 0.1 
mg/kg; # p<0.01 vs LPS 1.0 mg/kg by Kruskal-Wallis test
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4.10.4 Discussion
The dose-dependent activation of COX-2 following LPS supports the 
hypothesis that PGE2 production may be involved in LPS effects on seizure 
threshold to flurothyl and this finding is also compatible with the concomitant 
changes in proinflammatory cytokines expression. Generally, the accumulation 
of free arachidonic acid and the formation of prostaglandins and lipoxigenase 
reaction products in the brain during seizures is well established (Cole-Edwards 
and Bazan, 2005). However, we are interested in investigating the role of high 
levels of PGE2 on seizure induction. It was shown that ibuprofen, a non-selective 
COX inhibitor, delays the onset of flurothyl-induced seizures in adult rats 
(Wallenstein and Mauss, 1984), suggesting a proconvulsant role of PGE2. On 
the one hand, this evidence appears to be in contradiction with our results 
related to the administration of low doses of LPS (a delay of seizure onset), 
while, on the other hand, this finding could account for the lack of protection on 
seizure susceptibility of the highest doses of LPS (see fig. 14, panel A and B). 
We focused our attention on the role of PGE2 on seizure susceptibility following 
the administration of a protective dose of LPS. We showed that the protective 
effect of low doses of LPS in rat pups is mediated by the occupancy of 
mineralocorticoid receptors by corticosterone. This effect is triggered by the 
activation of the HPA axis, presumably by the LPS-induced production of PGE2. 
Thus, it is conceivable that the prevention of PGE2 production could significantly 
increase the susceptibility to seizure in our experimental conditions. In the 
following experimental section we tested the relevance of PGE2 production as a
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key mechanism for LPS-induced protection on seizure susceptibility by inhibiting 
the activity of COX-2.
289
4.11 Role of COX-2 in LPS-mediated effect 
on flurothyl-induced seizures in PN 9 
rats
We studied whether a selective COX-2 inhibitor modulates flurothyl- 
induced seizure susceptibility in PN 9 rats. Pups were pre-treated with a 
selective COX-2 inhibitor (SC58125) and the effect of LPS administration alone 
or in combination with canrenoic acid on flurothyl-induced seizure onset was 
measured.
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4.11.1 Materials and methods
Technical details related to seizure-threshold testing by flurothyl 
inhalation have already been reported in ‘Materials and methods - general 
procedures’.
LPS was dissolved in 0.1 M PBS and injected at 0.1 mg/kg. Flurothyl 
delivery occurred 2 h after the endotoxin challenge. The selective COX-2 
inhibitor SC58125 (Cayman chemicals, USA) was dissolved in 0.1 M PBS and 
injected intraperitoneally (3 mg/kg) 30 min before flurothyl delivery (i.e 90 min 
after the systemic LPS administration) alone or co-administered with canrenoic 
acid. Canrenoic acid (Sigma, USA) was dissolved in PBS 0.1 M and co-injected 
with SC58125 intraperitoneally (50 mg/kg) 30 min before flurothyl delivery (i.e. 
90 min after the systemic LPS administration).
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4.11.2 Results
Figure 27, (A, B), shows the effect of the selective COX-2 inhibitor 
SC58125 on the LPS-induced delay of flurothyl-induced seizure in PN 9 rats. In 
the same experimental section, seizure-threshold was also tested in a group of 
animals which were treated with canrenoic acid, an antagonist to 
mineralocorticoid receptors.
SC58125 abolished the protective effect of LPS (panels A and B) but did 
not modify seizure-threshold when administered alone.
Canrenoic acid alone did not affect the susceptibility to seizures. When 
administered with SC58125 Canrenoic acid reversed LPS action by anticipating 
seizure onset by approximately 20% vs PBS-injected rats (p<0.01, panels A and 
B).
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Fig. 27
Effect of COX-2 inhibitor SC58125 ± Canrenoic acid on 
LPS effect on flurothyl-induced clonic (panel A) and tonic- 
clonic (panel B) seizures in PN 9 rats
Onset to clonic seizures
□ PBS
■ LPS 0.1 mg/kg
□ SC58125
□ LPS+SC58125
□ Canrenoic acid
□ LPS+Canrenoic acid+SC58125
Onset to tonic-clonic seizures
□ PBS
■ LPS 0.1 mg/kg
□ SC58125
□ LPS+SC58125
□ Canrenoic acid
□ LPS+Canrenoic acid+SC58125
Data are the mean ± SEM (n=6). * p<0.05 ** p<0.01 vs PBS; § p<0.01 vs 
SC58125, LPS+SC58125, Canrenoic acid and LPS+Canrenoic
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acid+SC58125; # p<0.01 vs LPS+SC58125 and Canrenoic acid; 
p<0.05 00 p<0.01 vs SC58125 by Kruskal-Wallis test
4.11.3 Discussion
These results support a relevant role of prostaglandins in the LPS effect 
on seizure susceptibility, since rat pups pre-treated with the selective COX-2 
inhibitor SC58125 and subsequently challenged with the most protective dose of 
LPS showed a seizure-threshold similar to control rats. In addition, in all 
experimental groups, inhibition of COX-2 significantly enhanced seizure 
susceptibility in rat pups treated with canrenoic acid and LPS.
It is of interest to observe that inhibition of COX-2 by SC58125 does not 
appear to affect seizure susceptibility in the absence of a stimulus capable of 
increasing COX-2 mRNA expression such as LPS administration, as is evident 
by comparing seizure-threshold of the control and SC58125 administered 
groups. So, it appears that elevation of PGE2 levels is necessary to exert the 
anticonvulsant effect shown by a protective dose of LPS.
Generally, the use of COX-2 inhibiting drugs on seizure modulation 
provided controversial results in the literature. As mentioned, inhibition of COX-2 
activity by ibuprofen was shown to increase flurothyl-induced seizure 
susceptibility in adult rats (Wallenstein and Mauss, 1984). In addition, Kim and 
Jang (Kim and Jang, 2006) showed that inhibition of COX-2 protein expression 
by celecoxib delayed flurothyl-induced seizure onset in PN 10 rats which 
undergo a protocol of recurrent seizures and were sacrificed at PN 15 and PN 
22. These data are in agreement with others showing that COX-2 inhibitors 
reduce the severity of seizure and protect the brain from irreversible damage
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induced, for instance, by KA administration in adult rats (Baran et al., 1994; 
Kunz et al., 2001).
However, several studies have reported that prostaglandin exert 
protective effects on seizures (Forstermann et al., 1982; Baik et al., 1999). In 
particular, if levels of cerebral prostaglandins were enhanced by a preceding 
electroshock, the toxicity of pentylenetetrazole was significantly reduced and 
seizure onset was markedly delayed. Both these effects (neuroprotection and 
increased latency to seizure-onset) were reversed when prostaglandins 
production was prevented by administration of indomethacin, or by increasing 
the time interval between the electroshock and pentylenetetrazole administration 
so that the electroshock-induced prostaglandins production returned to basal 
levels (Forstermann et al., 1982). Accordingly, our results showed that the 
administration of a protective dose of LPS induces COX-2 mRNA expression, 
thus resulting in increased levels of prostaglandins before flurothyl delivery. After 
impairment of prostaglandins production by the COX-2 inhibitor, the worsening 
effect of canrenoic acid on LPS-induced seizure-threshold was potentiated.
In general, the controversial results on seizures obtained using COX 
inhibitors (also called non-steroidal anti-inflammatory drugs, NSAIDs) may be 
ascribed to i) mechanisms of action of NSAIDs which extend beyond inhibition of 
COX enzymatic activity and ii) the emerging role of PGE2 as an anti­
inflammatory molecule. As far as NSAIDs mechanisms of action are concerned, 
it has been shown that some COX inhibitors also exert effects on transcriptional 
factors. For instance, acetyl salicylic acid and its derivative salicylate were 
shown to inhibit NF-kB activity (Kopp and Ghosh, 1994) as well as other 
transcription factors including AP-1 and CREB (Beauparlant and Hiscott, 1996).
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However, other NSAIDs appear to affect NF-kB activation only at certain drug 
concentrations and in certain cell types (Aeberhard et al., 1995).
As far as PGE2 is concerned, although this prostaglandin has frequently 
been considered as a possible cause of brain damage and degeneration, it may 
exert beneficial effects in the CNS. For instance, indirect evidence for its 
protective role in vivo derives from the detection of increased cerebral levels of 
PGE2 during the remitting phase of EAE (Khoury et al., 1992) and from the 
beneficial role of cAMP elevating agents, including PGE2 itself, in ischemia or 
EAE (Kato et al., 1995; Genain et al., 1995; Sommer et al., 1995; Wiegmann et 
al., 1995). Furthermore, PGE2 might exert a beneficial role also in multiple 
sclerosis and other human brain diseases where increased levels of this 
prostaglandin have been detected (Fretland et al., 1992; Griffin et al., 1994; 
Froldi et al., 1992).
Experiments in vitro also support a protective role of PGE2. This 
prostaglandin was reported to protect cultured neurons from several kinds of 
noxious insult, including hypoxia/reoxigenation, glutamate-induced injury 
(Cazevieille et al., 1994; Akaike et al., 1994) and microglial toxic products (Thery 
et al., 1994), all these effects being mediated by cAMP elevation.
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4.12 Involvement of EP2 receptors in the 
modulation of PGE2 effects on seizure 
susceptibility in PN 9 rats
4.12.1 Introduction
Our experiments support an indirect role of PGE2 in the modulation 
of seizure susceptibility in rat pups through the activation of the HPA axis, 
thus promoting, on the one hand, a protection against seizure induction. 
However, on the other hand, PGE2 has been shown to enhance synaptic 
excitability by acting through its cognate receptors located in key areas of 
the brain. It is of interest to observe that our experimental system supports 
a PGE2-mediated down-regulation of proinflammatory cytokines production. 
Evidence from literature has shown the involvement of EP2 receptor in 
modulation of PGE2-induced down-regulation of IL-1(3 and TNF-a mRNA 
expression. Therefore, it is conceivable that EP2 receptors may play a 
relevant role also in our experimental conditions. In principle, the 
pharmacological targeting of the EP2 receptor could constitute a potential 
therapeutic tool when proinflammatory molecules in the CNS need to be 
limited. However, the usefulness of such a hypothetical pathway of 
therapeutic intervention depends on the effect that the specific activation of 
EP2 receptor exerts on seizure susceptibility. Recently, the specific
involvement of EP2 receptors in modulating the state of excitability of 
nervous tissue was investigated in hippocampal slices and in cultured 
hippocampal neurons (Sang et al., 2005). Indeed, it was shown that 
postsynaptically synthesized PGE2 modulates hippocampal synaptic 
transmission via activation of a presynaptic EP2 receptor. Interestingly, 
another recent paper (Zhu et al., 2005) showed the localization and the 
level of expression of EP receptor in the hippocampus. In general, all four 
EP receptors have been found in the rat hippocampus and it has been 
shown that EP1, EP2 and EP4 are localized at presynaptic sites whereas 
EP3 is mainly located at postsynaptic sites, although a minority can be 
found at the presynaptic terminal (Zhu et al., 2005). Astrocytes have been 
shown to express EP receptors as well, although to a much lesser extent. 
However, PGE2 was shown to stimulate Ca2+-dependent glutamate release 
from astrocytes. This would lead to a subsequent increase of intracellular 
Ca2+ concentration in neighbouring neurons through the activation of 
neuronal glutamate receptors (Bezzi et al., 1998), among which the 
ionotropic receptors were shown to depolarize neuronal membranes 
(Sanzgiri et al., 1999).
Generally, since EP1 receptor is coupled to activation of PLC with a 
subsequent increase of intracellular Ca2+ concentration (whereas both EP2 
and EP4 receptors are coupled to adenylyl cyclase activation) then it 
appears that the main effect mediated at the synapse by PGE2 in the 
hippocampus might be, almost exclusively, excitatory. However, under 
physiological conditions, EP2 and EP3 are the most expressed receptor 
populations (EP3 being the most abundant), whereas EP1 and EP4 are
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barely detectable. Thus, it might be that in physiological conditions the 
effect mediated by presynaptic EP2 activation might be counteracted by the 
concurrent activation of postsynaptic EP3 receptors which are known to 
down-regulate adenylyl cyclase activity.
Nonetheless, it is interesting to observe how these receptors are 
modulated by inflammatory stimuli such as IL-1 p. Indeed, IL-ip was shown 
to selectively up-regulate mRNA and protein levels of EP2 and EP4 
receptors in primary cultured hippocampal neurons, leaving EP1 and EP3 
receptors unaffected (Zhu et al., 2005), hence priming the system to a more 
excitatory action of PGE2 in the hippocampus following a proinflammatory 
stimulus. Interestingly, the same group of investigators showed how this 
selective up-regulation also occurs following LTP induction.
These data refer to EP receptor distribution and responsiveness to 
inflammatory stimuli in a specific rat brain area such as the hippocampus. 
However, relevant changes in EP expression following systemic 
administration of an inflammatory stimulus such as IL-1 p also occur in other 
brain areas (Zhang and Rivest, 1999). In particular, the hypothalamic PVN 
(paraventricular nucleus) was shown to undergo a selective overexpression 
of EP4 receptors (Zhang and Rivest, 2000) which accounts for the HPA axis 
activation by PGE2 under IL-1 (3 and LPS challenges. Thus, it is conceivable 
that only two receptor populations are relevant in our experimental 
conditions, namely EP2 and EP4.
We evaluated the effect of pharmacological intervention of EP2 
receptors on seizure susceptibility modulation by administration of a 
protective dose of LPS. Butaprost was used as a selective EP2 agonist. In
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addition, we investigated the role of EP1 receptors in that the activation of 
its signaling pathway leads to an increase of intracellular Ca2+ thus 
contributing to increase the level of excitability. Nonetheless, this receptor 
population being faintly expressed both in physiological conditions and 
following a proinflammatory stimulus, it is expected to not significantly affect 
seizure susceptibility in our experimental system. We used SC19220 as a 
selective EP1 antagonist.
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4.12.2 Materials and methods
Technical details related to seizure-threshold testing by flurothyl 
inhalation have already been reported in ‘Materials and methods - general 
procedures’.
LPS (0.1 mg/kg) was dissolved in 0.1 M PBS. Flurothyl delivery occurred 
2 h after the endotoxin challenge.
Butaprost and SC19220 (Cayman Chemicals, USA) were dissolved in 
25% Tween 80 and injected subcutaneously (3 mg/kg, each), alone or 90 min 
after the endotoxin challenge.
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4.12.3 Results
Figure 28, (A, B), depicts the effect of butaprost, an EP2 receptor agonist, 
and SC19220, an EP1 receptor antagonist, on flurothyl-induced seizures in PN 9 
rats.
Effect of butaprost
25% Tween 80, used as a vehicle to dissolve butaprost, affected seizure- 
threshold per se (29% above PBS, p<0.01). This effect was not statistically 
different from that observed with butaprost (39% above PBS, p<0.001).
When butaprost was administered with LPS, it reversed the protective 
effect of the endotoxin on clonic seizure-threshold (panel A). Tonic-clonic 
seizures were observed only in 2 out of 6 pups treated with butaprost and LPS. 
These seizures were apparently less severe than those occurring in PBS-treated 
rats (panel B).
Effect of SC19220
The EP1 receptor antagonist SC19220 did not affect seizure susceptibility 
in PN 9 rats (panels A and B). The amount of flurothyl required to elicit clonic
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and tonic-clonic seizures was not significantly different from vehicle and LPS 
treated rats.
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Fig. 28
Effect of Butaprost and SC19220 on flurothyl- 
induced clonic (panel A) and tonic-clonic (panel 
B) seizure-onset in PN 9 rats
A
Onset to clonic seizures
□  PBS
B LPS 0.1 mg/kg
□  25% Tween 80
□  LPS (25% Tween 80)
□  Butaprost
B LPS+Butaprost
□  SC 19220
□  LPS+SC19220
B
Onset to tonic-clonic seizures
(0 o
----
□  PBS
■  LPS 0.1 mg/kg
□  25% Tween 80
□  LPS (25% Tween 80)
□  Butaprost
l  nd =  LPS+Butaprost
□  SC19220
□  LPS+SC19220
Data are the mean ± SEM (n=6). * p<0.05 ** p<0.01 vs PBS; § 
p<0.001 vs LPS 0.1 mg/kg; A p<0.05 vs 25% Tween 80; #
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p<0.05 vs LPS 0.1 mg/kg (25% Tween 80); ° p<0.001 vs 
Butaprost; nd = not determined by Kruskal-Wallis test
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4.12.4 Discussion
In comparison with LPS dissolved in PBS, the administration of LPS 
dissolved in 25% Tween 80 reduces the protective effect onto seizure 
susceptibility. Meanwhile the seizure-onset in rats administered with 25% 
Tween 80 alone increases. Indeed, this vehicle makes the seizure-onset of 
these two experimental groups comparable, as it was also seen during the 
evaluation of the effect of RU486 onto seizure susceptibility (fig. 17). 
Nonetheless, the individual roles of EP2 and EP1 receptors in our 
experimental system can be sketched out.
As far as the EP1 receptor is concerned, there is a substantial lack of 
effect of the antagonist SC19220.
On the other hand, the EP2 agonist seems to suggest a dual role of 
PGE2. Indeed, the EP2 agonist abolishes the protective effect of LPS onto 
clonic seizure-onset and affects the pattern of seizure spread in that the 
occurrence of tonic-clonic seizures (a hallmark of massive involvement of 
brain motor areas) cannot be determined.
We are aware that data regarding the patterns of distribution and 
inflammation-induced responsiveness of EP receptors in a specific brain 
area such as the hippocampus might only partially account for our results 
which are related to the involvement of the whole brain (see paragraph 
4.12.1). Nonetheless, it could be that the lack of a substantial effect of the 
EP1 antagonist SC19220 in our experimental system, compared to basal 
and LPS challenged groups, might be ascribed to the ordinary paucity of 
EP1 receptors both under physiological conditions and following LPS
challenge. Conversely, the EP2 agonist butaprost acts on a receptorial 
population which is significantly expressed under physiological conditions 
and overexpressed following an inflammatory stimulus.
Thus, the activation of EP2 receptors appears to exert a 
proconvulsant action, as shown in our experiments with butaprost, and this 
effect was shown strong enough to overwhelm the protective effect 
mediated by the systemic administration of LPS (which is expected to 
indirectly involve the activation of the EP4 receptor subtype).
Although speculative, a possible explanation of our results might 
come from the aforementioned experimental evidence (Sang et al., 2005). 
Thus, the pre-treatment with a relatively selective EP2 agonist such as 
butaprost might lead to an increase of glutamate release via activation of 
presynaptic EP2 receptors. The subsequent increase of glutamate, through 
the activation of its cognate postsynaptic receptors, yields a general 
increase of neuronal excitability, thus contributing to foster seizure 
susceptibility. This proconvulsant effect appears not to be counteracted by 
the activation of mineralocorticoid receptors following systemic LPS 
administration, and therefore ictal events can be more easily induced by 
flurothyl inhalation.
In our opinion, these findings support our working hypothesis that the 
dose-dependent decrease of the protective effect of LPS on seizure 
susceptibility might be due to an overproduction of PGE2 . From this point of 
view, PGE2 seems to preserve its intrisic proconvulsant activity also in rat 
pups but, differently from adults, this effect is overwhelmed by the 
concomitant activation of the HPA axis, provided the levels of the
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prostaglandin are not strongly expressed. From a more general perspective, 
it might be that in rat pups a moderate inflammatory state might be 
beneficial to counteract seizure susceptibility.
At present, we have no a reasonable explanation for the apparent 
lack of a tonic-clonic phase during the occurrence of ictal events (fig. 28, 
panel B).
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5. Conclusions
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5.1 General discussion
We sum up the principal findings as they emerged from our study:
1. the pattern of expression of proinflammatory cytokines following 
SE might be due to the age-dependent stimulus-specific 
expression of their transcriptional factors. The temporal profile of 
induction of proinflammatory cytokines, perse, cannot be regarded 
as a general mechanism which underlies the appearance of 
neurodegeneration;
2. there are no clear indications emerging from our data concerning 
the role of proinflammatory cytokines in modulating seizure 
susceptibility in rat pups;
3. microglia appear insensitive to corticosteroids and production of 
proinflammatory molecules such as IL-1 p and TNF-a might be 
down-regulated on elevation of parenchymal PGE2 levels.
PGE2 is expected to originate from non-microglial cells;
4. PGE2 production and the activation of the HPA axis play a relevant 
role in the modulation of seizure susceptibility in rat pups.
Obviously, our results are not intended as definitive. Indeed, several 
limitations may affect the interpretation of our findings, as it will be discussed in 
the following paragraph. Nonetheless, our findings are worth a few comments 
from a more general perspective. Indeed, a more general overview to our results
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leads to define two main findings in relation to ictal events and 
neurodegeneration in pups, i) an uncertain role of proinflammatory cytokines 
such as IL-1 (3 and TNF-a and ii) a possible relevant role of the functional 
relationship between COX-2 /PGE2 and the HPA axis in pups. Interestingly, it is 
worth wondering what functional mechanism, if any, may significantly contribute 
to account for the molecular and behavioural differences among rats aged PN 9- 
15-21. Likely, this is a multifactorial phenomenon. However, any mechanistic 
explanation could only be expressed in terms of a developmental continuum into 
which our experimental animals span through. Indeed, we already observed that 
the pattern of expression of IL-1 p and TNF-a induced by SE in pups is 
dependent on the proconvulsant agent used and the age of occurrence of ictal 
events. Interestingly, KA and flurothyl induce ictal events by different 
mechanisms (see ‘material and methods -  general procedure’). This is indicative 
of how the behaviour of cerebral areas involved in the insurgence of ictal events 
is affected by the degree of maturation of fundamental systems such as 
neuronal connections, signalling pathways and transcriptional/translational 
machineries. It is important to note that in rodents the most striking 
developmental changes occur in the early two postnatal weeks. From this point 
of view, we speculated that the pattern of induction of proinflammatory cytokines 
could be ascribe to the age-dependent expression of specific transcriptional 
factors. Nonetheless, during this developmental time-window, other relevant 
changes occur concomitantly and they may act synergistically with the age- 
dependent induction of proinflammatory molecules. In particular, developmental 
changes affecting GABAergic and glutamatergic synapses are worth to be 
mentioned, as they are relevant to brain excitability regulation and predisposition
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to neurodegenerative phenomena. It is known that GABAa receptors switch to 
be inhibitory during the first 7-10 postnatal days (Ben-Ari, 2001). During this 
period of time synaptic density reaches the highest level then progressively 
decreases while sub-serving the establishment of functional circuitries of the 
mature brain (Insel et al., 1990; McDonald et al., 1992). Usually, GABAa 
receptors are expected to be definitively hyperpolarizing by PN 15. Also 
glutamatergic synaptic transmission undergoes significant changes during 
development. It has been shown that during the first two postnatal days, 
glutamatergic transmission is exclusively mediated by NMDA receptors, without 
any significant contribution of AMPA receptors (Durand et al., 1996). 
Interestingly, the voltage-dependent Mg2+ block of NMDA channels is fully 
functional in neonatal brain as it is in adults and, consequently, these premature 
synapses are actually ‘silent’ at resting membrane potential (Durand et al., 1996; 
Ben-Ari, 2001). However, the proportion of pure ‘silent’ NMDA synapses 
decreases during the first week of postnatal development, shifting from 
approximately 80% at PN 2 to about 30% at > PN 7 (Durand et al., 1996). 
Generally, the NMDA receptor density peaks late in the first postnatal week, 
while AMPA receptor density peaks later in the second postnatal week 
(approximately at PN 10). Kainate receptors have been shown to be already 
present at birth. Their density is initially low and gradually increases to adult 
levels by the fourth postnatal week (Chapman, 1998).
The developmental profile of expression related to GABAa and, in 
particular, ionotropic glutamate receptors during the first two postnatal weeks 
may partially account for the progressive relevance that proinflammatory 
cytokines gain in ictal and neurodegenerative phenomena the more the age
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approaches adulthood. For instance, as already stated in this work, it is 
conceivable that the age-dependent strengthening of transcriptional and 
translational machineries of a proinflammatory cytokine such as IL-1 (3 may age- 
dependently affects the level of tissue excitability by the modulation of the 
NMDA channel conductance. Subsequently, seizure susceptibility and 
predisposition to excitotoxic insult may become age-dependently affected by the 
establishment of a proinflammatory state in the brain.
Also developmental changes affecting the HPA axis are indeed relevant 
and may significantly contribute to account for the difference among rats aged 
PN 9-15-21. From this perspective, as relevant parameters, we already 
discussed the age-dependent decrease of the ratio between MR and GR, the 
reversal of the functional role of MR receptors (shown as proconvulsant in adult 
rodents) and the maturation of negative feedbacks which limit the elevation of 
circulating corticosterone levels upon stimulation of the HPA axis. However, it is 
important to note that in adult rats persistent elevation of glucocorticoid levels 
increases the likelihood of neurodegeneration to occur. Indeed, glucocorticoids 
have been shown to impair glutamate removal from the synaptic cleft, Ca2+ 
extrusion from the cytoplasm of the postsynaptic neuron and blunt the 
compensatory increase in antioxidant enzyme activity during insults. All these 
effects act against the capability of neurons to face neurological insults, in 
particular those implying excitotoxicity as it occurs during seizures. Indeed, a 
significant finding has been shown in relation to the effects of elevation of 
glucocorticoid levels on KA-induced inflammation in the CA3 area of rat 
hippocampus (Dinkel et al., 2003). Although glucocorticoid are known for their 
anti-inflammatory and immunosuppressive properties both in periphery and in
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the CNS, chronically high levels of circulating corticosterone yielded a surprising 
proinflammatory effect, showing an anticipation of neuronal damage at shorter 
time points, higher infiltration of inflammatory cells in the KA-administered CA3 
area as well as much higher levels of both transcript and protein of IL-1 p and 
TNF-a. Indeed, this finding is not surprising. Although successfully employed to 
treat inflammatory diseases within the CNS such as edema arising from brain 
tumors (Barnes and Adcock, 1993), bacterial or viral encephalitis (Coyle, 1999) 
or to improve the rate of recovery from acute exacerbation in multiple sclerosis 
patients (Filippini et al., 2000), in the context of various neurological insults GCs 
have been shown to exacerbate neuron loss especially in concomitant with 
excitotoxic insults.
Thus, in regard to seizure susceptibility and seizure-induced 
neurodegeneration, the concomitant maturational changes affecting the 
proinflammatory cytokines production, the glutamatergic transmission and the 
HPA axis activation may indeed account for the molecular and behavioural 
differences among pups at different ages and between young pups and adult 
rodents.
As it regards the functional relationship between PGE2 and the HPA axis 
activation, it should be mentioned that the functional features mediated by PGE2 
in pups appear similar to those observed in adult rodents. Indeed, PGE2 
activates the HPA axis, down-regulates the expression of proinflammatory 
markers such as IL-1 (3 and TNF-a and preserves a potentially proconvulsant 
effect. Conversely, the HPA axis activation in rat pups is peculiar. In particular, 
two features have been shown relevant at young ages, i.e., the long-lasting 
increase of circulating corticosterone levels and the anticonvulsant effect
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mediated by the occupancy of membrane MR. Our experiments have prompted 
the possibility that functional mechanisms shown to occur in adult rats are 
operative also at young ages. However, upon a moderate proinflammatory 
stimulus that does not induce overwhelming levels of parenchymal PGE2 , this 
mechanistic similarity in pups takes the advantage of being protective against 
the occurrence of ictal events. This effect is modulated by the age-dependent 
anticonvulsant feature of membrane MRs. In our opinion, the proposal of this 
mechanistic hypothesis represents the most intriguing result coming out from 
our study. Figure 29 (page 317, see also legend on page 318) provides a 
schematic representation of this mechanistic hypothesis.
316
o>
CM
6)
CM
CM
CM
S3cn x
317
Le
ge
nd
: 
 
► 
st
im
ul
at
io
n,
 a
ct
iv
at
io
n
 
1 
in
hi
bi
tio
n
318
5.2 Major limitations of the study
As already stated, the interpretation of the great majority of our 
experimental data relies on the assumption that upon mRNA increasing a 
corresponding protein synthesis occurs. Nonetheless, several evidence has 
shown that transcription can be an isolated event from translation. LPS, IL-1 p 
and TNF-a, were shown to increase IL-1 (3 transcription without affecting 
translation, depending on the system under investigation. Indeed, the complexity 
of gene transcription modulation of molecules such as proinflammatory 
cytokines and the immaturity of the organism under investigation make the 
possible dissociation between transcription and translation a conceivable 
hypothesis. From this point of view, it cannot be ruled out that the production of 
several modulators potentially relevant for bridging the gap between 
transcription and translation may not be appropriately entered into play at young 
ages, maybe due to the immaturity of signalling pathways and 
transcriptional/translational machineries.
Another major limitation of our study is the lack of measurement of 
circulating corticosterone levels. We are aware that our interpretation of results 
obtained and the subsequent working hypothesis were confident on the 
assumption that the pattern of induction of corticosterone levels in our 
experimental conditions was similar to that reported to occur in the literature in 
similar experimental paradigms. As already stated, it should be also observed 
that the lack of a protective effect of the highest doses of LPS might be ascribed 
to an inadequate amount of corticosterone due to an inefficient machinery of the
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immature HPA axis when facing an intense stimulation, as shown to occur in 
regard to the ACTH levels in young pups (Vazquez, 1998). Thus, the 
measurement of corticosterone levels released during our experiments is indeed 
a relevant parameter needed to strongly validate our hypothesis.
Finally, it should be also observed that 2 hours interval between 
proinflammatory stimuli administration and the evaluation of mRNA expression 
of molecules of interest is indeed a short time-window. The time interval of 
observation should be significantly extended. Longer time-windows would 
significantly increase the probability that several relevant molecules would come 
into play in our experimental system. In particular, it is conceivable that the 
production of IL-1 p and TNF-a following LPS administration could become 
affected by the induction of gene expression and translation of classical anti­
inflammatory molecules such as IL-4 and IL-10, which are known to be 
synthesised following longer time-exposure to proinflammatory stimuli. 
Additionally, PGE2 production would also increase, thus likely affecting the 
balance among brain excitability, HPA axis activation and the expression of 
proinflammatory molecules in concert with anti-inflammatory cytokines. It should 
be also mentioned that the limited time of observation of our experimental 
protocols could also affect the validity of our hypothesis that makes the 
activation of the HPA axis pivotal in limiting seizure susceptibility in pups. 
Indeed, it cannot be excluded that upon prolonged stimulation by 
proinflammatory stimuli the immature HPA axis could significantly limit 
corticosterone release.
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5.3 Future work
The goal of future work is to established whether the hypothesis depicted 
in fig. 29 holds true. In particular, we will focus on the evaluation of 
corticosterone levels released in association with the administration of a 
proinflammatory stimulus such as LPS. Specifically, we will investigate the 
temporal profile of corticosterone induction shortly after the administration of a 
protective dose of the endotoxin. In particular, the evaluation of corticosterone 
levels at time-points as short as 15-30 minutes after LPS administration would 
allow to verify the hypothesis of the involvement of membrane mineralocorticoid 
receptors in the quick modulation of seizure susceptibility in our experimental 
system, being this time-window hardly compatible with effects mediated by an 
action of corticosteroids at genomic level. Additionally, we will also evaluate the 
pattern of induction of corticosterone levels induced by a non-protective dose of 
LPS as it cannot be ruled out that the lack of a protective effect of the highest 
doses of LPS might be ascribed to an inadequate amount of corticosterone due 
to an inefficient machinery of the immature HPA axis when facing an intense 
stimulation, as shown to occur in regard to the ACTH levels in young pups. 
Related to the latest experimental proposal, we will test the hypothesis that the 
lack of proconvulsant activity of the icv administration of IL-1 (3 in rat pups might 
be due to the involvement of mineralocorticoid receptors by the quick activation 
of the HPA axis following the injection of the cytokine. This goal may be simply 
achieved by pre-treating pups with canrenoic acid.
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The experiments above mentioned will be paralleled by others aimed to 
better characterize the role of the COX-2 /PGE2 system in our experimental 
conditions. As a first step toward this direction, we will evaluate the dose- 
response effect of the COX-2 inhibitor SC58125 on the protective effect of LPS 
administration on seizure susceptibility, alone and in combination with canrenoic 
acid treatment. The rationale of this experiment is in that PGE2 seems to play a 
dual role in our experimental system and the critical parameter appears to be 
the amount of PGE2 produced. Therefore, by keeping under pharmacological 
control the PGE2 production induced by a proinflammatory stimulus, it is 
conceivable to hypothesize the existence of a range of concentrations of 
SC58125 suitable to sustain and to reinforce the protective effect on seizure 
susceptibility of LPS administration.
In principle, these experiments could disclose new therapeutic pathways 
for seizure control at young ages. Indeed, it is conceivable that new 
pharmacological tools could arise from a better understanding of the effect of the 
modulation of PGE2 levels in conjunction with pharmacological intervention on 
the HPA axis and mineralocorticoid receptors.
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